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ABSTRACT 
 
 
Although many medically important Candida species are commensal to the gut or 
colonizers of the skin, these organisms have the propensity to cause disease in the event 
of a waning immune system Clinical manifestations of infections with Candida species 
can range from superficial mucosal infections to deep organ involvement usually 
resulting from haematogenous spread of infection. Despite significant progress made in 
the management of patients with fungal infections, the emergence of antifungal resistant 
clinical isolates creates significant problem in regards to antifungal prophylaxis and 
empirical treatment strategies. Antifungal resistance is associated with high mortality 
rates and hefty medical costs. The azole-antifungal class has been the “work horse” of 
antifungal pharmacotherapy for the past 20 years defined by its efficacy against Candida 
species and paucity of side effects. As the only oral option available for systemic 
antifungal treatment, the azoles are the most suitable option for the long treatment periods 
sometimes required for antifungal prophylaxis and therapy. As the azoles are fungistatic 
to Candida species, the lengthy and repeated treatment courses have resulted in azole-
resistant clinical isolates resulting in treatment failure and increased patient mortality.  
Candida albicans is the most prevalent etiologic cause of fungal disease. High-level 
azole resistance in this species is a result of the interplay of several mechanisms of 
resistance. Overexpression of the efflux transporter genes CDR1, CDR2, and MDR1 is a 
common mechanism of drug resistance in C. albicans and the majority of previous 
investigations pertained to defining mechanisms of transcriptional regulation of efflux 
transporters. Alternatively to efflux transport, point mutations in the ERG11 gene, whose 
gene product is the target of azoles, result in reduced target binding affinity without 
precluding enzymatic function. In addition to point mutations, overexpression of ERG11 
has also been shown to decrease fluconazole susceptibility. ERG11 gene amplification by 
chromosome 5 duplication or the presence of a chr5L isochromosome is known to 
contribute to azole resistance. Additionally, the zinc-cluster transcription factor Upc2 has 
been shown to regulate the expression of ERG11 and other genes involved in ergosterol 
biosynthesis.  
 
In a large group of clinical C. albicans isolates enriched for azole resistance, I created 
a transcriptional profile defining expression of genes known to cause azole resistance 
such as ERG11, CDR1, CDR2 and MDR1. Not surprisingly, CDR1 and CDR2 
overexpression was generally coordinately regulated and quite prevalent among these 
isolates. Of those isolates that did overexpress MDR1, even fewer isolates expressed 
MDR1 to the levels previously observed in azole-resistant isolates. ERG11 was found to 
be upregulated in almost three-fourths of the fluconazole-resistant isolates examined. 
This suggests that ERG11 overexpression is a common contributor to fluconazole 
resistance in C. albicans. Among the ERG11-overexpressing isolates studied here, I 
repeatedly recovered eight distinct single-nucleotide substitutions in UPC2. Five of these 
substitutions in UPC2 have not been described previously. Of the five novel mutations, 
four mutations resulted in increased ERG11 expression and increased resistance to 
fluconazole but to various degrees. Genome-wide transcriptional analysis was performed 
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for the four strongest Upc2 amino acid substitutions (A643V, G648D, G648S, and 
Y642F). Genes commonly upregulated by all four mutations included those involved in 
ergosterol biosynthesis, in oxidoreductase activity, the major facilitator efflux pump 
encoded by the MDR1 gene, and the uncharacterized ATP binding cassette transporter 
CDR11. These findings demonstrate that gain-of-function mutations in UPC2 are more 
prevalent among clinical isolates than previously thought and make a significant 
contribution to azole antifungal resistance, but the findings do not account for ERG11 
overexpression in all such isolates of C. albicans. 
 
Although prevalent, not all ERG11-overexpression in this group of isolates could be 
explained by GOF mutations in Upc2. In C. albicans, the Pho-G transcription factor 
NDT80 has been implicated in azole resistance not only due to its regulation of CDR1 but 
also due to its regulation of genes involved in the ergosterol biosynthesis pathway. In the 
next set of experiments, NDT80 alleles for genetically matched pairs of isolates 945/1619 
and 1002/3795 were sequenced. In both matched sets, the fluconazole resistant isolate 
overexpresses ERG11. Sequencing of the NDT80 allele of both matched sets revealed 
several mutations that resulted in amino acid substitutions when compared to SC5314. 
This analysis also showed that a loss of heterozygostiy event occurs so that the resistant 
counterpart was homozygous for one allele. A strain carrying the NDT80 allele derived 
from fluconazole-resistant isolate 1619 did not result in increased ERG11 expression and 
increased fluconazole resistance. The mechanism by which ERG11 is upregulated in the 
absence of UPC2 gain-of-function mutations is currently under investigation. 
In addition to ERG11-overexpression, mutations in ERG11 that result in amino acid 
substitutions in lanosterol demethylase have also been associated with decreased azole 
susceptibility. In the third study, I examined the prevalence and variance of ERG11 
mutations in the same group clinical C. albicans isolates. In this collection, I identified 
that 55 of the 63 isolated contained missense mutations in ERG11 that resulted in at least 
one amino acid substitution. From this sequencing data, a selected a group of mutant 
ERG11 alleles were expressed in an azole-susceptible background so I could determine 
the specific contribution of the mutant ERG11 allele on antifungal susceptibility. In this 
analysis, I was particularly interested in characterizing amino acid substitutions that 
occurred alone and also when accompanied by another mutation. In total, I characterized 
ten ERG11 alleles containing one amino acid substitution and nine alleles which carried 
ERG11 alleles with a combination of amino acid substitutions. Fluconazole, itraconazole 
and voriconazole susceptibilities for these strains were tested. Our data demonstrated 
many of these mutations resulted in fluconazole resistance, but most were not as 
significant when tested against voriconazole or itraconazole. Itraconazole, in particular 
seemed less effected by ERG11 mutations which produced significant resistance to 
fluconazole although amino acid combination Y132F and F145L resulted in increased 
itraconazole resistance. Specific combinations of ERG11 mutations resulted in increased 
azole resistance beyond single mutations. These data suggest that structural differences 
between azole effect activity against specific mutant ERG11 alleles. 
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CHAPTER 1.    INTRODUCTION 
 
 
CANDIDA ALBICANS 
 
 
The historical importance of fungus and fungal pathogens 
 
As immunocompetent mammals are naturally resistant to fungus, infections by fungal 
organisms seem enigmatic and dangerous. Mammals’ innate immunity to fungal 
infections is likely due to a combination of the innate and adaptive immune system in 
addition to elevated body temperatures characterized by our endothermic lifestyle (19). A 
computational model has determined the optimal temperature that provides maximal 
protection against fungus to be 36.7 °C, which is close to mammalian temperatures (11). 
This data suggests that vertebrate endothermic physiologic temperatures could be in part 
selected by pathogenic fungal species (19). An example of protection conferred by both a 
competent immune system and an endothermic physiological temperature has been 
demonstrated recently in the local bat population. In August of 2013, British 
Broadcasting Company reported a “bat killing fungus” detected in Arkansas that is 
responsible for the devastation of the North American bat population. The visual 
symptom of infected bats is a white fungus that typically grows on the nose, ears or tails, 
earning the title “white nose syndrome” (31). The etiologic cause of this infection is the 
fungus Pseudogymnoascus destructans. This fungus is unable to grow at temperatures 
above 20°C and infects bats as their body temperature lowers due to hibernation (30). Dr. 
Arturo Casadevall, from Albert Einstein School of Medicine has attributed mammalian 
immunity to disseminated fungal infections with the dominance of mammals after the 
Cretaceous-Tertiary (K-T) Boundary (19). In his article entitled “Fungi and the Rise of 
Mammals”, Dr. Casadevall describes how the “fungal bloom” resulting from catastrophic 
events 65 million years ago set the stage for mammals replacing reptiles as the dominant 
land animals (19, 192).  
 
Historically, the progress defining the significance of medically relevant mycology 
was slow due to the infrequency of disease and lack of experience of medical 
practitioners. The first observations of Candida infections is thought to date back to the 
ancient Greek physician Hippocrates who described an oral candidiasis, or thrush, around 
400BC in book three in “Of the Epidemics”(10). In this selection, what is presumed to be 
an observation of oral candidiasis is described as “mouths affected with aphthous 
ulcerations”. Much later in history but prior to Louis Pasteur, the Hungarian physician 
David Gruby identified the human pathogen, later named Achorion schoenleinii, to cause 
the scalp condition called favus (72). He was able to demonstrate causation of human 
disease by culturing the microorganism on potato slices and infecting healthy tissue.  
 
Despite the early observation and detection of diseases caused by fungal pathogens, 
bacterial diseases are better studied. This is most likely due to the frequency and severity 
of bacterial and mycobacterial epidemics that affect large populations as opposed to 
infrequent and isolated encounters with fungal pathogens. The current accepted genus for 
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C. albicans was introduced in 1923 by Christine Berkhout, who was later credited with 
deriving the first “rational systematics of anascosporogenous yeasts” (10). The genus 
Candida is derived from ancient Roman political candidates, or candidatus, who wore 
white togas. The species name albicans is derived from Albico, which also means “to be 
white” (10). Prior to the 1980s, mortality attributed to mycosis was ranked 10th in the 
United States when compared to mortality rates from alternate infectious etiologies. 
Between the time periods of 1980 to 1997, a marked increase of mortality attributed to 
fungal pathogens occurred, which is a time period that correlates with the onset of HIV 
and medical advancements that prolong the life of critically ill patients that are 
susceptible to these pathogens (118).  
 
On June 5, 1981, the Centers for Disease Control and Prevention (CDC) published in 
their Morbidity and Mortality Weekly Report (MMWR) describing independent case 
studies of five homosexual, previously healthy young men presenting with what was then 
known as Pneumocystis carinii, which is an opportunistic pathogen. (1). These men 
presented with other opportunistic infections and three cases noted oral candidiasis on 
their medical problem list. This publication is considered by many the beginning of the 
AIDs epidemic. With the spread of AIDs, detection of mucosal and invasive fungal 
opportunistic pathogens exploded (118). The most common pathogens in this population 
were Candida albicans and Cryptococcus neoformans (6). Mucocutaneous candidiasis 
was the most frequently identified fungal opportunistic infection and the most common 
early identifier of people with Human Immunodeficiency Virus (HIV)(118). With the 
implementation of Highly Active Antiretroviral Therapy (HAART), the frequency of 
Candida spp. infections in HIV patients has dramatically decreased (188). However, in 
populations that do not have access to antiretrovirals or in cases where patients are non-
compliant or are non-responders to their HAART regimen, treatment courses of azole 
antifungals have resulted in a subset of isolates that have become resistant to treatment 
(188). 
 
Despite the successful development of treatments for HIV, the population susceptible 
to invasive fungal infections continues to grow and Candida spp are leading the charge. 
Advances made in invasive medical technology, immunosuppressive and chemotoxic 
treatments have resulted in a wide range of subjects susceptible to invasive fungal 
disease. In nosocomial derived bloodstream infections, Candida spp the rank overall as 
the fourth most commonly isolated pathogen in hospitals and are identified as the second 
most frequent cause of infection in North American intensive care units (198, 205). C. 
albicans remains the most prevalent etiological agent of Candida infection. 
 
 
Biology and classification 
 
C. albicans is both a commensal organism and a medically important opportunistic 
pathogen. This species taxonomically belongs to the Fungi kingdom, the phylum 
Ascomycota, which is the largest phylum within the kingdom Fungi, and the class 
Saccharomycotina (87). The genus Candida is within the class of Deuteromycetes, since 
many species of this genus were not observed to have a sexual cycle. Candida spp. 
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includes more than 160 species but only 20 of these are clinically relevant in human 
disease (10). 
 
C. albicans is a diploid, polymorphic fungus that is member of the CTG clade defined 
by a unique codon exchange from a leucine to a serine (183). Its mode of reproduction is 
predominately clonal but still exhibits substantial heterozygosity due to its ability to 
undergo recombination and ploidy changes based on chromosomal loss and reformation 
(134). C. albicans possesses homologous of the mating-type genes that are characterized 
in Saccharomyces cerevisiae and can undergo a mating process which results in a 
tetraploid cell (76). C. albicans lack genes to undergo meiosis so return to the diploid 
state is a result of random chromosomal loss and is also a source of genomic 
microvariation in this species (12, 133). DNA fingerprinting techniques have been 
developed to identify population structure and microevolution in C. albicans. Results of 
these studies have defined five major genetically related groups, designated as clades, 
which are geographically linked to specific areas of the world (179).  
 
 
Genetics and genetic manipulation 
 
C. albicans generally is considered to be an obligate diploid organism but has been 
recently shown to have a viable haploid state that is recovered both in vitro and in vivo 
(70). C. albicans propagates predominantly by clonal methods however, a parasexual 
cycle has been defined for this species (12, 80). The nuclear genome is around 16 million 
base pairs comprised of eight chromosomes (82). The chromosomes are numbered from 1 
(~4.3 Mb) to 7 (~1.03 Mb) and also chromosome R, which varies in size depending on 
the number of ribosomal DNA repeats. The complete sequence of C. albicans is available 
on the Candida Genome Database (CGD) website from Stanford University 
(www.candidagenome.org). 
 
The success of C. albicans as an opportunistic pathogen is due to its ability to adapt 
to various niches aided by genetic changes such as point mutations, loss of heterozygosity 
(LOH) events, and instances of aneuploidies (134). C. albicans has a high level of single 
nucleotide polymorphisms (SNPs), which cause amino acid changes in the protein 
sequence. Previous work has shown that out of the approximate 6,000 total genes of the 
C. albicans genome, about 2,792 open reading frames (ORFs) carry at least one SNP 
resulting in heterozygous alleles in almost half the genome (18). 
 
Over the last few decades, molecular pathogenicity and drug resistance mechanisms 
in Candida species have been intensely investigated using genetic tools and molecular 
techniques which were often times developed to study genetics in S. cerevisiae. Creating 
libraries of gene disruptants has been a powerful tool in the examination genetic 
regulatory networks of specific cellular processes (69, 132). In C. albicans, homozygous 
gene disruption requires two rounds of transformation because it is a diploid species. By 
this method, a linear fragment of exogenous DNA is introduced with a selectable marker 
flanked by specific homologous regions which facilitates the targeted incorporation into 
the genome (69). This disruption cassette can be constructed by using polymerase chain 
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reaction (PCR) or traditional cloning techniques and selectable markers can be either 
auxotrophic genes (LEU2, ARG4 and URA3) or drug resistance genes such as SAT1 
(156). Using URA3 auxotrophic strains have generally lost favor due to the observation 
that URA3 expression is correlated with virulence in this species (182). 
 
The use of DNA mircroarrays has been the method of choice for examining genome-
wide gene transcription of C. albicans. Simply put, an array is a collection of single 
stranded DNA probes fixed on a solid surface. These probes can be deposited or 
synthesized in situ onto materials such as nitrocellulose, nylon or glass (56). Custom 
arrays for various species are now commercially available but variation can occur that 
affect gene expression levels such as labeling efficiency of specific dyes, concentration 
and quality of RNA starting material, and preparation of PCR products. Our lab has 
employed the use of microarrays to examine the differences in gene expression between 
fluconazole-susceptible and fluconazole-resistant strains in order to identify genes 
important for azole resistance (44, 50, 158). Gene expression in azole resistance will be 
discussed in a later section. 
 
Unlike bacteria who can acquire antimicrobial resistance by transposable elements, 
antifungal resistance in pathogenic fungi is primarily due to genetic variability such as 
single nucleotide polymorphisms (SNPs) (125). In bacteria, whole-genome sequencing 
techniques have provided insight into the development and transmission of antimicrobial 
resistant pathogens (64). In Candida spp. the acquisition of drug resistance has been 
studied by strains that have developed resistant mutations in vitro or by targeted 
sequencing and expression analysis of genes known to cause resistance in clinical 
matched-paired isolates (155). Developments in sequencing technology allows us to 
examine sequence on a genome-wide scale and permits the detection mutations that leads 
to drug resistance or even accompanying mutations that may mitigate fitness costs of 
resistance mutations. Recently, the first study to examine the genome-wide sequence 
analysis of echinocandin resistance in clinical isolates of C. glabrata was published 
(178). In this study authors were able to identify mutations in previously unidentified 
genes conferring resistance to echinocandins, but also identified a compensatory mutation 
that mitigated the fitness cost of echinocandin resistance.  
 
 
Pathogenicity and virulence 
 
C. albicans has the ability to cause a range of infectious from superficial mucosal or 
vaginal infections to disseminated disease.  The ability of C. albicans to cause such a 
diverse range of diseases is due to its arsenal of virulence and fitness attributes (117). 
Attributes such as phenotypic switching between a yeast and hyphal form, expression of 
adhesins, invasins and hydrolytic enzymes and biofilm formation are considered 
virulence factors that contribute to its ability to cause disease (62). Additionally, C. 
albicans displays a robust transcriptional response to changes in environment such as 
fluctuations in pH, nutrient acquisition and stress response which are fitness 
characteristics that allows this organism to colonize or invade a variety of niches within 
the human host. 
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Phenotypic changes. C. albicans has the ability to grow as a yeast cell or in 
filamentous form either as elongated cells with constrictions as septa (pseudohyphae) or 
as true hyphae with parallel separations in the cell wall. The ability to transition between 
yeast and filamentous form is important for its pathogenicity (79). The hyphal form is 
important for invasion of tissues while the yeast form is primarily responsible for its 
dissemination. Strains that have been constructed to be unable to transition to filamentous 
form show attenuated virulence (101). There are several environmental conditions that 
cue the transition of C. albicans to grow in filamentous form. Alkaline conditions (pH > 
7), presence of serum, N-acetyl-glucosamine, physiologic temperature, low cell density 
(> 107 cells ml-1) and CO2 all promote hyphal growth (117). Hyphal formation is also 
linked to the expression of a subset of genes associated with virulence such as HWP1, 
ALS3 and the secreted aspartyl proteases SAP4, SAP5 and SAP6. 
 
C. albicans isolates that have become homozygous at the mating type locus (MTLa/a 
or MTLα/α) can also switch between the white yeast form to an elongated opaque form 
(80). Opaque cells are the mating competent form of this species and can mate with other 
mating-competent isolates to produce progeny. When compared to white yeast cells, 
opaque cells exhibit a distinct genetic expression pattern and data suggest they are better 
colonizers of the skin (and GI tract) but also show attenuated virulence in mouse models 
(126). Although opaque cells have been reported to be more susceptible to killing by 
neutrophils than white cells, they also don’t release a polymorphonuclear (PMN) 
chemoattractant, which suggests they avoid detection of neutrophils (93, 94). A recent 
study by Sasse et al. compared internalization of white yeast, filamentous and opaque 
cells by various phagocytic cells.  Their data demonstrate that although opaque cells 
avoid recognition by human neutrophils on a glass slide, they cannot avoid detection and 
are efficiently phagocytosed by dendritic cells and by neutrophils in a collagen matrix 
environment (167). 
 
Adhesins and invasins. In order for C. albicans to become pathogenic, three 
different processes occur: (i) adherence, (ii) invasion, and (iii) induction of host damage 
(62). C. albicans is able to adhere to other microbial cells, abiotic surfaces in addition to 
host cells. Adherence is important in both the commensal and the pathogenic state (33). 
In C. albicans, adherence is mainly regulated by adhesins such as the agglutinin-like-
sequence (ALS) family, and also by hyphal wall protein 1 (Hwp1) (117). ALS genes 
encode glycosylphosphatidylinositol (GPI)-linked cell surface glycoproteins.  The ALS 
family is composed of eight members (Als1-7 and Als9) of which Als3 is particularly 
important.  In addition to Als3, Hwp1, which is a hypha-associated GPI-linked protein, is 
also important for adherence (117).  
 
Invasion of C. albicans cells can occur by two different mechanisms: induced 
endocytosis by host cells and active penetration by C. albicans (33, 212). Als3, along 
with a member of the heat-shock protein 70 (Hsp70) family, Ssa1, are considered 
invasins and these proteins have been shown to trigger endocytosis by inducing host 
cytoskeletal arrangments; however, this process does not require viable fungal cells (129, 
184). The more predominate form of invasion is active penetration. Hyphae penetrate the 
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cell wall by using physical force in combination with hydrolytic enzymes, specifically 
serine-aspartic-proteases (SAPS). The molecular mechanisms behind active penetration 
have not all been defined. Although this process results in the host secretion of pro-
inflammatory cytokines and activation of host cellular immunity, hyphae invasion is 
assumed to play a role in gaining access to deep tissue and the blood stream (117). 
 
Biofilms. C.albicans is the third leading cause of catheter related infections, which 
serve as reservoirs for pathogens by releasing cells into the blood stream (29). Biofilm 
formation in C. albicans occurs through a number of different phases including 
attachment, yeast cell proliferation, hyphal cell formation, extracellular matrix 
accumulation and dispersion of yeast cells from the mature biofilm (104, 117). 
Transcription factors such as Bcr1, Tec1 and Egf1 are important regulators of biofilm 
formation and strains constructed to be defective for these regulators in addition to 
NDT80, ROB1 or BRG1 were deficient in biofilm formation (132). Dispersion of cells 
from a mature biofilm contributes to its pathogenicity as dispersed cells have been shown 
to be more virulent in a mouse model (191). Mature biofilms also exhibit higher 
resistance to antifungal agents and to host immunity than planktonic cells (46, 48). 
 
Environmental stress response. C. albicans possesses a number of stress responses 
that facilitates its survival in a number of challenging and changing niches within the 
host. Pathways involved in stress response are responsible not only for its survival but are 
also required for virulence. Phagocytic cells within the host produce highly reactive 
oxygen species (ROS), reactive nitrogen species (RNS) and antimicrobial peptides that 
cause oxidative and nitrosative stress to the pathogen (117). C. albicans produces catalase 
Cta1 and superoxide dismutases Sod1 and Sod5 to detoxify ROS. Likewise, in a response 
to nitrosative stress, flavohemoglobin-related protein Yhb1 mediates the detoxification of 
RNS (77, 116, 207). Host macrophages and neutrophils can effectively phagocytose 
fungal pathogens and create a nutritionally starved environment (54). Inside these cells, 
C. albicans switches from glycolysis to gluconeogenesis while lipids and amino acids can 
serve as nutrient sources. In addition, induction of hyphae while inside the phagocyte can 
pierce the immune cell and permit escape (61, 106). 
 
Stress signals are also transmitted by the mitogen-activated protein (MAP) kinase 
pathways, which require a series of phosphorylation events. The three MAP kinase 
pathways in C. albicans are the Mkc1 (MAP kinase from C. albicans), Hog1 (high 
osmalarity glycerol response) and the Cek1 (Candida ERK-like response) pathways (4, 
32, 41). These pathways facilitate processes such as cellular integrity, biofilm formation, 
osmotic and thermal stress, filamentation in addition to mating. Strains deficient in these 
pathways are shown to have decreased virulence (41). 
 
 
Infections caused by Candida species 
 
Candida species are the most common cause of invasive fungal infections (IFIs), 
which include blood stream infections (BSIs) deep tissue infections and also organ 
disseminated disease (143). Numerous surveys have shown that the frequency of 
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candidemia and invasive candidiasis (IC) has increased world-wide in the last three 
decades, which merits study of infections caused by Candida species. According to a 
recent survey which describes the epidemiology and outcomes of candidemia in 3,648 
patients enrolled in the Prospective Antifungal Therapy (PATH Alliance) registry, 97% 
of all infections are caused by five different species of Candida. In order of prevalence, 
these species are C. albicans (42.1%), C. glabrata (26.7%), C. parapsillosis (15.9%), C. 
tropicalis (8.7%) and C. krusei (3.4%) (143). This Candida species hierarchy varies in 
different areas of the world (99, 204). Among the medically relevant fungal species, C. 
albicans is the most frequently recovered from human samples in the United States. This 
organism is responsible for a wide range of infections, from infection of superficial 
mucosal surfaces to invasive life-threatening disseminated disease. Invasive fungal 
infections are associated with health care costs over $32,000 per patient combined with 
an increase of about seven days of hospital stay (9). 
 
Candida species are part of the normal flora that exist commensally in over 70% of 
the healthy population (58). Individuals of advanced age or have oral prosthesis, such as 
dentures, exhibit higher instances of colonization. Colonization is defined as Candida 
species generated from one or more samples from non-sterile sites and the extent of 
colonization has been repeatedly linked to subsequent infection (3, 97, 150, 196). 
Previous work has shown that isolates responsible for invasive disease are often of the 
same karyotype of those of which the patient is colonized (134). Patients treated 
extensively with broad spectrum antibiotics can lead to an over-colonization of Candida 
species and may be at higher risk for IC. Other risk factors include gastrointestinal 
surgery, chemotherapy, immunosuppression, or other invasive medical treatments. 
Mortality associated with IC has been estimated between 14.5% - 49% (139). 
 
Mucocutaneous candidiasis can be classified into genitourinary and non-genitourinary 
candidiasis. The most common type of genitourinary candidiasis is vulvocandidiasis 
(VVC), which usually occurs in healthy women. It is estimated that 75% of women are 
diagnosed with VVC at least once in their childbearing years and although still less 
common than bacterial vaginosis, VVC is the second most common diagnosis (40%) in 
woman with vaginal complaints in the primary care center (2, 7). Although Candida 
species may asymptomatically colonize the vaginal cavity, VVC is associated with 
clinical signs of inflammation. In studies where Candida species where identified in 
VVC infections, C. albicans was the most commonly isolated causative organism 
followed by C. glabrata (2). Recurrent vulvocandidiasis (RVVC) is defined as over four 
VVC diagnosis within one year and in these cases, long term antifungal suppressive 
therapy is indicated. Of note, incidence of the non-albicans species, specifically C. 
glabrata, are more prevalent in RCCV than VVC. Non-albicans species are also more 
prevalent in women with HIV, who have uncontrolled diabetes and who are advanced in 
age (35, 181, 195). 
 
The diagnosis and management of candiduria remains controversial among providers. 
Candiduria is prevalent among critically ill patients and studies show a positive 
correlation between candiduria and mortality, however, the role of candiduria as an 
indicator of invasive disease is unclear (196). The differential diagnosis between a 
  
8 
urinary tract infection (UTI), colonization and sample contamination is difficult so the 
decision to treat is often provider specific (49). The most common risk factor for 
candiduria is colonization of urinary catheters, which may mask the signs and symptoms 
of infection. Alternatively, hematogenous spread is the most common etiology of renal 
candidiasis; a much more serious diagnosis is an indication to treat with aggressive 
antifungal therapy (71). 
 
Oral pharyngeal candidiasis (OPC) is the most common opportunistic infection with 
Human Immunodeficiency Virus (HIV) (140). OPC is more common in patients with low 
CD4+ count or high HIV titers however, since the widespread implementation of highly 
active antiretroviral therapy (HAART), OPC rates have declined (37, 42). Even in the era 
of HAART therapy and fluconazole prophylaxis, C. albicans is still the most commonly 
detected species (62%), followed by C. glabrata (17%) and C. dubliniensis (12%) (140). 
This non-albicans shift in the causative etiology of OPC creates concern regarding azole 
resistance. 
 
 
Treatment of Candida infections 
 
There are currently only four structurally distinct antifungal classes available for the 
treatment of invasive candidiasis. Unlike bacteria, both fungal cells and mammalian cells 
are eukaryotic, which makes targeting fungal-specific processes more difficult. The most 
exploited strategy for antifungal development targets the ergosterol biosynthesis pathway 
or ergosterol incorporated into the fungal cell membrane. Other strategies include 
inhibiting RNA and DNA synthesis by compounds that are selectively transported into 
the fungal cell and inhibition of the fungal cell wall. Mortality rates in neutropenic 
patients for yeast and mold infections are still unacceptably high and time to 
implementation of the correct antifungal has a significant impact on patient outcomes 
(57). 
 
Amphotericin B. Amphotericin B (AmB) is a polyene macrolide antifungal that was 
first isolated from Streptomyces nodosus in the 1950s. Over the past five decades, 
amphotericin B deoxycholate formulation (AMBd; Fungizone) has been the gold-
standard for the treatment of life-threatening fungal infections and generally remains 
refractory to resistance. Its primary fungicidal mechanism of action is direct binding to 
ergosterol; the primary sterol found in the fungal cell membranes. Its dual 
complementary action of aggregating to form membrane-permeabilizing ion channels 
increases its potency but is not required for fungicidal activity (63). Pharmacodynamic 
studies demonstrate that fungicidal activity can be enhanced by optimizing the 
concentration-to-MIC ratio (89). Unfortunately, the clinical utility of AMBd is often 
times limited by its associated adverse effects such as nephrotoxicity and infusion-related 
reactions (39). Because of these treatment-limiting adverse effects, newer lipid-associated 
formulations of amphotericin B (Ambisome, Abelcet and Amphotec) have replaced 
conventional AMBd as first-line therapy for many types of infections. 
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Flucytosine. (5FC) is a pyrimidine analog that inhibits DNA replication and protein 
synthesis. Flucytosine is selectively transported into the fungal cell by cytosine permease 
and is then deaminated by cytosine deaminase to 5-fluorouracil. It is then converted to its 
active form, 5-fluorodeoxyuridylic acid to inhibit DNA synthesis (194). Due to the rapid 
development of resistance, 5FC is rarely used as monotherapy. In a murine model of 
disseminated candidiasis, time over MIC was the best pharmacodynamic parameter 
correlated with efficacy (8). Although the Clinical Practice Guidelines for the 
Management of Candidiasis recommend 5FC in combination with amphotericin B or 
fluconazole for a variety of infection types, concerns regarding toxicity such as bone 
marrow suppression and hepatic transaminase elevation often times prevent its use (139). 
Its current utility is primarily limited to treatment of cryptococcal meningitis (159). 
 
Echinocandins. Echinocandins are the newest members in the spectrum of 
antifungals. Current approved agents by the U.S. Food and Drug Administration are 
caspofungin (Cancidas; Merck and Co.), micafungin (Mycamine; Astellas 
Pharmaceuticals) and anidulafungin (Eraxis; Pfizer Pharmaceuticals). Echinocandins are 
used for treatment of invasive candidiasis based on results of three defining clinical trials 
in which caspofungin, micafungin and anidulafungin were shown non-inferior to 
amphotericin B, liposomal amphotericin B and fluconazole, respectively (92, 121, 154). 
These agents are characterized by their broad spectrum of activity, low incidence of drug-
drug interactions and a relative lack of adverse effects (211). Echinocandins are 
lipopeptides that bind to 1,3-β-D glucan synthase, inhibiting production of β-1,3 glucan 
which, along with chitin, is responsible for integrity and shape of the fungal cell wall. 
1,3-β-D glucan synthase is a multi-unit enzyme that is made of a catalytic subunit Fksp, 
the target of echinocandins, and the regulatory unit Rho1p. All three echinocandin agents 
are fungicidal in a dose dependent fashion against the Candida species including those 
isolates resistant to azole antifungals (137, 146, 147, 180). Unlike the azole class, 
echinocandins are noted to retain activity against fungal biofilm and biofilm formation 
(180). 
 
Azole antifungals. Members of the azole class are the most widely used of all 
antifungals. Their utility is mainly due to their activity against a broad spectrum of fungal 
pathogens and a mild spectrum of side effects, specifically lacking the treatment limiting 
nephrotoxicity experienced by patients undergoing treatment with AmB. There are four 
azoles currently used for the treatment of invasive fungal infections. Although these 
agents are all of the same class, they vary individually in regards to spectrum of activity, 
pharmacokinetic and toxicity profiles. Appropriate utilization of these agents is based 
upon these unique characteristics. 
 
The primary target of all azole antifungals is 14-α lanosterol-demethylase, which is 
the product of the ERG11 gene (209). Lanosterol demethylase is a member of the 
cytochrome P450 (CYP450) class of enzymes, and is a critical enzyme in the 
biosynthesis of ergosterol. As ergosterol is not found in the mammalian cell membrane, 
inhibition of this pathway is a fungal specific mechanism of action for this class. 
Treatment with azoles results in decreased cellular ergosterol and leads to the 
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accumulation of toxic methylated sterols. Azoles are considered fungistatic for Candida 
and other yeast species but some are fungicidal to Aspergillus species (110). 
 
Fluconazole (FCZ; Diflucan; Pfizer). Fluconazole is available in both an oral and 
intravenous and has been widely studied in treating invasive fungal disease. When 
compared to AmB, fluconazole is defined by a limited toxicity profile, but its spectrum of 
activity is limited to yeast. Species such as C. krusei display inherent resistance to this 
agent and C. glabrata has been observed to exhibit both inherent and acquired resistance 
secondary to treatment (136, 144). Fluconazole has excellent bioavailability independent 
of pH or concomitant meals and exhibits linear kinetics (65, 214, 215). This agent also 
exhibits limited protein binding (~10%), a high volume of distribution and achieves 
appreciable concentrations in the cerebrospinal fluid (CSF)(16, 187). Fluconazole is 
primarily eliminated unchanged in the urine and requires dosage adjustment in renal 
insufficiency (15). As fluconazole is a moderate inhibitor of CYP450 enymes 3A4, 
CYP2C9 and CYP2C19, it potentially interacts with the metabolism of a wide variety of 
drugs (131). In addition, fluconazole also inhibits uridine diphosphate (UDP)- 
glucuronosyltransferase (UGTs), which mediates drug metabolism by glucuronidation 
(190). Like all triazole antifungals, area under the concentrations curve (AUC) to MIC is 
the best pharmacodynamic parameter that predicts azole antifungal activit (89).  
 
Itraconazole (ICZ; Sporanox; Janssen Pharmaceuticals). Itraconazole, 
voriconazole, and posaconazole are all considered extended-spectrum triazoles as they 
exhibit greater potency than fluconazole against most fungal species. Itraconazole is 
effective against most yeast however, C. krusei and C. glabrata may show cross 
resistance with FCZ (144). When compared to fluconazole, itraconazole gains activity 
against certain molds such as Aspergillus and dimorphic endemic fungi.  Itraconazole is 
only available orally and is formulated as either a capsule or a solution. Oral 
bioavailability of itraconazole is significantly less than fluconazole (213). The oral 
solution exhibits better bioavailability than the capsule, and this improves under acidic 
fasting conditions (214). Itraconazole is highly protein bound and is metabolized in the 
liver by CYP3A4, which results in the formation of the pharmacologically active 
metabolite hydroxyitraconazole (151, 186). Itraconazole is a strong inhibitor of CYP3A4 
and has the potential for numerous drug-drug interactions (78). 
 
Voriconaozle (VCZ; Vfend; Pfizer). Voriconazole is also an extended spectrum 
triazole and is structurally related to fluconazole. Voriconazole displays excellent activity 
against Candida spp. including C. krusei and is the drug of choice for treatment of 
invasive aspergillosis (68). Voriconazole exhibits activity against endemic fungi but 
notably lacks activity against Zygomycetes. Voriconazole is formulated in orally and also 
intravenously with a cyclodextrin carrier. Like fluconazole, voriconazole is well absorbed 
and displays high bioavailability upon oral administration (81). Voriconazole displays 
non-linear kinetics and absorption is independent of pH and food administration.  
Voriconazole is moderately protein bound (~58%) and demonstrates CSF penetration 
(107). Unlike itraconazole, voriconazole is primarily metabolized by CYP2C19. The 
argument has been made for therapeutic drug monitoring (TDM) of voriconazole levels 
due to inter-patient genetic differences in CYP2C19 activity (40, 202). Renal function 
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should be monitored in patients receiving the intravenous formulation due to the 
sulphobutylether-beta-cyclodextrin carrier (138). 
 
Posaconazole (PCZ; Noxafil; Schering Corporation). Posaconazole is the newest 
addition to the triazole class and is structurally related to itraconazole. Global 
surveillance studies have noted that posaconazole is more active than itraconazole and 
fluconazole, and as effective as voriconazole against a diverse population of clinically 
relevant Candida spp (148, 149). Posaconazole is available as a 40 mg/mL oral 
suspension and due to its lipophilicity, should be administered with a full meal or a 
nutritional supplement (27). Absorption of posaconazole is saturable so the 
administration of PCZ in divided doses has been shown to increase the relative 
bioavailability when compared to a single dose (45). Additionally, gastric pH also plays a 
role in posaconazole absorption so administration with an acidic beverage is 
recommended while coadministration with acid suppressing drugs may decrease 
absorption (25). Posaconazole is highly protein bound and distributes widely to the 
tissues. Metabolism is largely mediated by UGT (glucoronosyl transferase) which allelic 
polymorphisms have been shown to alter pharmacokinetics (60). Excretion of 
posaconazole has also been shown to be mediated in part by P-glycoprotien and inducers 
of P-glycoprotein have been shown to increase clearance (26). Posaconazole is not 
metabolized significantly by CYP450 enzymes but remains an inhibitor of CYP 
isoenzyme 3A4 which can contribute to drug interactions (91).  
 
 
AZOLE RESISTANCE IN CANDIDA ALBICANS 
 
 
Clinical impact of azole resistance 
 
Candida spp are the principle causative organisms of orophyryngeal (OPC) 
candidiasis and also the fourth most common pathogen isolated from nosocomial 
bloodstream infections.  Due to the implementation of Highly Active Antiretroviral 
Therapy (HAART) and fluconazole prophylaxis, the incidence of OPC among HIV+ 
patients has declined (42). There is a population that for various reasons is noncompliant 
with their drug regimen, do not have access to antiretrovirals or do not tolerate HAART 
therapy for whom OPC remains a problem. Recent studies and current IDSA treatment 
guidelines show that for AIDS patients, recurrent prophylactic fluconazole regimens for 
OPC results in decreased colonization and did not appear to cause resistance (139, 140). 
Data show that the likelihood of resistant yeast was increased in patients with recurrent 
candida esophagitis and denture use (140). In these cases, the prolonged and repeated 
fluconazole treatment course has created a fluconazole-resistant population of C. 
albicans. Repeated fluconazole treatment has created a non-albicans shift in the causative 
organisms of OPC, many of which have decreased susceptibilities to azoles (188). 
 
The increased incidence of invasive candidiasis is largely a result of progress in 
medical technology or therapies that have created an immunosuppressed population 
susceptible to fungal pathogens. Invasive candidiasis has a significant impact on patient 
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outcomes and medical costs. The mortality attributable to invasive disease varies by 
source. The IDSA guidelines state that mortality attributable to disseminated candidiasis 
ranges between 14.5-49% in adults and 10-15% in neonates and children (139). As 
patients who acquire invasive candidiasis often have multiple comorbidities, the mortality 
attributed to candidiasis is difficult to calculate. As fluconazole has been the “work 
horse” of antifungal therapy, a non-albicans shift has also been observed in nosocomial 
isolates that may be less sensitive to azole treatment. 
 
Resistance in Candida species is often distinguished into pathogens who exhibit 
intrinsic versus acquired resistance. Species such as C. krusei and some of the C. 
glabrata population exhibit intrinsic resistance, meaning resistance without prior 
introduction to the drug. C. glabrata and other Candida species can acquire resistance in 
response to a drug challenge. Recently, the Clinical Laboratory and Standards Institute 
(CLSI) have redefined their standards for in vitro antifungal susceptibility testing. 
Current standards now consider species-specific clinical break points (CBP) using 
established epidemiological cutoff values (ECV), defined as the upper cutoff value for 
wild-type MIC, pharmacokinetic (PK)/pharmacodynamic (PD) parameters and 
relationship between MIC and clinical outcome. Although previous CLSI CBPs 
reasonably predicted therapeutic success or failure, the new CBPs exhibit increased 
sensitivity in the detection of emerging resistance (145). The current interpretation of in 
vitro susceptibility testing of C. albicans after 24-hour incubation to fluconazole is 
“susceptible” ≤ 2 µg/mL, “susceptible dose dependent” 4 µg/mL and “resistant” isolates 
have an MIC of 8 µg/mL. Break points vary regarding species and antifungal. 
 
 
Molecular mechanisms of azole resistance in C. albicans 
 
The efficacy of fluconazole is decreased in clinical isolates of C. albicans by the 
interplay of several mechanisms of resistance. The azole antifungal agents inhibit the 
biosynthesis of ergosterol, the major membrane sterol of fungi. By binding to the heme in 
the active site of the cytochromeP450 enzyme, lanosterol demethylase, the azoles inhibit 
its activity (59). We currently do not know the mechanism of azole uptake into the fungal 
cell but recent kinetic data supports the hypothesis that its uptake is facilitated (113). 
Several mechanisms of resistance to the azole antifungal agents directly involving 
ERG11 have been described in C. albicans. One major mechanism involves accumulation 
of point mutations in the gene encoding lanosterol demethylase (ERG11) (162). These 
mutations have long been accepted to confer azole resistance by producing 
conformational changes that prevent effective binding between the azoles and their target 
while not affecting the function of this enzyme in ergosterol biosynthesis (5, 15). In 
addition to mutations in ERG11, constitutive overexpression of this gene requires higher 
concentrations of intracellular fluconazole for sufficient inhibition. ERG11 
overexpression occurs by either gain-of-function mutations in the transcriptional 
regulator UPC2 or by instances of aneuoploidy, specifically, increased chromosome 5 
copy number, on which ERG11 resides (discussed below).  
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A less common mechanism of azole resistance is alterations in the ergosterol 
biosynthesis pathway which results in alternate sterols in the fungal cell membrane. This 
usually occurs by inactivation of sterol Δ5,6-desaturase, encoded by ERG3 (125). Erg3 
converts nontoxic 14α-methylated sterol intermediates that accumulate due to azole-
mediated Erg11 inhibition, into the toxic sterol 14α-methylergosta-8,24(28)-dien-3β,6α-
diol (193). Non-functional ERG3 alleles result in high-level azole resistance by allowing 
cells to avoid the synthesis of the toxic sterols. Inactivation of this enzyme has been 
shown to result from either a nonsense mutation in ERG3 or a SNP, which allegedly 
inactivates the enzyme (119). Although strains containing these inactivating mutations 
are usually unable to filament and display decreased virulence, isolates containing 
inactive Erg3 yet are still filamentous and do not display decreased virulence have been 
documented (123, 193). 
 
Overexpression of efflux pumps is a common mechanism of resistance to drugs toxic 
to the fungal cell. In C. albicans, there are two families of efflux transporters which are 
important in azole resistance (23, 43, 125). Two ATP Binding Cassette (ABC) 
transporters, CDR1 and CDR2, harness the energy from ATP hydrolysis to actively 
transport fluconazole from the cell while the Major Facilitator Superfamily (MFS) 
transporter, MDR1, requires a proton gradient to drive efflux. The CaCDR1 gene is a 
homologue to the PDR5 ABC efflux transporter in S. cerevisiae. CaCDR1 was shown to 
functionally compliment a S. cerevisiae pdr5Δ mutant by restoring fluconazole 
susceptibility phenotypes (152). Disruption of CDR1 in C. albicans resulted in increased 
levels of intracellular fluconazole and increased sensitivity not only to azoles but also 
other drugs (164). CDR2 is very similar to CDR1 but disruption of this pump alone does 
not affect fluconazole susceptibilities (164). The disruption of CDR2 in a mutant already 
deficient for CDR1 further increases susceptibility to fluconazole (164). Similar studies 
were done for CaMDR1 however, overexpression of this transporter increased resistance 
specifically to fluconazole and not other azoles. In a fluconazole-susceptible isolate, these 
efflux pumps are usually expressed in a low or non-detectable level but expression is 
stimulated in response to azoles and other chemicals (25). In fluconazole-resistant strains, 
constitutive overexpression of the CDR1, CDR2 and MDR1 genes is commonly observed. 
Our lab and others have shown constitutive overexpression of CDR1, CDR2 and MDR1 is 
due to activating mutations in zinc-cluster transcriptional regulators, Tac1 and Mrr1 
respectively (3, 5). Analysis of mutants where genes encoding for these transporters are 
disrupted has proven that the contribution of CDR1 is greater than CDR2 to multidrug 
resistance (189). In addition, post-transcriptional studies have demonstrated that azole-
resistant isolates do not only display higher transcription initiation rates, but CDR1 
mRNA is more stable when compared to the azole-susceptible counterpart (112). 
 
The genome of C. albicans can tolerate changes in chromosomal rearrangement and 
chromosomal aneuploidies (124). Although reproduction is primarily asexual, a 
parasexual cycle has been identified in this species. C. albicans does not undergo meiosis 
therefore, the tetraploid result of mating undergoes recombination mediated by the 
endonuclease Spo11 and concerted chromosomal loss by mitosis, which results in a high 
degree of aneuploidy (51). C. albicans has also been observed to undergo substantial 
genetic variation in a short time in a murine model of infection (52). A study that 
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observed the chromosomal abnormalities that result from fluconazole exposure 
demonstrated the rapid acquisition of isochromosome 5L [i(5L)] in response to drug 
(174). Both ERG11 and TAC1 reside on chromosome 5 and increased chromosome 5 
copy number has been shown to contribute to azole resistance in a clinical isolate (173). 
Genetic abnormalities have been detected on all eight chromosomes in C. albicans but 
these changes are usually transient and will normalize without drug pressure. Other 
conditions promote genetic abnormalities such as low nitrogen containing media in 
addition to growth on specific carbon sources such as l-sorbose or d-arabinose (124). 
These established mechanisms of resistance are all able to individually contribute to azole 
resistance but high-level resistance is mainly due to multiple mechanisms of resistance 
that accumulate over time (155). 
 
 
TRANSCRIPTIONAL REGULATORS OF AZOLE RESISTANCE 
 
 
Zinc-cluster transcription factors  
 
Zinc-cluster transcription factors (TFs) are a class of exclusively fungal zinc-finger 
proteins comprised of six cysteine residues bound to two zinc atoms (Zn(II)2Cys6) (109). 
Zinc-cluster transcription factors recognize the conserved DNA motif CX2CX6CX5-
12CX2CX6-8C and bind as either monomers, homodimers or heterodimers. Apart from the 
cysteine rich DNA binding domain (DBD), zinc-cluster TFs also contain regulatory and 
activation domains. Included in their target gene repertoire, many zinc-cluster TFs 
regulate the expression of other zinc-cluster proteins or may also auto-regulate. 
 
The best studied zinc-cluster family member is Gal4. Gal4 regulates genes involved 
in the transport and metabolism of galactose via upstream activation sequences (UASGAL) 
in their promoters (102). Gal4 is localized in the cytoplasm and upon activation, is 
directed towards and imported into the nucleus facilitated by a characterized nuclear 
localization signal (NLS) (20). In the absence of galactose, Gal4 is inhibited by the 
repressor protein Gal80 (206). Relief of inhibition by Gal80 is mediated by its interaction 
with Gal3, a relationship which is not completely understood, but is dependent upon the 
presence of galactose (13, 141). Although not necessary for activation, Gal4 undergoes a 
series of phosphorylation events on serine residues 691, 696 and 837. These 
modifications are thought to help “fine tune” Gal4 activation (160). Gal4p turnover may 
also be post-transcriptionally regulated by the ubiquitin degradation system (128). Other 
zinc-cluster proteins are constitutively localized in the nucleus bound to their target 
promoters. Large scale and targeted protein localization studies have increased our 
insight of cellular location of zinc-cluster transcription factors in budding yeast (75, 115). 
 
As DNA in chromosomes are wound tightly and organized into chromatin, zinc-
cluster proteins require the participation of chromatin remodeling machinery, histone-
modifying enzymes and co-activators to activate genes. Transcription of several genes in 
S. cerevisiae are known to be dependent on histone actetyltransferases such as Spt-Ada-
Gcn5-acetyltransferase, known as the SAGA complex. Previous work has shown that 
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ScPdr1, a zinc-cluster TF and the primary regulator of the ABC transporter PDR5, 
interacts with the SAGA complex to activate transcription (55). Likewise, Ume6, a 
repressor zinc-cluster TF, relies on a histone deacetylase complex (HDAC) to exert its 
regulatory control (83). 
 
 
Zinc-cluster transcription factors and azole resistance in C. albicans 
 
Constitutive activation of efflux pumps MDR1, CDR1 and CDR2 are a prevalent and 
important mechanism of multidrug resistance in C. albicans. Studies performed in S. 
cerevisiae demonstrate that CaCDR1 and CaCDR2 can functionally compliment a strain 
the lacks ABC transporter PDR5 (152, 163). Regulatory elements for both genes are 
defined.(36) The promoter region of CDR1contains both a basal expression element 
(BEE), responsible for basal expression, and a drug responsive element (DRE), which is 
required for fluphenazine and estradiol induction of expression. Only a single DRE was 
detected in the promoter of CDR2 but it shared a 21 base pair consensus sequence with 
CDR1. This consensus DRE (5’-CGGA(A/T)ATCGGATATTTTTTTT-3’) contains two 
CGG triplet repeats suggesting the involvement of a zinc-cluster transcription factor in 
their regulation. In 2004, Coste et al, established the role of zinc-cluster transcription 
factor, TAC1 (transcriptional activator of CDR genes) as the regulator of both CDR1 and 
CDR2 overexpression in response to fluphenazine (23). Tac1 is localized to the nucleus 
and GOF mutations in azole resistant isolates are prevalent, resulting in the constitutive 
overexpression of drug efflux transporters (22). Hyperactive TAC1 alleles have been 
shown to be co-dominant with wild-type alleles and resistant phenotypes occur when 
strains are homozygous for a GOF TAC1 allele (22). The mechanism by which 
homozygous TAC1 alleles arise is by recombination between portions of chromosome 5 
or by duplication of a portion of chromosome 5, on which TAC1 resides. Tac1 also 
indirectly induces the transcription of PDR16 encoding a phosphatidylinositol transfer 
protein (216). As CDR1 and CDR2 function as general phospholipid translocators in 
addition to their role in pleiotropic drug resistance, this link demonstrates the importance 
of these two processes for C. albicans survival in a wide range of environments (216). A 
recent study has demonstrated that artificial activation of zinc-cluster transcription factor 
designated Mrr2 can also increase CDR1 transcription with similar efficacy to Tac1 
(168). Unlike Tac1, Mrr2 was selective for CDR1 expression and not CDR2. The clinical 
significance of Mrr2 in azole resistance is not yet known. 
 
MDR1 constitutive expression in C. albicans is also a frequent cause of azole 
resistance in clinical isolates. The mechanism of MDR1 overexpression in azole 
resistance was identified using genome-wide profiling analysis of match isolate pairs of 
fluconazole-susceptible and fluconazole-resistant counterparts that overexpressed MDR1 
(127). Orf19.7372, designated MRR1 was overexpressed in all three resistant isolates and 
disruption of MRR1 in a fluconazole susceptible background abolished MDR1 expression 
in response to fluconazole. Sequence analysis of resistance isolates revealed GOF 
mutations in MRR1. As seen with TAC1, the majority of MDR1 overexpressing strains 
had become homozygous for the MRR1 GOF allele either through recombination 
between chromosome 3 homologous, on which MRR1 resides, or may also occur by 
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chromosomal duplication events, which results in two mutated MRR1 alleles combined 
with a complete loss of the wild-type allele (43). An artificially activated form of the 
transcription factor Cap1 also results in increased MDR1 expression and to a lesser 
degree, Upc2 containing a GOF mutation can increase MDR1 expression in a MRR1 
dependent fashion (120). Adding another level of transcriptional regulation is the 
involvement of the MADS box transcription factor Mcm1, which is essential for MDR1 
overexpression by activated Mrr1 but unnecessary for activated Cap1 (120).  
 
In clinical-azole resistant isolates of C. albicans, constitutive overexpression of 
ERG11 and other genes in the ergosterol biosynthesis pathway (ERG genes) is observed. 
This is often a result of transcriptional activation of Upc2 (177). Previous work has 
identified Upc2-specific sterol response elements (SRE) core motif in the promoter 
region of ERG11 and other ERG genes (135). Deletion of UPC2 in a fluconazole- 
susceptible background results in hypersusceptibility to fluconazole, diminished 
ergosterol levels in the cell membrane and the inability to increase ERG11 expression in 
response to drug treatment (135, 177). Introducing a triple hemagglutinin epitope tag at 
the C terminus of UPC2, the putative activation domain, resulted in a gain-of-function 
effect in the fusion protein, resulting in increased expression of Upc2 target genes (108). 
CHIP-Chip analysis has also identified Upc2 to be enriched in the promoters of genes 
involved in ergosterol biosynthesis and other pathways. In a fluconazole-resistant clinical 
isolate, our lab first identified a GOF mutation in UPC2 resulting in constitutive 
overexpression of genes involved in the ergosterol biosynthesis pathway in addition to 
genes involved in the oxidative stress pathway (44). Our recent data show that a variety 
of UPC2 GOF mutations are prevalent in azole-resistant clinical isolates and these 
mutations contribute to azole resistance (50). Notably, our lab and others have observed 
clinical isolates that overexpress ERG11 yet do not contain UPC2 GOF mutations, which 
suggest alternative mechanisms of ERG11 overexpression. 
 
FCR1 has been previously characterized as a zinc-cluster transcription factor and its 
contribution to pleiotropic drug resistance has been studied in S. cerevisiae. Talibi and 
Raymond expressed C. albicans FCR1, FCR2 and FCR3 genes in S. cerevisiae and 
showed that that these genes were able to increase the expression of PDR5, which 
encodes a transporter in the ATP binding cassette (ABC) superfamily and participates in 
the efflux of azole antifungals (185). Surprisingly, fcr1Δ/fcr1Δ mutant strains were more 
resistant to fluconazole, ketoconazole, itraconazole, and Brefeldin A. Therefore, 
characterization of FCR1 as either a positive or negative regulator of antifungal resistance 
as yet to be clarified in S. cerevisiae. In addition to the FCR1 pathway, it has been shown 
that azole resistant isolates ability to grow in the presence of fluconazole is abrogated in 
the presence of a calcineurin inhibitor (17). Targets of calcineurin include the genes 
CRZ1 and CRZ2, which are also transcription factors and have been linked to fluconazole 
susceptibility. In a study by Bruno and Mitchell, mutants with the crz1 homozygous null 
genotype, like when treated with cyclosporine A, would reverse the ability of azole 
resistant mutants to grow in the presence of drug (17). 
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CENTRAL HYPOTHESIS AND RESEARCH OBJECTIVES 
 
Candida albicans is an opportunistic fungal pathogen that causes mucosal, cutaneous, 
and systemic infections, including oropharyngeal candidiasis (OPC), the most frequent 
infection in people with AIDS. Fluconazole and other azole antifungal agents have 
proven effective in the management of OPC; however, with increased use of these agents, 
treatment failures have occurred that have been associated with the emergence of azole-
resistant strains of C. albicans. The long term goal is to improve the treatment of Candida 
infections by understanding the molecular basis of azole resistance. The overall objective 
of this dissertation was to understand mechanisms by which Erg11 mediates resistance to 
fluconazole. Three specific aims were developed to investigate this overall objective. 
 
In a large group of clinical C. albicans isolates enriched for azole resistance, I created 
a transcriptional profile defining expression of genes known to cause azole resistance 
such as ERG11, CDR1, CDR2 and MDR1. ERG11 was found to be upregulated in almost 
three-fourths of the fluconazole-resistant isolates examined. These data suggest that 
ERG11 overexpression is a common contributor to fluconazole resistance in C. albicans. 
Prior to this work, only 3 GOF mutations in Upc2 (G648D, A643T and A643V) have 
been reported in characterized genetically-matched sets of isolates. In light of this 
preliminary evidence, I hypothesized GOF mutations in UPC2 were responsible for the 
majority of ERG11 overexpression in this collection. My first specific aim was to 
investigate the prevalence and role of UPC2 gain-of-function mutations in the over-
expression of ERG11 in fluconazole-resistant C. albicans isolates. Among the ERG11-
overexpressing isolates studied, 29 isolates contained at least one amino acid substitution 
in Upc2. I frequently recovered and characterized eight distinct single-nucleotide 
substitutions in UPC2. Five of these substitutions in UPC2 have not been described 
previously. Of the five novel mutations, four mutations resulted in increased ERG11 
expression. I determined that transcriptional activation of ERG11 by a variety of GOF 
mutations in transcription factor Upc2 are prevalent in a large group of azole resistant 
isolates. 
 
Although GOF mutations in Upc2 were prevalent in this collection, there were 
several ERG11-overexpressing isolates that did not contain UPC2 mutations. Other 
groups have also observed ERG11-overexpression in clinical isolates that do not contain 
GOF mutations in UPC2. These data suggest that there are UPC2-independent 
mechanisms of ERG11-overexpression. In C. albicans, the Pho-G transcription factor 
NDT80 has been implicated in azole resistance not only due to its regulation of CDR1 but 
also due to its regulation of genes involved in the ergosterol biosynthesis pathway. 
Investigation of CaNDT80 has identified putative binding sites in the UPC2 promoter 
area and ChIP-chip data has shown enrichment of Ndt80 in the promoter region of genes 
involved in ergosterol biosynthesis. In light of this preliminary data, I hypothesized that 
GOF mutations in NDT80 result in increased ERG11 expression and azole resistance in 
clinical isolates. My second specific aim was to investigate NDT80 mutations derived 
from the resistant component of two genetically matched isolate sets on ERG11 
expression and fluconazole resistance. Sequencing of the NDT80 allele of both matched 
sets revealed several mutations that resulted in amino acid substitutions when compared 
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to SC5314. This analysis also showed that a loss of heterozygostiy event occured so that 
the resistant counterpart was homozygous for one allele. A strain carrying the NDT80 
allele derived from fluconazole-resistant isolate 1619 did not result in increased ERG11 
expression and increased fluconazole resistance. The mechanism by which ERG11 is 
upregulated in the absence of UPC2 gain-of-function mutations is currently under 
investigation. 
 
In addition to transcriptional regulation of the ERG11 gene, it is well known that 
fluconazole resistance in clinical isolates of C.albicans are associated with specific point 
mutations in ERG11 but there are no studies that show the effects of these mutations 
within the pathogen itself. In my third aim, I investigated the contribution of specific 
amino acid substitutions to a panel of azole antifungals. To investigate this, I sequenced 
both ERG11 alleles in the 63 unmatched clinical isolates with reduced susceptibility to 
fluconazole. Sequencing data revealed that 55 of the 63 isolated contained missense 
mutations in ERG11 that resulted in at least one amino acid substitution. I selected a 
group of mutant ERG11 alleles and expressed them in SC5314. In this analysis, I was 
particularly interested in characterizing amino acid substitutions that occurred alone and 
also when accompanied by another mutation. In total, I characterized ten ERG11 alleles 
homozygously carrying one amino acid substitution and nine alleles which 
homozygously carried ERG11 alleles with a combination of amino acid substitutions. 
Fluconazole, itraconazole and voriconazole susceptibilities were performed for strains 
carrying each mutant ERG11 allele homozygously with an identical ERG11 mutation. 
Our data demonstrate many of these mutations resulted in fluconazole resistance, but 
most single mutations are not as significant when tested against voriconazole or 
itraconazole. Itraconazole, in particular seemed less effected by ERG11 mutations which 
produced significant resistance to fluconazole although amino acid combination Y132F 
and F145L resulted in increased itraconazole resistance. Specific combinations of ERG11 
mutations resulted in increased azole resistance beyond single mutations. These data 
suggest that structural differences between azole effect activity against specific mutant 
ERG11 alleles. 
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CHAPTER 2.    GAIN-OF-FUNCTION MUTATIONS IN UPC2 ARE A 
FREQUENT CAUSE OF ERG11 UPREGULATION IN AZOLE-RESISTANT 
CLINICAL ISOLATES OF CANDIDA ALBICANS* 
 
 
INTRODUCTION 
 
Candida albicans is an opportunistic fungal pathogen that causes mucosal, cutaneous, 
and systemic infections, including oropharyngeal candidiasis (OPC), the most frequent 
infection in people with AIDS (47, 88). In the United States, Candida is the fourth-most-
common organism isolated from nosocomial bloodstream infections and is associated 
with a mortality rate approaching 40% (153). Fluconazole and other azole antifungal 
agents have proven effective in the management of OPC; however, with increased use of 
these agents, treatment failures have occurred that have been associated with the 
emergence of azole-resistant strains of C. albicans (157). The azole class of antifungals 
works by inhibiting the cytochrome P450 enzyme lanosterol demethylase, a critical 
enzyme in the synthesis of ergosterol which is encoded by the ERG11 gene (90). The 
efficacy of fluconazole is decreased in clinical isolates of C. albicans by the interplay of 
several mechanisms of resistance (105, 125, 142, 203). Overexpression of the efflux 
transporter genes CDR1, CDR2, and MDR1 is a common mechanism of drug resistance 
in this organism (53, 105, 165). Point mutations in the ERG11 gene result in reduced 
binding affinity of azoles to their target without precluding enzymatic function (200). In 
addition to point mutations, overexpression of ERG11 has also been shown to decrease 
fluconazole susceptibility. ERG11 gene amplification by chromosome 5 duplication or 
the presence of a chr5L isochromosome is known to contribute to azole resistance 
(173).The zinc-cluster transcription factor Upc2 has been shown to regulate the 
expression of ERG11 and other genes involved in ergosterol biosynthesis (108, 177). 
Previous studies show that activating mutations in Upc2 result in increased expression of 
ERG11 and decreased fluconazole susceptibility; however, only three substitutions 
(G648D, A643T, and A643V) in Upc2 have been identified in clinical isolates that 
contribute to azole resistance (44, 66, 74). In all cases, these substitutions have been 
identified in fluconazole-resistant clinical isolates of genetically matched isolate pairs.  
 
In this study, I examined the prevalence of overexpression of ERG11, as well as the 
overexpression of efflux pump genes CDR1, CDR2, and MDR1, in a group of 63 
unrelated fluconazole-resistant clinical isolates. I also investigated the prevalence of 
UPC2 mutations among isolates that overexpress ERG11. I determined which UPC2 
mutations, both previously described and novel, result in increased ERG11 expression, 
altered cellular ergosterol content, and increased resistance to azoles, as well as to  
 
 
------------------------------------ 
*Reprinted with permission of the publisher. Flowers, S. A., K. S. Barker, E. L. Berkow, 
G. Toner, S. G. Chadwick, S. E. Gygax, J. Morschhauser, and P. D. Rogers. 2012. Gain-
of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-
resistant clinical isolates of Candida albicans. Eukaryot Cell 11:1289-99..  
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terbinafine. Finally, I identified genes that are coordinately differentially expressed in 
four strains expressing unique UPC2 gain-of-function mutations. 
 
 
MATERIALS AND METHODS 
 
 
Strains and growth conditions 
 
All C. albicans strains (Table 2.1) were stored as frozen stock in 20% glycerol at 
80°C and cultured on YPD (1% yeast extract, 2% peptone, and 1% dextrose) agar plates 
at 30°C. YPD liquid medium was used for routine growth of strains. For selection of 
strains containing the SAT1-flipper cassette (156), nourseothricin (200 µg/ml) was added 
to YPD agar plates. One Shot Escherichia coli TOP10 chemically competent cells 
(Invitrogen, Carlsbad, CA) were used as the host for plasmid construction and 
propagation. These strains were grown in Luria-Bertani (LB) broth or on LB agar plates 
supplemented with 100_g/ml ampicillin (Sigma) or 50 µg/ml kanamycin (Fisher 
BioReagents, Fair Lawn, NJ) when required. 
 
 
qRT-PCR 
 
First-strand cDNAs were synthesized separately from 1 µg of total RNA in a 21-µl 
reaction mixture volume using the SuperScript first-strand synthesis system for reverse 
transcription (Invitrogen). Quantitative PCRs (qRT-PCRs) were performed in triplicate as 
technical replicates using the 7000 sequence detection system (Applied Biosystems). 
PCRs were performed, independently amplifying 18S rRNA or the ACT1gene 
(normalizing genes) and the genes of interest (GOI) from the same cDNA, using SYBR 
green PCR master mix (Applied Biosystems). Genespecific primers were designed using 
Primer Express software (Applied Biosystems) synthesized by Integrated DNA 
Technologies (Coralville, IA) and are listed in Table 2. The PCR conditions consisted of 
AmpliTaq Gold activation at 95°C for 10 min, followed by 40 cycles of denaturation at 
95°C for 15 s and annealing/extension at 60°C. Determination of the dissociation curve 
and detection of SYBR green fluorescence was performed by using software provided 
with the 7000 sequence detection system. The cycle threshold (CT) value of the 
normalizing gene was subtracted from the GOI to obtain the ΔCT value. The ΔCT value 
of a calibrator was subtracted from the sample ΔCT value to obtain the ΔΔCT value. The 
change in fold expression was obtained by calculating 2-ΔΔCT. The standard error was 
calculated from ΔCT values as previously described (44). 
 
 
Plasmid construction for allele sequencing 
 
C. albicans UPC2 coding sequences were amplified by PCR (Pfu DNA polymerase; 
Stratagene) from C. albicans genomic DNA using the primers UPC2-A and UPC2-E 
(Table 2.2). Products were cloned into pCR-BLUNTII-TOPO using a Zero Blunt TOPO
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Table 2.1. C. albicans strains used in this study. 
 
Strain 
Strain 
background 
Relevent characteristics or 
genotype Source 
SC5314 N/A UPC2-1/ UPC2-2 ATCC 
Clinical isolates  (#1-#10) N/A azole-susceptible University of Iowa 
Clinical isolates (#11-#72) N/A azole-resistant University of Iowa 
Constructed laboratory strains 
UPC2M4A SC5314 upc2-1Δ::FRT/upc2-2Δ::FRT Dunkel, 2008 
11A8A2A UPC2M4A UPC2G648S::FRT/UPC2G648S::FRT This study 
SC11A1A SC5314 UPC2/UPC2G648S::FRT This study 
22A1A13A UPC2M4A UPC2G304R::FRT/UPC2G304R::FRT This study 
SC22A3A SC5314 UPC2/UPC2G304R::FRT This study 
YFA3A2K1 UPC2M4A UPC2Y642F::FRT/UPC2Y642F::FRT This study 
SCYFA2A SC5314 UPC2/UPC2Y642F::FRT This study 
AVA1A16A UPC2M4A UPC2A646V::FRT/UPC2A646V::FRT This study 
SCAVA4 SC5314 UPC2/UPC2A646V::SAT1-FLIP This study 
25B2D1 UPC2M4A UPC2W478C::FRT/UPC2W478C::FRT This study 
SC25A1 SC5314 UPC2/UPC2W478C::FRT This study 
28A7A10A UPC2M4A UPC2A643V::FRT/UPC2A643V::FRT This study 
SC28A3A SC5314 UPC2/UPC2A643V::FRT This study 
SCUPC2R12A SC5314 UPC2G648D::FRT/UPC2-2 Heilmann, 2010 
SCUPC2R14A SC5314 UPC2G648D::FRT/UPC2G648D::FRT Heilmann, 2010 
SCUPC2R32A SC5314 UPC2A643T::FRT/UPC2-2 Heilmann, 2010 
SCUPC2R34A SC5314 UPC2A643T::FRT/UPC2A643T::FRT Heilmann, 2010 
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Table 2.2. Primers used in this study. 
 
Primer Sequence 
qRT-PCR 
ACT1-F 5'-ACGGTGAAGAAGTTGCTGCTTTAGTT-3' 
ACT1-R 5'-CGTCGTCACCGGCAAAA-3' 
18S-F 5'-CACGACGGAGTTTCACAAGA-3' 
18S-R 5'-CGATGGAAGTTTGAGGCAAT-3' 
ERG11-F 5'-CCCCTATTAATTTTGTTTTCCCTAATTTAC-3' 
ERG11-R 5'-CACGTTCTCTTCTCAGTTTAATTTCTTTC-3' 
CDR1-F 5'-ATTCTAAGATGTCGTCGCAAGATG-3' 
CDR1-R 5'-AGTTCTGGCTAAATTCGTAATGTTTTC-3' 
CDR2-F 5'-TAGTCCATTCAACGGCAACAAT-3' 
CDR2-R 5'-CACCCAGTATTTGGCATTGAAA-3' 
BMR1-F  5'-ACATAAATACTTTGCCCATCCAGAA-3' 
BMR1-R 5'-AAGAGTTGGTTTGTAATCGGCTAAA-3' 
UPC2 mutant 
construction 
UPC2-A 5'-GGGCCCGAGATCTTGATGTCATTAG-3' 
UPC2-B 5'-CTCGAGCTATATCTTCAATGAACTG-3' 
UPC2-E 5'-CTCGAGCACCACAGTAACGAATCAC-3' 
UPC2-C 5'-CCGCGGACAGGTCAATACCGCGTAG-3' 
UPC2-D 5'-GAGCTCGTTCCTCTAGTATCACTCTT-3' 
UPC2 sequencing 
UPC2seqA 5'-CTGCAGAGAATCACAGTGAAGTTC-3' 
UPC2seqB 5'-CTCAGCCGGTGATTCCTCCA-3' 
UPC2seqC 5'-CGGTCAAACCTCAATATGCTTGAC-3' 
UPC2seqD 5'-GTTTCCAGTGCTTTTGGACTCTCC-3' 
UPC2seqZ 5'-CCTATCATCTACGCGGTATTGACC-3' 
UPC2seqF 5'-TGGAGGAATCACCGGCTGAG-3' 
UPC2seqG 5'-GTCAAGCATATTGAGATTTGACCG-3' 
UPC2seqH 5'-GGAGAGTCCAAAAGCACTGGAAAC-3' 
                                                                                                                          
Underlined sequence reflects the introduction of a restriction site sequence. 
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PCR cloning kit (Invitrogen) and transferred into Escherichia coli TOP10 cells with 
selection on LB agar plates containing 50 µg/ml kanamycin. Plasmid DNA was purified 
(QIAprep; Qiagen, Germantown, MD) and sequenced on an ABI model 3130XL genetic 
analyzer using the UPC2 sequencing primers (Table 2.2), resulting in a full-length 
sequence from both strands of the C. albicans UPC2 gene. The sequencing was 
performed using six sets of clones derived from three independent PCRs for each 
strain/isolate sequenced. 
 
Sequenced plasmids containing the UPC2 open reading frame (ORF) whose predicted 
translation indicated an amino acid substitution were digested with restriction enzymes 
ApaI and XhoI, which excised the fulllength ORF from the plasmid, and the UPC2 
alleles were cloned upstream of the SAT1-flipper cassette into the ApaI and XhoI sites of 
plasmid pSFS2 (25). The UPC2 downstream segments were amplified with Ex Taq 
(TaKaRa) using primers UPC2C and UPC2D and cloned downstream of the SAT1-flipper 
cassette in pSFS2 using the SacI and SacII sites. This process generated plasmids 
pUPC2-G648S, pUPC2-M597I, pUPC2- G304R, pUPC2-A643V, pUPC2-Y642F, and 
pUPC2-A646V. 
 
 
Construction of UPC2 allele strains 
 
C. albicans strains UPC2M4A (7) and SC5314 were transformed by electroporation 
with gel-purified inserts from plasmids pUPC2-G648S, pUPC2-M597I, pUPC2-G304R, 
pUPC2-A643V, pUPC2-Y642F, pUPC2-W467C, and pUPC2-A646V derived from the 
plasmid pSFS2. pSFS2 contains the SAT1-flipper disruption cassette developed by Reuss 
et al. (156), consisting of the SAT1 selectable marker which confers resistance to 
nourseothricin and the FLP flipper recombinase gene, both flanked by FRT sites (flipper 
recombinase target sequences). Nourseothricin-resistant transformants were selected as 
previously described (156). Upon induction of the FLP gene, the cassette is excised such 
that only the UPC2 allele with a downstream FRT is left in the UPC2 locus. Integration 
of constructs was confirmed by Southern hybridization. 
 
 
Fluconazole susceptibility testing 
 
MICs were obtained by using a modified CLSI protocol outlined in CLSI document 
M27-A3 using RPMI or YPD medium. Overnight cultures grown at 30°C were streaked 
onto Sabouraud’s agar. Plated cultures were grown for 24 h at 30°C. Individual colonies 
were suspended in sterile water until anOD600 of 0.1 was reached. The working colony 
concentration was made by making a 1:50 dilution and a 1:20 dilution sequentially in 
medium. Aliquots of 100 µl from the working stock were used to inoculate a series of 
fluconazole-YPD medium dilutions, the highest being 64 µg/ml. Similar procedures were 
used for terbinafine and amphotericin B dilutions; however, the highest concentration 
used for these agents was 8 µg/ml. Cultures were incubated at 35°C for 48 h, and MICs 
were recorded. Azole MICs for constructed strains were obtained by Etest (bioMérieux) 
following the manufacturer’s instructions. Briefly, yeast cultures were grown in YPD 
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broth medium overnight at 30°C in a shaking incubator and plated to Sabouraud dextrose 
agar at 18 h. Isolated colonies were then selected from these plated cultures, suspended in 
deionized water to achieve 0.5 McFarland turbidity, and streaked evenly across YPD 
plates by rotating 90° in three directions. Etest strips were then applied to the inoculated 
agar surface, and MICs were read at both 24 and 48 h. 
 
 
Ergosterol quantification analysis 
 
Ergosterol was extracted and quantified as described previously (100). Briefly, a 
single colony of C. albicans from a freshYPDplate was used to inoculate 50 ml of RPMI 
1640 plus 2% glucose (Sigma, St. Louis, MO) and incubated for 16 h with shaking at 
35°C. Stationary-phase cells were collected by centrifugation for 5 min at 2,700 rpm and 
washed twice with sterile distilled water. The net weight of the pellet was determined. To 
each pellet, 3 ml of 25% alcoholic potassium hydroxide solution (25 g of KOH, 35 ml of 
sterile distilled water, with final volume adjusted to 100 ml with 100% ethanol) was 
added, and then the pellet was vortexed for 1 min. Cell suspensions were transferred to a 
sterile borosilicate glass screw-cap tube and incubated at 85°C for 1 h. Sterols were then 
extracted from cooled tubes by the addition of a mixture of 3 ml n-heptane and 1 ml 
sterile distilled water followed by vortexing for 3 min. The heptane layer was transferred 
to a clean sterile borosilicate glass tube and stored at 20°C for up to 24 h.A100-µl amount 
of the sterol-heptane mixture was scanned spectrophotometrically between 240 nm and 
300 nm with a DU530 life science UV spectrophotometer (Beckman Coulter, La Brea, 
CA). The presence of ergosterol in the extracted sample resulted in a characteristic four-
peaked curve. The absence of detectible ergosterol was indicated by a flat line. All 
samples were blanked to n-heptane. A decrease in the height of the absorbance peaks 
correlates to a decrease in ergosterol content. Statistical significance was determined by 
using Student’s t test (P < 0.05).  
 
 
Transcriptional profiling 
 
Gene expression profiles were obtained by hybridizing labeled cRNAs generated 
from C. albicans total RNA onto Affymetrix C. albicans custom expression arrays 
(CAN07, 49-5241 array format), which have been described previously (127). Total RNA 
was isolated as described earlier and subsequent cRNA synthesis/labeling, as well as 
probe hybridization, array scanning, and data analysis, were performed as previously 
described (127). 
 
Among direct comparisons between strains, genes were considered to be 
differentially expressed if their change in expression was at least 1.5-fold greater (for 
upregulated genes) or at least 1.5-fold less (for downregulated genes) in both independent 
experiments of each comparison. Cells that were empty were called “absent” by the 
Affymetrix criteria for the corresponding comparison/experiment, and thus, their 
expression values were not valid. Examination of gene ontology (GO) classification 
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enrichment of microarray data was performed using the CGD gene ontology term finder 
(http://www.candidagenome.org/cgi-bin/GO/goTermFinder). 
 
 
Accession numbers 
 
The coding sequences of the UPC2 alleles described in this study have been 
deposited in GenBank with the following accession numbers: JX494823, JX494820, 
JX494821, JX494822, JX494818, JX494819, JX494816, JX494817, JX494824, and 
JX494825. Data files for each scanned Affymetrix microarray chip were submitted to the 
Gene Expression Omnibus database (Chalfont, United Kingdom) and given the accession 
number GSE39201. 
 
 
RESULTS 
 
 
Expression of ERG11, CDR1, CDR2, and MDR1 in 62 fluconazole-resistant clinical 
isolates of C. albicans 
 
In order to examine the prevalence of and identify possible UPC2 GOF mutations, I 
obtained a collection of 72 clinical C. albicans isolates from the laboratory of Daniel 
Diekema (University of Iowa). All isolates were unrelated, and they were collected from 
both oral and nonoral sources, including blood, tissue, and abdominal fluid (see 
Appendix A table). Fluconazole susceptibilities were confirmed in our laboratory. I 
defined all isolates with a MIC of ≥16 µg/ml as having resistance to fluconazole for the 
purpose of this study. From our collection of 72 isolates, 9 were classified as fluconazole 
susceptible, while the remaining isolates were resistant. We then measured the levels of 
expression of ERG11, CDR1, CDR2, and MDR1 for all isolates in order to determine the 
relative prevalence of overexpression of genes indicative of specific mechanisms of azole 
resistance (Figure 2.1). I defined overexpression as an increase in expression of at least 
2-fold. I observed that 77% (n = 49) of resistant isolates overexpressed both CDR1 and 
CDR2. MDR1 overexpression was increased by at least 2-fold in 76% (n = 48) of 
resistant isolates, but only 21% (n = 13) expressed MDR1 at levels consistent with the 
levels observed in isolates with MDR1-mediated fluconazole resistance, in which MDR1 
expression is substantially increased. For example, in a study by Morschhäuser et al., the 
clinical isolates examined exhibited 400- to 1,200-fold increases in MDR1 
expression.(127) Surprisingly, ERG11 was found to be overexpressed in 75% (n =47) of 
fluconazole-resistant isolates in this collection.  
 
 
Most but not all isolates that overexpress ERG11 carry a GOF mutation in UPC2 
 
Twenty-nine of the 47 isolates that overexpressed ERG11 possessed one or both 
UPC2 alleles with a mutation that resulted in a predicted amino acid substitution. 
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Figure 2.1. Expression levels of CDR1, CDR2, MDR1, and ERG11 in 63 
fluconazole-resistant clinical isolates. 
All gene expression levels were measured by qRT-PCR in triplicate, and fold expression 
of genes in resistant isolates was compared to the average of the expression levels in 
three susceptible isolates.Results for 63 isolates with reduced susceptibility to 
fluconazole are represented, but only even-numbered isolates’ results are labeled. Error 
bars show standard errors. 
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Although many silent mutations were observed in the UPC2 alleles tested, eight distinct 
single UPC2 mutations were also recovered, three of which had been described  
previously: G648D, A643T, and A643V (Table 2.3). Eighteen clinical isolates were 
found to overexpress ERG11 yet contained no amino acid substitution in Upc2. These 
data suggest an alternate mechanism of activating ERG11 expression in these isolates. 
 
 
GOF mutations in UPC2 result in increased expression of ERG11 
 
In order to assess the contribution of each individual mutant UPC2 allele to 
fluconazole resistance, I expressed each mutant allele alone, with the other UPC2 allele 
disrupted (data not shown), as a heterozygote with a wild-type UPC2 allele, and as a 
homozygote. ERG11 mRNA abundance was measured by qRT-PCR (Figure 2.2). The 
homozygous null upc2Δ strain showed a significant decrease in ERG11 expression 
compared to that of its parental wild-type strain. Seven of the eight mutations tested 
resulted in increased ERG11 expression, with the strongest expression observed among 
homozygous strains. Interestingly, different mutations elicited different levels of ERG11 
expression, with the G648D substitution resulting in the highest level of expression. 
 
 
GOF mutations inUPC2 result in elevated cellular ergosterol content 
 
In order to confirm that activation of Upc2 results in a global increase of ergosterol 
biosynthesis, I compared the cellular ergosterol content in the wild type to the amounts in 
derivatives that were heterozygous or homozygous for various UPC2 mutations. I found 
that strains carrying UPC2 GOF alleles generally contained larger amounts of ergosterol 
than the wild-type strain (Figure 2.3). For many isolates, increased ergosterol levels 
correlated with the increased ERG11 transcript levels resulting from each individual 
UPC2 mutation; however, this was not the case for the A643V allele, which resulted in 
strong ERG11 expression but a nonsignificant increase in cellular ergosterol content. 
UPC2 alleles containing the G648D, W478C, and Y642F amino acid substitutions 
showed statistically significant increases in ergosterol content relative to the amount in 
the wild-type strain, while strains carrying other UPC2 GOF alleles trended toward larger 
amounts of cellular ergosterol. 
 
 
GOF mutations in UPC2 influence susceptibility to antifungals 
 
To examine the impact of distinct UPC2 mutations on antifungal resistance, I 
determined the susceptibilities of strains constructed to carry mutant UPC2 alleles to a 
panel of antifungals (Table 2.4). Included in this panel were agents in the azole class 
(fluconazole, itraconazole, and voriconazole). Also included were terbinafine, which 
inhibits another ergosterol biosynthesis enzyme (squalene epoxidase), and amphotericin 
B, which targets ergosterol in the fungal cell membrane. All strains constructed were 
compared to the background strain, strain SC5314, and the upc2Δ/upc2Δ strain  
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Table 2.3. Occurrence of Upc2 amino acid substitutions in predicted translated sequence in fluconazole 
resistant clinical ERG11-overexpressing isolates. 
 
   Expression of efflux transporter genesa 
Upc2 
substitution Isolate Genotype 
Fluconazole 
MIC 
(µg/mL) 
ERG11 
(±SE) 
CDR1 
(±SE) 
CDR2  
(±SE) 
MDR1  
(±SE) 
G648D 21 Heterozygous 32 6.2 (±0.2) 14.7 (±5.5) 883.3 (±301.9) 10.4 (±3.1) 
38 Heterozygous 64 3.8 (±0.3) 3.9 (±0.7) 111.0 (±57.1) 1.4 (±0.2) 
47 Heterozygous 128 7.9 (±1.2) 11.8 (±5.1) 327.0 (±166.3) 8.2 (±3.1) 
52 Heterozygous 256 3.7 (±1.4) 1.2 (±0.3) 17.1 (±3.2) 0.3 (±0.1) 
59 Heterozygous >256 7.2 (±1.0) 6.5 (±0.3) 48.5 (±0.3) 8.0 (±0.2) 
71 Heterozygous >256 9.4 (±1.1) 5.6 (±1.9) 149.8 (±56.5) 4.6 (±1.8) 
G648S 25 Heterozygous 64 3.6 (±0.6) 1.1 (±0.5) 2.8 (±1.1) 160.5 (±78.9) 
35 Heterozygous >256 4.4 (±1.3) 1.2 (±0.4) 0.7 (±0.3) 79.9 (±22.8) 
55 Homozygous >256 2.6 (±0.6) 1.7 (±1.5) 26.2 (±17.4) 0.9 (±3.2) 
56 Homozygous >256 2.1 (±1.0) 8.0 (±3.1) 167.8 (±94.0) 2.5 (±0.9) 
57 Homozygous >256 19.4 (±12.4) 10.2 (±3.5) 263.3 (±106.0) 12.9 (±5.2) 
58 Homozygous >256 6.6 (±1.5) 9.7 (±4.2) 226.6 (±131.7) 3.8 (±1.2) 
65 Heterozygous >256 4.2 (±0.3) 9.8 (±1.5) 294.9 (±128.4) 2.4 (±0.1) 
67 Heterozygous >256 4.7 (±0.7) 7.4 (±2.8) 105.1 (±43.3) 1.2 (±0.5) 
69 Heterozygous >256 5.6 (±0.9) 7.2 (±0.5) 136.8 (±69.3) 1.4 (±0.5) 
A643T 13 Homozygous 16 2.4 (±1.1) 6.4 (±2.9) 185.9 (±80.9) 2.4 (1.6) 
A643V 30 Heterozygous 64 4.6 (±1.6) 1.4 (±0.3) 18.0 (±15.7) 18.9 (±16.7) 
68 Heterozygous >256 4.9 (±0.4) 6.3 (±2.2) 64.5 (±31.8) 216.3 (±98.9) 
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Table 2.3.      Continued. 
 
    Expression of efflux transporter genesa 
Upc2 
substitution Isolate Genotype 
Fluconazole 
MIC 
(µg/mL) ERG11 (±SE) CDR1 (±SE) CDR2 (±SE) MDR1 (±SE) 
A646V 45 Heterozygous 128 3.5 (±0.3) 4.8 (±0.3) 147.8 (±71.7) 15.5(±7.7) 
67 Heterozygous >256 4.7 (±0.7) 7.4 (±2.8) 105.1 (±43.3) 1.2 (±0.5) 
Y642F 33 Homozygous 36 12.6 (±1.8) 6.8 (±2.0) 201.5 (±129.0) 1.5 (±0.5) 
34 Homozygous 37 7.5 (±0.6) 5.4 (2.5) 126.8 (±62.6) 1.2 (±0.5) 
W478C 15 Heterozygous 16 8.1 (±2.7) 15.9 (±3.8) 
1415.1 
(±400.1) 4.0 (±3.0) 
27 Heterozygous 64 6.2 (±2.8) 14.2 (±4.7) 629.7 (±255.3) 1.1 (±0.1) 
28 Heterozygous 64 18.1 (±7.3) 18.1 (±6.3) 
1439.7 
(±570.8) 23.2 (±20.6) 
G304R 18 Heterozygous 32 5.6 (±1.2) 10.4 (±2.4) 575.0 (±117.2) 1.0 (±0.3) 
  19 Heterozygous 32 5.2 (±1.4) 10.0 (±4.8) 401.3 (±204.5) 4.6 (±3.0) 
 
aq-RT-PCR was performed in triplicate. (SE) is calculated standard error.  
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Figure 2.2. ERG11 transcription levels in strains carrying mutant UPC2 alleles 
are represented as averages from three independent qRT-PCR assays. 
Error bars show standard errors. ERG11 expression was quantified for each mutant strain 
listed and is compared to that of wild-type strain SC5314. 
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Figure 2.3. Ergosterol quantification in C. albicans laboratory strains expressing 
mutant UPC2 alleles.  
Increased ergosterol content was shown for strains expressing 2 UPC2 mutant alleles 
compared to the expression levels in heterozygote and wild-type strains. The heptane 
extraction layer from 16-h cultures was scanned spectrophotometrically between 240 and 
300 nm. The presence of ergosterol in an extracted sample resulted in a 4-peak curve. A 
decrease in absorbance peaks correlates to a decrease in ergosterol content. Each panel 
represents the results for a different Upc2 GOF mutation, as follows: G648S (A), A643V 
(B), Y642F (C), G648D (D), A646V (E), A643T (F), W478C (G), and G304R (H).UPC2 
mutant alleles were expressed as homozygotes with the same GOF mutation (○) or as 
heterozygotes with the wild-type allele (▲). Their absorbencies were compared to those 
of the wild-type strain SC5314 (●). The results for the homozygous revertants shown in 
panels C, D, and G showed statistically significant greater ergosterol contents than were 
found in the wild type (P < 0.05).  
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Table 2.4. MICs of strains expressing UPC2 mutant alleles to a panel of antifungals in YPD. 
 
FCZ (μg/mL) ICZ (μg/mL) VCZ (μg/mL) TBF (μg/mL) AMB (μg/mL) 
Strain  Relevant genotype 24hr  48hr 24hr 48hr  24hr 48hr  24hr 48hr 24hr 48hr 
SC5314 UPC2-1/ UPC2-2 0.5 4 0.016 0.023 0.008 0.032 0.5 2 0.0313 0.125 
UPC2M4A upc2-1Δ::FRT/upc2-2Δ::FRT 0.023 0.032 0.002 0.004 0.002 0.002 0.016 0.016 0.0313 0.5 
UPC2M2K21A UPC2-1S1-1-caSAT1/upc2-2Δ::FRT 0.25 1.5 0.012 0.023 0.004 0.008 0.25 1 0.0313 0.25 
11A8A2A UPC2G648S::FRT/UPC2G648S::FRT 4 >256' 0.5 0.75 0.25 >32' 2 4 0.016 0.125 
SC11A1A UPC2/UPC2G648S::FRT 1 >256' 0.032 0.19 0.047 >32' 2 4 0.0625 0.25 
28A7A10A UPC2A643V::FRT/UPC2A643V::FRT 2 >256' 0.125 >32 0.25 >32' 1 4 0.016 0.125 
SC28A3A UPC2/UPC2A643V::FRT 1 2 0.023 0.047 0.047 >32' 1 2 0.0313 0.25 
YFA3A2K1 UPC2Y642F::FRT/UPC2Y642F::FRT 2 >256 0.047 0.5 0.064 >32' 1 4 0.0625 0.5 
SCYFA2A UPC2/UPC2Y642F::FRT 0.75 1 0.023 0.032 0.023 0.19 1 2 0.0313 0.25 
AVA1A16A UPC2A646V::FRT/UPC2A646V::FRT 1.5 >256 0.064 0.25 0.064 >32 1 4 0.0313 0.25 
SCAVA4 UPC2/UPC2A646V::SAT1-FLIP 0.5 1.5 0.016 0.032 0.016 0.064 1 2 0.0313 0.5 
22A1A13A UPC2G304R::FRT/UPC2G304R::FRT 0.19 0.75 0.012 0.023 0.008 0.032 1 2 0.0313 0.5 
SC22A3A UPC2/UPC2G304R::FRT 0.75 >256 0.012 0.094 0.023 >32 1 4 0.0313 0.25 
25B2D1 UPC2W478C::FRT/UPC2W478C::FRT 1 2 0.047 0.047 0.016 0.5 0.25 1 0.0313 0.25 
SC25A1 UPC2/UPC2W478C::FRT 0.5 1 0.016 0.016 0.008 0.032 0.5 1 0.016 0.125 
SCUPC2R14A UPC2G648D::FRT/UPC2G648D::FRT 8 >256' >32 >32 0.064 >32' 2 4 0.016 0.125 
SCUPC2R12A UPC2G648D::FRT/UPC2-2 1.5 >256' 0.25 >32 0.047 >32' 1 2 0.0313 0.25 
SCUPC2R34A UPC2A643T::FRT/UPC2A643T::FRT 1.5 >256' 2 >32 0.064 >32' 2 2 0.016 0.125 
SCUPC2R32A UPC2A643T::FRT/UPC2-2 2 >256' 0.016 0.032 0.012 >32' 1 2 0.016 0.125 
 
FCZ-fluconazole; ICZ- itraconazole; MCZ- miconazole; VCZ- voriconazole; TBF- terbinafine ; AMB- amphotericin B. 
Susceptibility was tested at 24 and at 48 hours. Azole MICs were determined by Etest method while terbinafine and amphotericin B determined by broth 
microdilution methods. 
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UPC2M4A. Strain UPC2M4A was highly susceptible to terbinafine, as well as all the 
azoles tested. Interestingly, this strain exhibited a 4-fold-higher MIC of amphotericin B  
than SC5314 at 48 h. Strains expressing UPC2 alleles carrying the G648D, G648S, 
A643T, A643V, Y642F, W478C, and A646V substitutions in the predicted protein 
sequence all exhibited increased resistance to fluconazole compared to that of strain 
SC5314, irrespective of the additional presence of a wild-type allele. Strains expressing 
the G304R mutant allele did not show a decrease in susceptibility beyond that of the 
wild-type, indicating that this mutation does not result in gain of function. Correlating 
with increased ERG11 expression, fluconazole susceptibility also decreased, with the 
most prominent change occurring in the homozygous strains. A similar trend was 
exhibited for the other azole agents and also for terbinafine susceptibilities. For 
amphotericin B, strains homozygous for an activated UPC2 mutant allele generally 
demonstrated a reduction in MIC at 48 h compared to that of the parental wild-type 
strain. However, all strains tested were susceptible to this agent. These results 
demonstrate that seven of the eight mutations in UPC2 confer increased resistance to 
ergosterol biosynthesis inhibitors. 
 
 
Genome-wide transcriptional-profile analysis of strains carrying activated UPC2 
alleles 
 
I identified genes whose expression is influenced by Upc2 by comparing the 
transcriptional profiles of strains that were engineered to carry one of the four GOF 
UPC2 alleles with the strongest effects on ERG11 expression. The 11A8A2A 
(UPC2G648S/UPC2G648S) constructed strain expressed 170 upregulated genes and 9 
downregulated genes compared to the expression profile of SC5314. Strain 
SCUPC2R14A (UPC2G648D/UPC2G648D) expressed 520 upregulated and 292 
downregulated genes. There were 119 genes upregulated and 81 genes downregulated for 
strain YFA3A2K1 (UPC2Y642F/ UPC2Y642F), while strain 28A7A10A 
(UPC2A643V/UPC2A643V) expressed 352 upregulated and 169 downregulated genes. There 
were 61 commonly upregulated genes and 5 commonly downregulated genes among the 
four strains carrying unique UPC2 gain-of-function alleles (Tables 2.5 and 2.6). Genes 
commonly upregulated in all four mutant strains included those involved in ergosterol 
biosynthesis and in oxidoreductase activity, the major facilitator efflux pump encoded by 
the MDR1 gene, and the uncharacterized ATP-binding cassette transporter CDR11. 
 
 
DISCUSSION 
 
In Candida albicans, it is well established that activating mutations in transcription 
factors regulating genes encoding efflux pumps mediate resistance to azole antifungals. It 
has been shown that specific mutations in the transcription factor gene TAC1 mediate the 
expression of the genes encoding ABC transporters CDR1 and CDR2, resulting in 
increased azole resistance in C. albicans (22, 23). Likewise, Mrr1 has been identified as 
the regulator of the major facilitator superfamily (MFS) transporter Mdr1 in azole-
resistant isolates, and specific mutations in this transcriptional regulator result in its  
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Table 2.5.       Genes upregulated by at least 1.5- fold in strains carrying UPC2 GOF alleles 
 
   
Change in fold expressionb 
 ?  
G648S  G648D  Y642F  A643V 
Functiona CGD ?ame Orf19 ?esignation Exp1 Exp2  Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
Lipid metabolic process ERG1 orf19.406 1.8 1.8  2.7 2.3  2.2 2.0  2.3 2.3 
 
ERG2 orf19.6026 1.7 1.5  2.3 1.9  1.9 1.9  2.1 2.0 
 
ERG24 orf19.1598 1.7 1.7  2.3 2.1  1.7 1.8  2.1 2.3 
 
ERG27 orf19.3240 1.8 2.1  3.3 3.4  2.2 2.2  3.1 3.2 
 
ERG7 orf19.1570 1.5 1.6  2.8 2.1  1.8 1.6  2.7 2.4 
 
NCP1 orf19.2672 1.6 1.7  2.6 2.0  1.7 1.9  1.9 1.9 
  
orf19.3483 2.0 2.4  5.3 4.7  2.9 2.2  3.5 3.3 
  
orf19.1881 1.5 1.6  2.4 2.2  1.5 1.5  2.4 2.1 
  
orf19.6025 2.2 2.1  3.9 5.2  3.8 3.1  5.2 5.2 
     
 
  
 
  
 
  Transcription factor activity 
 
orf19.5210 1.5 2.1  2.7 2.7  1.8 1.5  2.9 2.3 
     
 
  
 
  
 
  Transport MDR1 orf19.5604 5.9 5.5  15.1 8.0  6.6 6.1  5.9 5.7 
  
orf19.5535 1.5 1.6  2.2 2.7  1.5 1.9  2.7 3.2 
 
FRP1 orf19.5634 5.4 5.7  17.3 17.5  8.1 5.9  16.3 14.7 
 
FTH1 orf19.4802 2.6 2.6  5.3 5.2  2.3 1.9  6.6 5.2 
 
GYP1 orf19.3811 1.6 1.6  3.7 3.5  1.8 1.5  3.7 3.4 
  
orf19.2350 1.7 1.7  3.4 4.4  2.0 1.9  3.2 3.0 
 
HXT5 orf19.4384 1.8 2.1  2.6 2.0  1.8 1.5  2.3 1.7 
     
 
  
 
  
 
  Protein modification process 
 
orf19.7329 1.6 2.1  3.1 3.0  1.7 1.8  2.5 2.3 
  
orf19.6025 2.2 2.1  3.9 5.2  3.8 3.1  5.2 5.2 
  
orf19.7547 1.8 1.5  2.8 2.7  2.0 1.5  3.1 2.3 
  
orf19.2285 1.7 2.5  1.8 1.5  1.8 2.4  2.1 2.1 
     
 
  
 
  
 
  
     
 
  
 
  
 
  Biosynthetic process COQ4 orf19.3008 1.5 1.5  2.3 2.8  1.9 1.6  2.6 2.5 
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Table 2.5.      Continued. 
 
   Change in fold expressionb 
   G648S  G648D  Y642F  A643V 
Functiona CGD ?ame Orf19 ?esignation Exp1 Exp2  Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
Biosynthetic process HEM14 orf19.4747 2.1 1.6  3.6 3.0  2.2 1.8  2.9 2.3 
     
 
  
 
  
 
  
     
 
  
 
  
 
  Pathogenesis SLD1 orf19.260 1.8 1.5  2.2 1.8  1.7 1.6  2.0 1.9 
 
PHO100 orf19.4424 1.5 3.4  4.8 2.7  1.6 1.5  2.0 2.3 
 
SET3 orf19.7221 2.8 2.7  6.3 5.7  4.4 3.6  4.8 4.8 
     
 
  
 
  
 
  Metabolic process 
 
orf19.3617 1.7 1.9  1.7 2.2  1.7 1.5  1.8 1.5 
  
orf19.329 2.1 2.3  2.4 2.6  2.0 1.6  2.5 2.5 
  
orf19.4031 1.8 1.8  2.5 2.5  1.6 1.5  2.9 2.5 
  
orf19.6025 2.2 2.1  3.9 5.2  3.8 3.1  5.2 5.2 
  
orf19.1865 2.4 2.2  3.7 2.9  2.4 2.2  3.4 3.1 
  
orf19.496 2.4 2.3  4.4 3.8  2.5 2.0  3.6 3.1 
 
ARO9 orf19.1237 1.5 3.4  5.8 4.2  1.5 1.9  2.1 2.8 
 
IDP2 orf19.3733 2.2 1.6  3.3 2.8  2.6 2.0  3.2 2.5 
     
 
  
 
  
 
  Response to stress DDR48 orf19.4082 2.2 4.3  5.8 4.7  2.7 2.9  3.4 4.3 
 
FMA1 orf19.6837 1.8 3.2  2.7 5.3  1.5 3.3  1.7 3.0 
 
YMX6 orf19.5713 1.6 2.6  2.9 2.0  1.6 1.6  1.7 1.8 
  
orf19.288 1.8 1.5  3.0 2.5  2.1 1.5  2.5 2.0 
     
 
  
 
  
 
  Biological activity unknown TEF4 orf19.2652 16.4 16.6  55.8 90.2  29.9 32.7  65.5 67.8 
  
orf19.3627 4.0 1.9  7.0 4.0  4.4 1.9  5.1 1.9 
 
PGA7 orf19.5635 2.3 3.7  5.7 7.4  2.7 3.8  4.8 6.1 
 
BUL1 orf19.5094 1.9 1.9  4.1 3.1  2.5 1.8  2.1 1.9 
 
PGA45 orf19.2451 1.7 1.5  2.1 2.2  1.7 1.9  2.0 2.3 
  
orf19.344 5.1 6.2  20.2 16.2  7.2 6.6  9.6 9.0 
  
orf19.5777 1.7 2.4  4.8 3.8  1.9 1.5  3.1 2.5 
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Table 2.5.      Continued. 
 
   Change in fold expressionb 
   G648S  G648D  Y642F  A643V 
Functiona CGD ?ame Orf19 ?esignation Exp1 Exp2  Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
Biological activity unknown 
 
orf19.5799 1.7 2.0  3.4 2.4  1.5 1.5  2.4 2.6 
  
orf19.7456 1.7 2.6  4.4 4.1  2.2 2.1  3.9 3.5 
  
orf19.7043 2.5 1.9  5.2 3.6  2.8 2.3  4.9 3.0 
  
orf19.4013 2.6 2.2  4.2 3.5  3.1 2.8  4.8 3.8 
  
orf19.4014 1.5 2.1  2.3 2.4  1.7 1.6  2.6 2.6 
  
orf19.6840 2.0 2.1  4.1 4.4  2.6 2.4  3.1 2.6 
  
orf19.286 2.1 2.5  2.3 2.2  1.9 1.9  3.5 1.9 
  
orf19.7504 2.1 1.8  3.0 3.3  1.9 2.0  2.2 2.1 
  
orf19.3737 1.6 1.9  2.9 3.4  2.0 1.8  3.1 2.6 
  
orf19.1964 2.0 1.8  2.5 2.2  1.7 1.6  2.2 1.6 
  
orf19.1800 2.3 2.2  4.6 3.9  2.5 2.2  4.5 3.4 
  
orf19.7263 1.8 1.9  2.9 2.8  1.6 1.7  2.1 1.9 
  
orf19.2496 1.7 1.8  2.6 2.5  1.8 1.7  2.0 1.5 
  ATO9 orf19.3261 1.8 2.2  2.7 3.4  1.6 2.3  4.5 4.5 
 
aDescriptions of gene from the Candida Genome Database (http://www.candidagenome.org).  
b Fold change defined as the average ratio of gene expression levels in the isolates compared in two independent microarray experiments. 
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Table 2.6. Genes downregulated by at least 1.5-fold in strains carrying UPC2 GOF alleles. 
 
 
   
Change in fold expressionb 
  
G648S  G648D  Y642F  A643V 
Functiona CGD ?ame Orf19 ?esignation Exp1 Exp2  Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
Transport HGT10 orf19.5753 0.6 0.5  0.2 0.2  0.5 0.6  0.2 0.3 
              
Pathogenesis SAP7 orf19.756 0.4 0.4  0.3 0.2  0.4 0.4  0.3 0.4 
              
Biological activity 
 unknown 
 
orf19.716 0.4 0.5 
 
0.4 0.4 
 
0.6 0.6 
 
0.4 0.4 
  
orf19.3621 0.3 0.5  0.3 0.3  0.6 0.4  0.5 0.5 
   orf19.4873 0.4 0.5  0.6 0.5  0.6 0.6  0.6 0.6 
 
aDescriptions of gene from the Candida Genome Database (http://www.candidagenome.org).  
bFold change defined as the average ratio of gene expression levels in the isolates compared in two independent microarray experiments. 
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constitutive activation, leading to the overexpression of Mdr1 (43, 127). Fluconazole-
resistant isolates that overexpress MDR1 have become homozygous for the mutated 
MRR1 allele and work in a semidominant fashion if expressed with a wild-type allele 
(43). Overexpression of these transporters is known to occur among azole-resistant 
clinical isolates and contributes significantly to this process.  
 
Considerably less is known about the prevalence of constitutive ERG11 
overexpression and its clinical impact on azole resistance. ERG11 encodes the azole 
target, lanosterol demethylase, a key enzyme in the ergosterol biosynthesis pathway. 
ERG11 is transcriptionally regulated by the zinc cluster transcription factor Upc2. In C. 
albicans, Upc2 is orthologous to two transcription factors in Saccharomyces cerevisiae, 
Upc2 and Ecm22, which regulate ergosterol biosynthesis and uptake of exogenous sterols 
(28, 34). The expression of these genes is affected by sterol depletion, but the exact 
mechanism of activation is currently unknown. Previous work in S. cerevisiae shows that 
ScUpc2 and ScEcm22 are localized to intracellular membranes outside the nucleus, and 
under sterol-depleting conditions, perinuclear localization is increased (115). Gain-of-
function mutations in the activation domain located near the C terminus have been 
recovered from both ScUpc2 and ScEcm22; however, mediation of ERG11 expression 
during hypoxic conditions or when chemically treated with azole antifungals is mediated 
by ScUpc2 (34). 
 
In C. albicans, only three mutations that increase the expression of ERG11 and result 
in decreased susceptibility to fluconazole have been described in Upc2. In the present 
study, I examined a large collection of unrelated azole-resistant C. albicans clinical 
isolates for possible UPC2 GOF mutations. As fluconazole resistance in C. albicans has 
most often been associated with OPC, the opportunity to examine resistant isolates 
cultured from both oral and nonoral sources was somewhat unique. Among the isolates 
studied here were 16 documented nonoral isolates, 12 of which were observed to exhibit 
reduced susceptibilities to fluconazole. Although our analysis cannot define the clinical 
implications for this observation, these data underscore that fluconazole resistance 
extends beyond oral manifestations of candidiasis. 
 
I further delineated the mechanisms of resistance in these isolates by determining the 
relative levels of expression of CDR1, CDR2, MDR1, and ERG11. Not surprisingly, 
CDR1 and CDR2 overexpression was generally coordinately regulated and quite 
prevalent among these isolates. Of those isolates that did overexpress MDR1, even fewer 
isolates expressed MDR1 to the levels previously observed in azole-resistant isolates 
(127). ERG11 was found to be upregulated in almost three-fourths of the fluconazole-
resistant isolates examined. This suggests that ERG11 overexpression is a common 
contributor to fluconazole resistance in C. albicans. 
 
Among the independent azole-resistant, ERG11-overexpressing isolates studied here, 
I repeatedly recovered eight distinct single-nucleotide substitutions in UPC2, of which 
the G648S substitution occurred in nine isolates and the G648D substitution occurred in 
six isolates. Five of these substitutions in UPC2 have not been described previously. Of 
the five novel mutations, four mutations resulted in increased ERG11 expression and 
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increased resistance to fluconazole but to various degrees. I observed that the 
homozygous strain carrying the G304R UPC2 allele was more susceptible to azoles than 
the strain carrying the G304R substitution heterozygously; however, neither strain 
resulted in any decrease in antifungal susceptibility or increase in ERG11 expression. As 
has been previously observed in UPC2 GOF mutations, amino acid substitutions resulting 
from activating mutations were localized near the C terminus, where the activation 
domain of zinc-cluster transcription factors is found (109). Mutations in this region of the 
protein are theorized to work by one of two mechanisms: (i) mutations in this domain 
could relieve the transcription factor from a repressor that would otherwise keep Upc2 
inactive in the absence of an activating signal or (ii) a mutation in this area could interfere 
with the transmembrane region of the protein, causing localization to the nucleus and 
constitutive activation of its target promoters.  
 
In total, seven of the eight Upc2 mutations observed resulted in increased expression 
of ERG11, but each mutation increased transcription to a different degree. For many 
strains, increased expression of ERG11 was directly correlated with the amount of 
ergosterol within the fungal cell, and this trend was also observed in the decreased azole 
susceptibility seen in strains that overexpressed ERG11. Unlike TAC1 GOF mutations, 
UPC2 GOF mutations were found to occur with a wild-type allele in many isolates. I 
observed that strains constructed to express two mutant alleles had increased levels of 
ERG11 expression and decreased levels of azole susceptibility compared to the levels in 
strains containing both an activated Upc2 and a wild-type allele. As seen with TAC1 or 
MRR1 mutations, a loss-of-heterozygosity event that results in two GOF alleles, either by 
a mitotic recombination event between homologous chromosomes or by a loss of a 
chromosome combined with a duplication of the homologous chromosome, would 
provide an advantage when challenged with antifungals (22, 127). Interestingly, I saw an 
opposite trend in the amphotericin B susceptibility of strains expressing activated UPC2 
alleles, in which UPC2 GOF homozygous strains with higher ERG11 expression had 
increased susceptibility to this agent compared to that of the heterozygous strains or the 
homozygous null upc2Δ strain. This is probably due to higher levels of cellular 
ergosterol, which is the target of amphotericin B. 
 
An important observation to note is the discrepancy between the levels of ERG11 
expression of the clinical isolate containing a UPC2 mutation and the laboratory strain 
constructed to carry the same mutant UPC2 allele. This difference may be due to 
additional levels of ERG11 regulation that are developed in a clinical isolate, such as 
alternate transcriptional regulations or alternate single-nucleotide polymorphisms that 
influence ergosterol biosynthesis. Furthermore, not all ERG11 overexpression in clinical 
isolates was a result of a GOF mutation in UPC2; therefore, it is likely that other 
regulators of ergosterol biosynthesis are contributing factors. Alternatively, instances of 
aneuploidy, specifically, chromosome 5 duplication or chr5L isochromosome formation, 
are known mechanisms of ERG11 overexpression in C. albicans (173). However, the 
ERG11 expression levels I observed in many clinical isolates in this study exceed what 
would be expected from an extra copy of ERG11 due to the presence of a chr5L 
isochromosome. It is possible that some isolates that do not carry mutations in UPC2 
actually overexpress UPC2 instead, due to a mutation in the UPC2 promoter region, gene 
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duplication, or a trans-acting mutation. Whether this has occurred is being explored in 
ongoing investigations.  
 
As azole resistance is mechanistically multifactorial in clinical isolates, I expected the 
fluconazole susceptibility of strains constructed to express specific UPC2 mutations to 
reflect the contribution of increased expression of genes of the ergosterol biosynthesis 
pathway, including ERG11, as a result of an activated UPC2 allele. In these clinical 
isolates, I have observed a high prevalence of mutations in the ERG11 gene itself (data 
not shown). It is likely that in clinical isolates, activated forms of Upc2 occur in 
conjunction with mutant ERG11 alleles and that its subsequent overexpression results in a 
combinatorial effect on azole susceptibility. The combinatorial effects of activated UPC2 
alleles and mutant ERG11 alleles on fluconazole susceptibility have not been explored.  
 
Although microarray analysis of the G648D UPC2 GOF mutation has been 
performed previously, I expanded this analysis with four of the seven strongest UPC2 
GOF mutations (G648D, G648S, Y642F, and A643V) for a more comprehensive 
examination (44). All four mutations caused the coordinate upregulation of 61 genes. As 
expected, many of the ergosterol biosynthesis genes (ERG1, ERG2, ERG7, ERG24, 
ERG26, and ERG27) were upregulated by at least 1.5-fold over their expression in 
SC5314 in two separate experiments. ERG11 was upregulated in three of the four 
laboratory strains carrying mutations G648D, Y642F, and A643V, but elevated 
transcription of ERG11 could only be detected in one of the two experiments with the 
strain carrying the G648S allele (Appendix B). Interestingly, UPC2 was not found to be 
upregulated in any of the four strains analyzed by microarray analysis, although Upc2 is 
thought to autoregulate and has been shown to bind its own promoter in experiments 
using chromatin immunoprecipitation with microarray technology (ChIP-chip) (217). 
 
Aside from genes involved in the ergosterol biosynthesis pathway, other core sets of 
target genes upregulated by Upc2 included those in the gene ontology (GO) functional 
grouping of oxidoreductase activity. Additionally, iron ion binding was a commonly 
found GO category identified by the GO term finder. Not surprisingly, MDR1 was 
overexpressed in all four strains with independent Upc2 GOF mutations; however, gene 
expression levels were not increased to those observed in fluconazole-resistant isolates 
containing an MRR1 GOF mutation. Upc2 has previously been shown to bind to the 
promoter of the drug efflux pump MDR1 but was not a cause of Mdr1-mediated drug 
resistance (169, 217). In the present study, CDR11 expression was increased in all 
independent UPC2 GOF mutations, and it increased 4.8-fold when two alleles of UPC2 
carrying the predicted G648D substitution in its translated sequence were expressed. 
Interestingly, the gene encoding an uncharacterized ABC transporter, CDR11, was 
previously shown to be upregulated by 1.5- to 3.5-fold in a laboratory strain carrying a 
single UPC2 allele containing a G648D amino acid substitution; this gene has been 
hypothesized to play a role in sterol transport, because of its similarity to sterol 
transporters in S. cerevisiae) (44). 
 
In conclusion, I found overexpression of ERG11 to be prevalent among a collection 
of clinical isolates with reduced susceptibility to fluconazole and have identified and 
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characterized novel UPC2 gain-of-function mutations that contribute to azole resistance 
in clinical isolates of C. albicans. Overexpression of ERG11 could be explained by a 
gain-of-function mutation in UPC2 in many but not all cases. Gain-of-function mutations 
led to increased resistance to azole antifungals and terbinafine, to increased cellular 
ergosterol levels, and to increased expression of genes involved in ergosterol biosynthesis 
and oxidoreductase activity, as well as the transporter genes MDR1 and CDR11. The 
mechanism by which ERG11 is upregulated in the absence of UPC2 gain-of-function 
mutations and the potential contribution of sterol uptake to Upc2-mediated azole 
resistance are under investigation.  
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CHAPTER 3.    NDT80 MUTATIONS FOUND IN CLINICAL ISOLATES 
OF CANDIDA ALBICANS DO NOT CONTRIBUTE TO AZOLE 
RESISTANCE BY ERG11 OVEREXPRESSION 
 
 
INTRODUCTION 
 
Not all ERG11 overexpression in azole-resistant isolates can be explained by GOF 
mutations in UPC2. Our lab and others have documented isolates with increased ERG11 
expression that do not carry a mutated UPC2 allele. These data suggest that there are 
alternate mechanisms of ERG11 overexpression in these isolates (50, 66). NDT80 is a 
Pho-G transcription factor that is an important in regulator of meiosis in S. cerevisiae 
(67). In C. albicans, NDT80 has been implicated in azole resistance not only due to its 
regulation of CDR1 but also due to its regulation of genes involved in the ergosterol 
biosynthesis pathway (21, 170, 171, 199). Recent ChIP-chip analysis has shown that 
NDT80 binds to the promoter region of ERG genes and also to genes involved in hyphal 
growth, the mitotic cycle and carbohydrate metabolism (171). A putative Ndt80 binding 
site has also been found in the regulatory region upstream of the UPC2 allele (73). 
Sellam and colleagues compared ERG gene expression of a strain constructed to be 
deficient for NDT80 to that of wild-type and an NDT80 revertant strain (171). The mutant 
strain deficient for NDT80 was unable to stimulate expression of ERG11 and other ERG 
genes to the extent of either the wild-type strain or the NDT80 revertant strain in response 
to fluconazole. This data indicated the potential role of NDT80 in ERG gene regulation as 
it relates to fluconazole treatment. 
 
In a previous search for UPC2 GOF mutations, genetically matched isolate pairs 945 
and 1619, and 1002 and 3795 were shown to constitutively overexpress ERG11 in the 
fluconazole-resistant respective counterpart (66). Sequence analysis performed on UPC2 
did not detect any mutations leading to amino acid substitutions in these isolates. Due to 
the possible role of NDT80 in ERG gene regulation, I hypothesized that the NDT80 allele 
expressed in the fluconazole-resistant isolates may contain activating mutations resulting 
in ERG11 overexpression and azole resistance. 
 
 
MATERIALS AND METHODS 
 
 
Strains and growth conditions 
 
C. albicans strains were cultured on YPD (1% yeast extract, 2% peptone, and 1% 
dextrose) agar plates at 30°C and stored as frozen stock in 20% glycerol at -80°C (Table 
3.1). YPD liquid medium was used for routine growth of strains.  Nourseothricin (200 
µg/ml or 25 µg/ml) was added to YPD agar plates for selection of strains containing the 
SAT1-flipper cassette. For plasmid construction and propagation, One Shot Escherichia 
coli TOP10 chemically competent cells (Invitrogen, Carlsbad, CA) were used as a host. 
These strains were grown in Luria-Bertani (LB) broth or on LB agar plates supplemented  
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Table 3.1. NDT80 strains and primers used in this study. 
 
Strains and 
primers Relevant genotype/sequence 
SC5314 Wild-type 
ScNDT80945A NDT80 allele derived from azole-susceptible isolate 
ScNDT80945B NDT80 allele derived from azole-susceptible isolate 
ScNDT801619A NDT80 allele derived from azole-resistant isolate 
ScNDT801619B NDT80 allele derived from azole-resistant isolate 
qRT-PCR 
NDT80-F 5'-CCT TTG GCT CAG CAA CA-3' 
NDT80-R 5'-GCT TGG TCT TGG TTT TGT GC-3' 
ACT1-F 5'-ACGGTGAAGAAGTTGCTGCTTTAGTT-3' 
ACT1-R 5'-CGTCGTCACCGGCAAAA-3' 
ERG11-F 5'-CCCCTATTAATTTTGTTTTCCCTAATTTAC-3' 
ERG11-R 5'-CACGTTCTCTTCTCAGTTTAATTTCTTTC-3' 
NDT80 mutant 
construction 
 
NDT80-A 5'-GGG CCC GCA CCA TCA ATT TGG AGA CC-3' 
NDT80-B 5'-ACG GCA GCT TCT TCA CTC GAG ACG TT-3' 
NDT80-C 5'-CAC TTC ATT GGG CCC GTT CAC TAG-3' 
NDT80-D 5'-GCC ACT AAG GTG TGA GCT CAA GAT CC-3' 
NDT80-E 5'-CTC GAG GAT TGG TAC ACG ACA CCT GG-3' 
NDT80 
sequencing 
NDT80seqA 5'-CAACAGAAACACCACCACCA-3' 
NDT80seqB 5'-GCTGACGCTCAATCACAAGC-3' 
NDT80seqC 5'-GAGTTGCCTGACCACGAGAC-3' 
NDT80seqD 5'-ATCAACCTTTCTTCGTCATCATC-3' 
NDT80seqE 5'-GTCCTCGTGGTCAGGCAACTC-3' 
NDT80seqF 5'-GCTTGTGATTGAGGGTCAGC-3' 
 
Underlined sequence reflects the introduction of a restriction site sequence. 
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with 50 μg/ml kanamycin (Fisher BioReagents, Fair Lawn, NJ) or 100 μg/ml ampicillin 
(Sigma) when required. 
 
 
RNA isolation 
 
RNA was isolated using a small-scale version of the hot phenol method of RNA 
isolation described by Schmitt et al. Briefly, overnight cultures were diluted to an OD600 
of 0.2 and then incubated at 30°C with shaking for an additional three or six hours to 
mid-log phase.  Cells were collected by centrifugation, resuspended in AE buffer and 
then transferred to a 2-mL microcentrifuge tube containing acid phenol (pH 4.3) with 1% 
SDS.  Cells were incubated at 65°C for 10 minutes, then lysates were clarified by 
centrifugation.  The supernatant was then transferred into a new tube containing 900 µl of 
chloroform and mixed.  The sample was then subjected to centrifugation again, and the 
top aqueous layer was transferred to a new tube containing one volume of isopropanol 
and 0.1 volume 2M sodium acetate.  The RNA pellet was subsequently washed with 500 
µl of 70% ethanol and collected by centrifugation.  The RNA pellet was resuspended in 
DNAse/RNAse-free H2O.  Quantity and purity were determined spectrophotometerically 
at absorbances of A260 and A280. 
 
 
Quantitative RT-PCR 
 
First-strand cDNAs were synthesized separately from 1 μg of total RNA in a 21-μl 
reaction volume using SuperScript first-strand synthesis system for RT-PCR (Invitrogen). 
Quantitative PCRs were performed in triplicate as technical replicates using the 7000 
sequence detection system (Applied Biosystems). PCRs were performed, independently 
amplifying 18S rRNA or ACT1 gene (normalizing genes) and the genes of interest (GOI) 
from the same cDNA, using the SYBR Green PCR master mix (Applied Biosystems). 
Gene-specific primers were designed using Primer Express software (Applied 
Biosystems) synthesized by Integrated DNA Technologies (Coralville, IA) and listed in 
Table 3.2. PCR conditions consisted of AmpiTaq Gold activation at 95°C for 10 minutes, 
followed by 40 cycles of denaturation at 95°C for 15 seconds and annealing/extension at 
60°C. The dissociation curve and detection of fluorescence of SYBR Green was 
performed by software provided with the 7000 sequence detection system. The cycle 
threshold value (CT) of the normalizing gene was subtracted from the GOI to obtain the 
ΔCT value. The ΔCT value of a calibrator was subtracted of the sample ΔCT value to 
obtain the ΔΔCT value.  Change in fold expression was obtained by calculating 2- ΔΔCT. 
Standard error was calculated from ΔCT values as previously described. 
 
 
Plasmid construction for allele sequencing 
 
 CaNDT80 coding sequences were amplified by PCR (Pfu DNA polymerase; 
Stratagene) from C. albicans genomic DNA using the primers NDT80-A and NDT80-E  
(Table 3.2). Products were cloned into pCR-BLUNTII-TOPO using a Zero Blunt TOPO  
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Table 3.2. NDT80 sequencing data from matched isolate sets 580, 2440 and 945, 1619 were compared to the 
SC5314.  
 
Isolate Allele Mutations in sequence as compared to SC5314 
580 
FCZS 
1 C72T, G240A, G247A, A249G, Deletion of CAA between bp 259-261, C783T, C804T, C735G, G741A, 
C783T, C804T, C825T, T1269C, A1398G, C1491A 
2 G243A, Deletion of CAA between bp 259-261, C783T, C804T,  C735G, G741A, C783T, C804T, 
C825T, T1269C,  C1491A 
2440 
FCZR 
1 G243A, Deletion of CAA between bp 259-261, C783T, C804T,  C735G, G741A, C783T, C804T, 
C825T, T1269C, A1328G, C1491A 
2 G243A, Deletion of CAA between bp 259-261, C783T,C804T,  C735G, G741A, C783T, C804T, C825T, 
T1269C, C1491A 
945 
FCZS 
1 A240G, A246G, A249G, Addition of 2 X CAA, A393T, G430A, A486C, C741G, G747A, C810T, 
C831T, T1276C, A1404G, C1497A 
2 A240G, A246G, Addition of 1X CAA, C741G, G747A, T1276C 
1619 
FCZR 
1 A240G, A246G, A249G, Addition of 2 X CAA, A393T, G430A, A486C, C741G, G747A, C810T, 
C831T, T1276C, A1404G, C1497A 
2 A240G, A246G, A249G,  Addition of 2 X CAA, A393T, G430A , A486C, C741G, G747A, C810T, 
C831T, T1276C, A1404G, C1497A 
 
Bolded mutations lead to amino acid substitutions. The G340A leads to A145T a.a. substitution. The A486C mutation leads to 
a Q162H aa substitution.  The A1328G mutations lead to a Y444C a.a. substitution. Shaded boxes defines NDT80 sequence of 
the second allele for each clinical isolate. 
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PCR Cloning Cloning Kit (Invitrogen) and transferred into Escherichia coli TOP10 cells 
with selection on LB agar plates containing 50 μg/ml kanamycin.  Plasmid DNA was 
purified (QIAprep; Qiagen; Germantown, MD) and sequenced on an ABI Model 3130XL 
Genetic Analyzer using the NDT80 sequencing primers (Table 3.2), resulting in full-
length sequence from both strands of the CaNDT80 gene. The sequencing was performed 
using six sets of clones derived from three independent PCRs for each strain/isolate 
sequenced. 
 
Sequenced plasmids of the ERG11 orf whose predicted translation indicated an amino 
acid substitution were digested with restriction enzymes ApaI and XhoI, which excised 
the full-length orf from the   plasmid, and the ERG11 alleles were cloned upstream of the 
SAT1-flipper cassette into the ApaI and XhoI sites of plasmid pSFS2. The NDT80 
downstream segments were amplified with ExTaq (Takara) using primers NDT80C and 
NDT80D and cloned downstream of the SAT1-flipper cassette in pSFS2 using the Sac1 
and SacII sites. This process generated plasmids pNDT80945 and pNDT801619. 
 
 
Construction of NDT80 allele strains 
 
C. albicans strain SC5314 were transformed by electroporation with gel purified 
inserts from plasmids derived from the plasmid pSFS2. Plasmid (p)SFS2 contains the 
SAT1-flipper disruption cassette developed by Reuss et al (156)., consisting of the SAT1 
selectable marker which confers resistance to nourseothricin and the FLP flipper 
recombinase gene both flanked by FRT sites (flipper recombinase target sequences). 
Nourseothricin-resistant transformants were selected as previously described (156). Upon 
induction of the FLP gene, the cassette is excised such that only the NDT80 allele with a 
downstream FRT is left in the NDT80 locus. Integration of constructs was confirmed by 
Southern hybridization.  
 
 
Fluconazole susceptibility testing 
 
Minimum inhibitory concentrations (MICs) were obtained by using a modified CLSI 
protocol outlined in M27-A2 using RPMI. Overnight cultures grown at 30°C were 
streaked onto Sabouraud’s agar.  Plated cultures were grown for 24 hours at 30°C. 
Individual colonies were suspended in sterile water until the optical density at 600 nm of 
0.1 was reached.  The working colony concentration was made by making a 1:50 dilution 
and a 1:20 dilution sequentially in media.  100 µl from the working stock was used to 
inoculate a series of fluconazole/YPD media dilutions, the highest being 64 µg/ml.  
Cultures were incubated at 35°C for 48 hours and MICs were recorded.   
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RESULTS 
 
 
Sequencing NDT80 of matched isolate sets 945/1619 and 1002/3795 revealed 
multiple single nucleotide polymorphisms and a loss of heterozygosity event in the 
NDT80 alleles of the resistant isolate 
 
NDT80 in both matched isolate sets, the NDT80 allele was sequenced for both the 
susceptible and resistant isolates (Table 3.2). In both matched pairs, the allele expressed 
in the resistant isolate contained mutations that result in amino acid substitutions within 
Ndt80 when compared to the strain published in the Candida Genome Database 
(http://www.candidagenome.org/) and also when compared with the respective 
susceptible isolate. Additionally, sequencing of both matched sets show that in the 
resistant isolate, a loss of heterozygosity event had occurred so that the resistant 
counterpart was homozygous for one allele. 
 
 
Mutations observed in NDT80 of resistant isolates do not result in fluconazole 
resistance or increased ERG11 expression 
 
In the fluconazole-susceptible isolate SC5314, a series of strains were constructed to 
test the role of mutant NDT80 alleles derived from clinical isolates on fluconazole 
resistance and ERG11 expression. For these experiments I used the matched isolate set 
945 and 1619 as the resistant isolate 1619 had the greatest expression of ERG11 (66). 
Fluconazole-susceptible isolate 945 was heterozygous for NDT80, containing two 
different alleles of NDT80, one of which was expressed homozygously in the resistant 
isolate 1619. In constructed strains, each allele was expressed homozygously in isolate 
SC5314 (Figure 3.1). Additionally, a strain disrupted for NDT80 was also constructed for 
MIC comparison. When compared to SC5314, neither strain constructed to carry the 
NDT80 allele observed in the susceptible or the resistant isolate resulted in increased 
resistance to fluconazole or increased ERG11 expression. I observed a two-fold decrease 
in fluconazole MIC in the strain in which NDT80 was disrupted (data not shown). 
 
 
DISCUSSION 
 
 In C. albicans, GOF mutations in zinc-cluster transcription factors resulting in 
increased expression of genes involved in azole resistance are well documented. As these 
mutations in Tac1, Mrr1 and Upc2 all contribute to azole resistance by distinct 
mechanisms, Ndt80 has been implicated in the regulation of ABC efflux-transporters 
CDR1 and CDR2 in addition to ergosterol biosynthesis genes. Due to this global 
association of NDT80 with azole resistance, I hypothesized that fluconazole-resistant 
isolates that overexpress ERG11 independent of UPC2 GOF mutations may contain 
mutations in NDT80 that resulted in an azole-resistant phenotype. 
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Figure 3.1. ERG11 expression of strains constructed to carry NDT80 alleles 
derived from clinically matched isolates 945 and 1619.  
ERG11 expression was measured in triplicate by qRT-PCR and fluconazole MICs were 
tested for strains expressing NDT80 alleles derived from fluconazole-susceptible isolate 
945 or fluconazole-resistant isolate 1619. 
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Previous work shows that specific mutations in the transcription factor gene TAC1 
regulate expression of the genes encoding ABC transporters CDR1 and CDR2. Mrr1 
mediates expression of the major facilitator superfamily (MFS) transporter Mdr1 in 
azole-resistant isolates, and specific mutations in this transcriptional regulator result in its 
constitutive activation, leading to the overexpression of Mdr1. Fluconazole-resistant 
isolates that overexpress MDR1 have become homozygous for the mutated MRR1 allele 
and work in a semidominant fashion if expressed with a wild-type allele. Loss of 
heterozygosity in TAC1 GOF mutations has also been observed in fluconazole-resistant 
isolates which overexpress CDR1 and CDR2. In this study, matched isolate sets exhibited 
a similar loss of heterozygosity of NDT80 alleles in the resistant counterpart, however, 
neither allele resulted in overexpression of ERG11 when expressed in SC5314. 
 
Since the completion of this study, the role of C. albicans NDT80 in drug resistance 
has been further explored. In this work, NDT80 has been shown to be dispensable to the 
upregulation of both MDR1, CDR1 and CDR2 in response to chemical inducers benomyl 
and fluphenazine respectively. Additionally, this work demonstrated that disruption of 
NDT80 did not affect the regulation of efflux transporters or ergosterol biosynthesis 
genes in strains that carry GOF mutations in zinc-cluster transcription factors that 
mediate these processes. In other work, strains deficient for NDT80 have been shown to 
be deficient in biofilm formation. As the purpose of this study was to explore the role of 
NDT80 in ERG11 expression, strains constructed in this study have not been tested for 
biofilm formation or other processes. 
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CHAPTER 4.    CLINICALLY DERIVED MUTATIONS IN ERG11 
CONTRIBUTE TO AZOLE RESISTANCE IN CANDIDA ALBICANS 
 
 
INTRODUCTION 
 
In the opportunistic fungal pathogen Candida albicans, ERG11, an important gene in 
the ergosterol biosynthesis pathway and target of the azole antifungals, has been shown to 
contribute to azole resistance in a number of ways. Overexpression of ERG11, either by a 
gain of function mutation (GOF) in the transcriptional regulator, Upc2, or increased copy 
number of chromosome 5, on which ERG11 resides, results in reduced azole 
susceptibility (50, 173). In addition, mutations in ERG11 that result in an amino acid 
substitution in lanosterol demethylase has been shown to alter the ability of the azole 
antifungals to bind to and inhibit this enzyme, especially in the presence of lanosterol, 
resulting in resistance to this class of antifungal (85, 86, 200, 201). There have been 
many reports of mutations in ERG11 associated with reduced azole susceptibility 
suggesting that lanosterol demethylase is tolerant to structural changes. Previous reports 
have defined three specific ‘hot spot’ regions that correspond to amino acids 105 to 165, 
266 to 287, and 405 to 488 in the translated sequence that are particularly permissive to 
substitutions (114). In order to show that ERG11 mutations can contribute to azole 
resistance, investigators have used several approaches including heterologous expression 
of mutated ERG11 alleles in other species, enzyme inhibition with fluconazole in cell free 
extracts and by biochemical analysis that demonstrate these mutations contribute to azole 
antifungal resistance (85, 86, 122, 162). A number of different mutations have been 
associated with the azole-resistant phenotype but the majority of these mutations have not 
been studied in C. albicans background. Advances in molecular biology and our 
knowledge of the C. albicans genome now allow us to study these mutations in this 
pathogen itself. 
 
In this study, I examined the prevalence and variance of ERG11 mutations in a group 
of 63 characterized clinical C. albicans isolates with reduced fluconazole susceptibility. 
A select group of mutant ERG11 alleles were then expressed in an azole susceptible 
background in order to determine the contribution of distinct mutations in ERG11 on the 
susceptibility of different azole antifungals. 
 
 
MATERIALS AND METHODS 
 
 
Strains and growth conditions 
 
C. albicans strains were cultured on YPD (1% yeast extract, 2% peptone, and 1% 
dextrose) agar plates at 30°C and stored as frozen stock in 20% glycerol at -80°C. YPD 
liquid medium was used for routine growth of strains. Nourseothricin (200 µg/ml or 25 
µg/ml) was added to YPD agar plates for selection of strains containing the SAT1-flipper 
cassette. For plasmid construction and propagation, One Shot Escherichia coli TOP10 
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chemically competent cells (Invitrogen, Carlsbad, CA) were used as a host. These strains 
were grown in Luria-Bertani (LB) broth or on LB agar plates supplemented with 50 
μg/ml kanamycin (Fisher BioReagents, Fair Lawn, NJ) or 100 μg/ml ampicillin (Sigma) 
when required. 
 
 
Plasmid construction for allele sequencing  
 
CaERG11 coding sequences were amplified by PCR (Pfu DNA polymerase; 
Stratagene) from C. albicans genomic DNA using the primers ERG11-A and ERG11-E 
(Table 4.1). Products were cloned into pCR-BLUNTII-TOPO using a Zero Blunt TOPO 
PCR Cloning Kit (Invitrogen) and transferred into Escherichia coli TOP10 cells with 
selection on LB agar plates containing 50 μg/ml kanamycin.  Plasmid DNA was purified 
(QIAprep; Qiagen; Germantown, MD) and sequenced on an ABI Model 3130XL Genetic 
Analyzer using the ERG11 sequencing primers (Table 4.2), resulting in full-length 
sequence from both strands of the CaERG11 gene. The sequencing was performed using 
six sets of clones derived from three independent PCRs for each strain/isolate sequenced. 
 
Sequenced plasmids of the ERG11 orf whose predicted translation indicated an amino 
acid substitution were digested with restriction enzymes ApaI and XhoI, which excised 
the full-length orf from the   plasmid, and the UPC2 alleles were cloned upstream of the 
SAT1-flipper cassette into the ApaI and XhoI sites of plasmid pSFS2 (156). The UPC2 
downstream segments were amplified with ExTaq (Takara) using primers UPC2C and 
UPC2D and cloned downstream of the SAT1-flipper cassette in pSFS2 using the Not1 and 
SacII sites. This process generated plasmids pERG11-2, pERG11-5, pERG11-6, 
pERG11-7, pERG11-7N, pERG11-8, pERG11-8O, pERG11-9, pERG11-10, pERG11-
13, pERG11-15/16, pERG11-19, pERG11-20, pERG11-21, pERG11-22, pERG11-27, 
pERG11-29 and pERG11-30. 
 
 
Construction of strains carrying specific ERG11 alleles 
 
C. albicans strain SC5314 were transformed by electroporation with gel purified 
inserts from plasmids (plasmids go here) derived from the plasmid pSFS2.  pSFS2 
contains the SAT1-flipper disruption cassette developed by Reuss et al. consisting of the 
SAT1 selectable marker which confers resistance to nourseothricin and the FLP flipper 
recombinase gene both flanked by FRT sites (flipper recombinase target sequences). 
Nourseothricin-resistant transformants were selected as previously described.(156) Upon 
induction of the FLP gene, the cassette is excised such that only the ERG11 allele with a 
downstream FRT is left in the ERG11 locus. Integration of constructs was confirmed by 
Southern hybridization.  
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Table 4.1.       C. albicans strains carrying mutant ERG11 alleles used in this study. 
 
Strain Strain background Relevant characteristics or genotype Source or reference 
SC5314 N/A ERG11-1/ERG11-2 ATCC 
Clinical Isolates 
10-72 N/A Azole resistant University of Iowa 
Constructed laboratory strains 
5A2A43A SC5314 ERG11Q21L::FRT/ERG11Q21L::FRT This study 
5B6A19A SC5314 ERG11Q21L::FRT/ERG11Q21L::FRT This study 
20E1II1G1 SC5314 ERG11Y132F::FRT/ERG11Y132F::FRT This study 
20B5A14A SC5314 ERG11Y132F::FRT/ERG11Y132F::FRT This study 
10C1B1M1 SC5314 ERG11K143R::FRT/ERG11K143R::FRT This study 
10B1A32A SC5314 ERG11K143R::FRT/ERG11K143R::FRT This study 
2A1A18A SC5314 ERG11F145L::FRT/ERG11F145L::FRT This study 
2B1A51A SC5314 ERG11F145L::FRT/ERG11F145L::FRT This study 
21C1M1A1 SC5314 ERG11S405F::FRT/ERG11S405F::FRT This study 
21B12A61B SC5314 ERG11S405F::FRT/ERG11S405F::FRT This study 
20NA50A8A SC5314 ERG11G448E::FRT/ERG11G448E::FRT This study 
7A5A5A SC5314 ERG11F499V::FRT/ERG11F499V::FRT This study 
7B4A29A SC5314 ERG11F449V::FRT/ERG11F449V::FRT This study 
15A3A108A SC5314 ERG11G450E::FRT/ERG11G450E::FRT This study 
16A14A47A SC5314 ERG11G450E::FRT/ERG11G450E::FRT This study 
22AABA56A SC5314 ERG11D446E::FRT/ERG11D446E::FRT This study 
22B12A58A SC5314 ERG11D446E::FRT/ERG11D446E::FRT This study 
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Table 4.1.       Continued. 
  
Strain Strain background Relevant characteristics or genotype Source or reference 
19A1A1C1 SC5314 ERG11G464S::FRT/ERG11G464S::FRT This study 
19B1A71A SC5314 ERG11G464S::FRT/ERG11G464S::FRT This study 
6A1A47A SC5314 ERG11K143R,E266D::FRT/ERG11K143R,E266D::FRT This study 
27A5A33A SC5314 ERG11Y132F, F145L::FRT/ ERG11Y132F, F145L::FRT This study 
27B7A63A SC5314 ERG11Y132F, F145L::FRT/ ERG11Y132F, F145L::FRT This study 
7NA35A40A SC5314 ERG11F145L, E266D::FRT/ERG11F145L, E266D::FRT This study 
13A38A25A SC5314 ERG11D278N, G464S::FRT/ERG11D278N, G464S::FRT This study 
9A14A21 SC5314 ERG11Y132F, K143R::FRT/ERG11Y132F, K143R::FRT This study 
9B4B34A SC5314 ERG11Y132F, K143R::FRT/ERG11Y132F, K143R::FRT This study 
8OB29A48A SC5314 ERG11G307S, G450E::FRT/ERG11G307S, G450E::FRT This study 
30A5A53A SC5314 ERG11M258L, G464S::FRT/ERG11M258L, G464S::FRT This study 
30B5A57A SC5314 ERG11M258L, G464S::FRT/ERG11M258L, G464S::FRT This study 
8A4A1A SC5314 ERG11I483V, G450E::FRT/ERG11I483V, G450E::FRT This study 
8B4A47A SC5314 ERG11I483V, G450E::FRT/ERG11I483V, G450E::FRT This study 
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Table 4.2.       ERG11 primers used in this study. 
 
Purpose, primer Sequence 
ERG11 mutant construction 
ERG11-A 5’-GGGCCCGGGTTATTTGAGAACAGCC-3’  
ERG11-B 5’-ATCCGTTCTCGAGCACTAAGGGACAA-3’ 
ERG11-C 5’-GTAATCAATTGAGCTCTTTTAACTTT-3’ 
ERG11-D 5’-GATTATAGTTCCGCGGTGGTTTTACC-3’ 
ERG11-E 5’-TGATGGTTTTTGTCCACTGGCTCGAG-3’ 
ERG11 sequencing 
T7 5'- TAATACGACTCACTATAGGG-3' 
ERG11seqB 5'-TATTTTCACTGCTTCAAGATCT-3' 
ERG11seqC 5'-CCAAAAGGTCATTATGTTTTAG-3' 
M13R 5'-CAGGAAACAGCTATGACC-3' 
ERG11seqE 5'CATTTAGGTGAAAAACCTCATT-3' 
ERG11seqF 5'-TACTCCAGTTTTCGGTAAAGGG-3' 
                                                                                                                                                                                         
aUnderlined sequence reflects the introduction of a restriction site sequence 
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Azole susceptibility testing 
 
Minimum inhibitory concentrations (MICs) were obtained by using a modified CLSI 
protocol outlined in M27-A2 using RPMI. Overnight cultures grown at 30°C were 
streaked onto Sabouraud’s agar.  Plated cultures were grown for 24 hours at 30°C. 
Individual colonies were suspended in sterile water until the optical density at 600 nm of 
0.1 was reached. The working colony concentration was made by making a 1:50 dilution 
and a 1:20 dilution sequentially in media. 100 µl from the working stock was used to 
inoculate a series of azole/RPMI media dilutions, the highest being 64 µg/ml for 
fluconazole. Similar procedures were used for voriconazole and itraconazole dilutions, 
however the highest concentrations used for these agents was 8 µg/ml. Cultures were 
incubated at 35°C for 48 hours and MICs were recorded. 
 
 
RESULTS 
 
 
Many clinical isolates with reduced fluconazole susceptibility carry mutations in 
ERG11 
 
Of the 63 isolates that were determined to have a reduced susceptibility to 
fluconazole (MIC ≥ 8 µg/mL), 55 carried a mutation in ERG11 that lead to an amino acid 
substitution. Although silent mutations were observed in the ERG11 alleles tested (data 
not shown), we recovered 26 distinct positions where mutations occurred that resulted in 
an amino acid substitution either alone or in combination with other mutations. Each 
isolate was homozygous for mutations in the ERG11 allele. Nine of these substitutions, 
either due to their position (Q21R, M258L, L403F and I483V) or the specific amino acid 
substitution (A114V, D446E, Y447S, F449I and I471M) have not been described in 
previous reports. Among the isolates that carry amino acid substitutions in Erg11, the 
number of substitutions varied between the isolates and ranged between 1 (n = 28) and 4 
(n = 2). Most isolates in this collection carried a single amino acid substitution in Erg11. 
In total, 30 unique ERG11 alleles were recovered from sequence analysis (Table 4.3). 
The most common polymorphisms detected were at positions E266 (n=10), Y132 (n=9), 
G464 (n=8) and K143 (n=7) (Table 4.2). 
 
 
Single mutations in ERG11 contribute to azole resistance in C. albicans 
 
In order to assess the contribution of each individual mutant ERG11 allele to azole 
antifungal resistance, we expressed specific mutant alleles homozygously with an 
identical mutant ERG11 allele (Table 4.4). Each strain was constructed in duplicate and 
susceptibilities were tested against fluconazole, itraconazole, and voriconazole. Azole 
susceptibilities of constructed strains were compared to the wild-type susceptible parent 
strain, SC5314 at 48 hours. 
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Table 4.3.       Occurrence of Erg11 amino acid substitutions in predicted translated sequence in fluconazole resistant 
clinical ERG11-overexpressing isolates. 
 
A.A. substitution 
 (mutation) ID Zygosity 
FCZ MIC 
 (µg/mL) 
UPC2 
mutation* 
     Other resistance 
   mechanism* 
None 36 64 ↑ ERG11, CDR1, CDR2 
37 64 ↑ ERG11, CDR1, CDR2 
53 >256 ↑ERG11 
55 >256 G648S ↑ERG11 
56 >256 G648S ↑ ERG11, CDR1, CDR2 
57 >256 G648S ↑ ERG11, CDR1, CDR2 
58 >256 G648S ↑ ERG11, CDR1, CDR2 
60 >256 ↑ERG11 
Q21R (A62G) 16 Hererozygous 16 ↑MDR1 
Y132F (A395T) 48 Homozygous 256 ↑ ERG11, CDR1, CDR2 
K143R (A428G) 13 Homozygous 16 A643T ↑ ERG11, CDR1, CDR2 
12 Homozygous 16 ↑ ERG11, CDR1, CDR2 
14 Homozygous 16 ↑ ERG11, CDR1, CDR2 
F145L (T435G) 22 Homozygous 32  ↑ERG11 
      
F449V (T1345G) 40 Homozygous 128  ↑ ERG11, CDR1, CDR2 
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Table 4.3. Continued. 
     
A.A. substitution 
(mutation) ID Zygosity 
FCZ MIC 
(µg/mL) 
UPC2 
mutation* 
Other resistance 
mechanism* 
S405F (C1214T) 18 Homozygous 32  ↑ ERG11, CDR1, CDR2 
 19 Homozygous 32   
 20 Homozygous 32  ↑ ERG11, CDR1, CDR2 
 41 Homozygous 128  ↑ERG11, MDR1 
      
D446E (T1338A) 25 Homozygous 32 G648Sh ↑ERG11, MDR1 
 35 Homozygous 64 G648Sh ↑ERG11 
 44 Homozygous 128  ↑ ERG11, CDR1, CDR2, MDR1 
      
G448E (G1341A) 31 Homozygous 64  ↑ ERG11, CDR1, CDR2 
 65 Homozygous >256 G648Sh ↑ ERG11, CDR1, CDR2 
 66 Homozygous >256  ↑CDR1, CDR2 
 67 Homozygous >256 G648Sh ↑ ERG11, CDR1, CDR2 
 69 Homozygous >256 G648Sh ↑ ERG11, CDR1, CDR2 
      
G450E (G1349A) 24 Homozygous 32  ↑CDR1, CDR2, MDR1 
 34 Homozygous 64 Y642F ↑CDR1, CDR2, MDR1 
 63 Homozygous >256  ↑ ERG11, CDR1, CDR2, MDR1 
 64 Homozygous >256  ↑ ERG11, CDR1, CDR2, MDR1 
      
G464S (G1390A) 32 Homozygous 64  ↑CDR1, CDR2, MDR1 
 38 Homozygous 64 G648Dh ↑ ERG11, CDR1, CDR2 
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Table 4.3. Continued. 
     
A.A. substitution 
(mutation) ID Zygosity 
FCZ MIC 
(µg/mL) 
UPC2 
mutation* 
Other resistance 
mechanism* 
G464S (G1390A) 39 Homozygous 64  ↑ ERG11, CDR1, CDR2 
continued 42 Homozygous 128  ↑ ERG11, CDR1, CDR2 
      
A114S (G340T), Y257H (T769C) 17 Homozygous 32  ↑CDR1, CDR2 
      
F126L (C378A), Y132F  (A395T) 30 Homozygous 64  A643Vh  ↑ERG11 
      
Y132F (A395T), K143R (A428G) 50 Homozygous 256   ↑CDR1, CDR2 
 61 Homozygous >256   ↑CDR1, CDR2 
      
Y132F (A395T), F145L (T435G) 29 Homozygous 64   ↑CDR1, CDR2 
      
K143R (A428G), E266D  (A798C) 10 Homozygous 16  ↑ ERG11, CDR1 
      
F145L (T435G), E266D (A798C) 33 Homozygous 64 Y642F ↑CDR1, CDR2 
      
M258L (A772T), G464S 
(G1390A) 70 Homozygous >256 A646Vh ↑ERG11 
      
E266D (A798C), G464S 
(G1390A) 45 Homozygous 128 A646Vh ↑ ERG11, CDR1, CDR2 
 15 Homozygous 16 W478Ch ↑ ERG11, CDR1, CDR2 
 27 Homozygous 64 W478Ch ↑ ERG11, CDR1, CDR2 
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Table 4.3. Continued. 
     
A.A. substitution 
(mutation) ID Zygosity 
FCZ MIC 
(µg/mL) 
UPC2 
mutation* 
Other resistance 
mechanism* 
D278N (G832A), G464S 
(G1390A) 43 Homozygous 128  ↑CDR1, CDR2 
 51 Homozygous 256  ↑ ERG11, CDR1, CDR2 
 62 Homozygous >256  ↑CDR1, CDR2 
      
G307S (G919A), G448R 26 Homozygous 32   
 54 Homozygous >256  ↑ERG11, MDR1 
      
G450E  (G1349A), I483V 
(A1309G) 23 Homozygous 32  ↑CDR1, CDR2, MDR1 
      
A114V (C341T), E226D (A798C), 
H283R (A848G) 21 Homozygous 32 G648Dh ↑ ERG11, CDR1, CDR2 
      
Y132F (A395T), T229A (A685G), 
F449L (T1345A) 59 Homozygous >256 G648Dh ↑ ERG11, CDR1, CDR2 
      
Y132F (A395T), V437I (G1309A) 
, F449L (T1345C) 71 Homozygous >256 G648Dh ↑ ERG11, CDR1, CDR2 
      
G307S (G919A), L403F 
(A1209T), G448R(G1342C) 46 Homozygous 128   
      
G307S (G919A), V437I 
(G1309A), Y447S (A1340C) 49 Homozygous 256  ↑ ERG11, CDR1, CDR2 
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Table 4.3. Continued. 
     
A.A. substitution 
(mutation) ID Zygosity 
FCZ MIC 
(µg/mL) 
UPC2 
mutation* 
Other resistance 
mechanism* 
A114V (C341T), D153E (T459G) 
, E266D (A798C) , G450E 
(G1349A) 72 Homozygous >256  ↑CDR1, CDR2 
      
A114V (C341T), Y132F (A395T), 
E266D  (A798C) , V437I  
(G1309A) 47 Homozygous 128 G648Dh ↑ ERG11, CDR1, CDR2 
      
A114V (C341T), Y132F (A395T), 
E266D  (A798C) , V437I  
(G1309A) 47 Homozygous 128 G648Dh ↑ ERG11, CDR1, CDR2 
 
*Data previously published in Flowers, S. A., K. S. Barker, E. L. Berkow, G. Toner, S. G. Chadwick, S. E. Gygax, J. 
Morschhauser, and P. D. Rogers. 2012. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in 
azole-resistant clinical isolates of Candida albicans. Eukaryot Cell 11: 1289-99 (50). hAmino acid substitution recovered in 
one of two UPC2 alleles. 
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I initially examined the effects of mutant ERG11 alleles containing a single amino 
acid substitution in the predicted protein sequence (Table 4.4). I identified 10 distinct 
ERG11 alleles containing a single amino acid substitution (Q21L, Y132F, K134R, 
F145L, F449V, S405F, D446E, G448E, G450E and G464S). With the exception of 
amino acid substitutions Q21L and G448E, most ERG11 mutations resulted in decreased 
susceptibility to fluconazole when compared to SC5314. Strains homozygously 
expressing K143R resulted in the strongest decrease in fluconazole susceptibility. Strains 
that carried two alleles containing amino acid substitutions Y132F, F145L, S405F, 
D446E, F449V G464S, and G450E had at least a four-fold increase in fluconazole MICs. 
No single mutation significantly affected itraconazole or voriconazole susceptibilities. 
These data suggest that structural differences between specific azoles affect activity 
against specific mutant ERG11 alleles. 
 
 
Multiple mutations in ERG11 can result in decreased azole susceptibility 
 
Previous observations show that combinations of ERG11 mutations can lead to 
considerable increases in MICs to fluconazole. To examine the effects of multiple 
mutations on azole susceptibility, I selected a group of clinically occurring ERG11 alleles 
that carried two amino acid substitutions. I were specifically interested in evaluating 
azole-susceptibilities of strains containing two amino acid substitutions, in which at least 
one substitution has been characterized alone (see above). 
 
The K143R + Y132F was the strongest characterized combination resulting in 
increased FCZ MICs and VCZ MICs of ten-fold and four-fold respectively over what 
was observed for SC5314. Interestingly, this combination did not affect ICZ 
susceptibilities. Other notable increases in FCZ MICs where detected when 
characterizing the Y132F + F145L and the G307S + G450E combinations, both resulting 
in an increase in FCZ MIC of eight-fold over that of SC5314. Notably, the Y132F + 
F145L combination also demonstrated significant effects on both ICZ and VCZ with an 
increase of MICs by four-fold and eight-fold respectively. Notably, this was the only 
mutant ERG11 allele characterized in this study that produced a significant decrease in 
ICZ susceptibility. 
 
I characterized other combinations of polymorphisms that arose clinically in our 
collection. I483V + G450E in combination increased FCZ MICs six-fold over SC5314 
and two-fold over what was observed for G450E as a single polymrphism. This 
combination did not result significant changes to either ICZ or VCZ MICs. I observed a 
similar trend in investigating the effects of the addition of M258L when combined with 
G464S, in which the combination increased FCZ MICs by two-fold over G464S alone.  
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Table 4.4. Forty-eight hour MICs to FCZ, ICZ and VCZ measured by 
using a modified CLSI broth microdilution methods of C. albicans constructed 
to carry mutant ERG11 alleles homozygously.  
 
  48 hour MIC (µg/mL) 
Erg11 SNP FCZ* ICZ* VCZ* 
SC5314 0.25 0.016 0.016 
Q21L 0.5 0.016 0.016 
Y132F 2 0.016 0.03 
K143R 4 0.06 0.03 
F145L 1 0.03 0.016 
S405F 2 0.03 0.016 
D446E 1 0.016 0.016 
F449V 1-2 0.03 0.016 
G448E 0.5 0.03 0.016 
G450E 1 0.03 0.016 
G464S 1 0.03 0.016 
K143R, E226D 4 0.016 0.016 
Y132F, F145L 4-8 0.06 0.25 
I483V, G450E 2 0.03 0.016-0.03 
Y132F, K143R 8 0.03 0.06 
F145L, E266D 1 0.03 0.016 
D278N, G464S 4 0.016 0.016 
E266D, G464S 1 0.016 0.016 
M258L, G464S 2 0.016 0.03 
G307S, G450E 4 0.016 0.016 
 
*FCZ, fluconazole; ICZ, itraconazole; VCZ, voriconazole 
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Amino acid substitution E266D does not contribute to azole resistance 
 
E266D was the most prevalent polymorphism detected by sequence analysis and 
occurred only in combination with other amino acid substitutions. To investigate the 
contribution of E266D to azole resistance, I compared the susceptibilities of ERG11 
alleles carrying one amino acid substitution alone to an allele containing an identical 
amino acid substitution combined with E266D. In our collection, K143R, F145L and 
G464S all clinically occurred as a single mutation and occurred combined with E266D in 
different isolates. In all three instances, I did not observe E266D to confer any additional 
effect on azole susceptibility beyond what was observed with the original amino acid 
substitution.  
 
 
DISCUSSION 
 
Resistance to azole antifungals in C. albicans is attributable to a number of distinct of 
mechanisms. It is well established that activating mutations in transcription factors 
regulating genes encoding efflux pumps mediate resistance to azole antifungals. Previous 
work has shown specific mutations in the transcription factor gene TAC1 mediate 
expression of ABC transporters CDR1 and CDR2, resulting in increased azole 
resistancein C. albicans (22). Similarly, Mrr1 has been identified as the regulator of the 
major facilitator superfamily (MFS) transporter Mdr1 in azole-resistant isolates, and GOF 
mutations in this transcriptional regulator produce constitutive activation (43). I have 
previously characterized the expression of genes involved in azole resistance in this large 
group of clinical isolates with decreased fluconazole susceptibility (50). I identified 
several mutations in the transcription factor UPC2, which resulted in the constitutive 
activation genes involved in the ergosterol biosynthesis pathway, including ERG11. In 
this study, I determined the frequency, variability and the specific contributions of 
ERG11 mutations from this characterized group of clinical isolates to azole resistance. 
 
The cytochrome P450 (CYP) superfamily of enzymes contains more than 2500 
members that can be roughly placed into two groups stratified by their function 
(http://drnelson.uthsc.edu) (98). In the first group, members metabolize a wide variety of 
xenobiotics while those in the second group generally participate in key biosynthetic 
processes such as sterol biosynthesis. Substrate specificity for this second group of P450s 
is narrow. Sterol 14α-demethylase (Cyp51 or Erg11) is considered to be the most ancient 
CYP family because it is the only P450 class that is found in different kingdoms such as 
animals, plants and bacteria (130, 210). In 2009, the first observed virally encoded 
CYP450 gene was observed and exhibited low-level sequence homology to CYP51 genes 
although its function remains unknown (95). Despite only the 22-33% of sequence 
homology demonstrated between kingdoms, there are only four known substrates for this 
class of enzymes. This substrate preservation between kingdoms suggests that the Cyp51 
structure is highly conserved regardless of low sequence homology (Figure 4.1). There 
are 41 amino acids conserved between the animal, bacterial and fungal Cyp51 enzymes 
(98). Of those 41 amino acids, there are three positions that are conserved in all CYP450  
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Figure 4.1. Cyp51 secondary structure is conserved despite low sequence 
homology between kingdoms.  
Alignment of C. albicans, T. cruzi, M. tuberculosis, and Wheat Cyp51 proteins 
performed by UniProt www.uniprot.org. Pink highlights alpha helical structure and 
purple highlights beta sheets as predicted by crystal structure when available. Light blue 
highlighted heme coordinating cysteine is conserved in all CYP450 enzymes. *indicates 
conserved amino acid residues in all represented organisms. The following accession 
numbers were used: C. albicans-P10613; T. cruzi-Q7Z1V1; T. aestivum-P93596; M. 
tuberculosis-P0A512. 
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enzymes. One of these positions is a cysteine thiolate that coordinates the heme group 
while the other two are the ExxR salt bridge in the K-helix (98).  
 
Sterols are an essential component of the eukaryotic membrane that functions to 
maintain fluidity as well as other regulatory processes. The azole class of antifungals 
function not only to inhibit ergosterol biosynthesis but also result in the accumulation of  
toxic methylated sterol precursors (24). The primary sterol in the fungal cell membrane is 
ergosterol and CYP51 in C. albicans is the rate limiting step in this biosynthetic process. 
 
CaCyp51 catalyzes a three-step reaction that ultimately results in the demethylation 
of lanosterol. Each step requires one molecule of oxygen and NADPH. The azoles inhibit 
lanosterol demethylase by binding of the nucleophilic N4 atom of the azole ring to the 
heme iron at its sixth coordinate position (162). The normal substrate for this enzyme is 
lanosterol and azole derivatives sit in the same binding pocket. Biochemical analysis 
show all azoles bind selectively to CaCyp51; however, Kd values show a two-to four-fold 
lower affinity to fluconazole when compared to itraconazole or voriconazole (200). 
 
In agreement with previous studies, the majority of our clinical isolates carried point 
mutations in ERG11 that lead to amino acid substitutions (122). In our collection, 87% of 
all isolates carried at least one nonsynonomous mutation that resulted in an amino acid 
substitution. Previous work has also defined mutations that occur in ERG11 susceptible 
isolates which means the presence of an ERG11 mutation may not be adequate to predict 
azole susceptibility. Substitutions in our collection were recovered in 26 distinct positions 
in which all but five were located in previously defined “hot spot” regions where 
CaERG11 mutations frequently occur. In our constructed strains, most ERG11 alleles 
containing single nucleotide changes resulted in meaningful changes in fluconazole MICs 
but no single mutation conferred significant changes in either itraconazole or 
voriconazole susceptibilities. K143R produced the strongest increase in fluconazole 
MICs in this study as a single amino acid substitution. Y132F also conferred increased 
resistance to fluconazole. Previous analysis performed with heterologous expression of 
CaCyp51(Y132H) in S. cerevisiae revealed a spectral change indicative of the inability of 
the azole nitrogen to interact in a typical fashion with the Cyp51 heme (85). Both the 
K143 and Y123 positions are conserved among fungal species and have been associated 
with resistance in previous work (5, 162). 
 
Sanglard et al. have formally determined that Cyp51 amino acid substitutions S405F, 
Y132H, and G464S independently resulted in increased azole resistance when 
heterologously expressed in S. cerevisiae (162). The S405 position is a highly conserved 
residue of the Cyp51 in different organisms and this mutation is exclusively recovered 
from azole-resistant strains (122). In our collection, S405F was recovered in four distinct 
clinical isolates and was only recovered as a single polymorphism. In another conserved 
position, the G464S amino acid substitution also resulted in increased fluconazole 
resistance in strains carrying two mutant ERG11 alleles. Previous spectral analysis of the 
G464S mutation reveals that this modification exerts its effects by a change in the heme 
environment(86).In this work, Kelly et al demonstrated the G464S substitution reduced 
affinity for fluconazole but the enzyme retained its catalytic activity. 
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In a fungal specific major insertion loop, I recovered multiple amino acid 
substitutions that occurred as single mutations and also combined with other amino acid 
substitutions. Modeling of amino acid residues at these positions is difficult due to the 
lack of fungal crystal structures. Homology modeling of this insertion loop was 
investigated previously in P. pastoris (5). Among fungal species, this unique sequence 
length varies and in C. albicans, this loop is comprised of 31 amino acid residues (5). 
Sequence analysis done for this loop in different fungal species show that the N-terminal 
portion of is variable in sequence and length while the C-terminal portion contains acidic 
residues followed by a more invariable portion with the motif DYG[FY]Gx[VI][ST]KG 
(Figure 4.2) (5). In this collection, amino acid substitutions were recovered at positions 
D446, G448, F449, and G450. These positions all occur within the C-terminal invariable 
motif within the fungal specific major insertion loop (Figure 4.3). Interestingly, 
mutations that occur independently at these position all increase fluconazole MICs by 
about fourfold in strains that express homozygous mutant ERG11 alleles. No amino acid 
substitution at these positions either occurring as a single mutation, or when combined 
with another amino acid substitution affects susceptibilities to either itraconazole or 
voriconazole.  
 
I also examined the collective effects of multiple mutations in ERG11 that were 
derived from clinical isolates. Specifically, I was interested in characterizing the effects 
of amino acid substitutions that occurred with a mutation that had been characterized 
alone. The K143R + Y132F combination resulted in the strongest increase in FCZ MIC 
by increasing fluconazole and voriconazole MICs by ten-fold and four-fold respectively 
over what was observed for SC5314. This combination occurred independently in two 
isolates that were highly resistant to fluconazole (MIC ≥ 256 µg/mL) accompanied with 
increased expression of ABC transporters CDR1 and CDR2 in both isolates. F145L + 
Y132F were the only amino acid substitutions that significantly affected MICs to all 
azoles. Previous modeling in Aspergillus fumigatis defined F145 as a position that 
interacts with posaconazole (208). Structurally, itraconazole is similar to posaconazole 
and notably, this combination was the only combination of amino acid substitutions that 
significantly affected susceptibility to itraconazole. This combination of substitutions was 
also shown to catalytically impair Cyp51 when derived from a clinical C. albicans 
isolate. Investigation of Cyp51 function in Aspergillus fumigatis showed that positions 
G464S and G307 disturb the heme environment (208). Our observed susceptibility 
phenotypes show increased fluconazole MICs to G464S and the combination of G307S + 
G450E. The combination of G307S + G450E increased fluconazole MICs beyond what 
was observed with G450E as a single mutation. 
 
Amino acid substitutions I483V, M258L, D278N, were demonstrated to have additive 
effects on fluconazole resistance when combined with an amino acid substitution that has 
been characterized alone. Substitution I483V has not been described previously in the 
literature and does not seem to be located near the active site when considering CaCyp51 
secondary structure. When combined with substitution G450E, fluconazole MICs 
increase by two-fold over that which was observed for G450E alone. A similar trend was  
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Figure 4.2. Sequence alignment highlighting the fungal specific major insertion loop in various fungal species and 
contrasted with the non-fungal species, M. tuberculosis.  
Alignment was generated by UniProt www.uniprot.org. The red bracketed sequence defines the invariable sequence where we have 
observed amino acid modifications which affect fluconazole susceptibility. The following accession numbers were used: C. albicans-
P10613; C. tropicalis-P14263; S. cerevisiae-P10614; P. italicum-Q12664; S. pombe-Q09736; C. glabrata-P50859; C. krusei-Q02315; 
M. tuberculosis-P0A512. 
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Figure 4.3. Observed amino acid subsitutions in Erg11 in C. albicans compared to other medically important Candida 
species and organisms in other kingdoms. 
The alignment was generated by using the UniProt alignment function www.uniprot.org. Amino acid numbering is based off the C. 
albicans sequence. Conserved amino acids are highlighted in blue. Amino acid substitutions highlighted in red are those observed in 
this study. Substitutions observed in black were noted in the literature. The following accession numbers were used: C. albicans-P1-
613; C. tropicalis-P14263; S. cerevisiae-P1-614; C. glabrata-P50859; C. krusei-Q02315; Human-Q16850; M. tuberculosis-POA512; 
T. Aestivum-P93596.  
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observed for M258L and D278N, which both independently occurred with a G464S 
mutation resulting in a twofold and a fourfold increase in fluconazole MICs, respectively, 
over that which was observed for G464S alone. Neither the M258L nor the D278N 
modifications have been described previously in the literature. D278E was previously 
shown to occur in azole resistant isolates however, the exchange of an aspartic acid (D) 
for a glutamic acid (E) may be a more conserved substitution when compared to the 
asparagine (N) modification observed in our collection (Table 4.3) (111). 
 
Not all mutations investigated contributed to azole resistance. ERG11 is observed in 
our studies and others to be highly permissive to genetic polymorphisms. The most 
common mutation observed in this collection was E266D (n=10) and was always 
recovered with an additional substitution. In this study, I investigated the E266D 
substitution when combined with K143R, F145L and G464S independently. In all three 
cases, the addition of the E266D polymorphism did not confer additional effects on azole 
resistance beyond that which was observed for K143R, F145L and G464S alone. In the 
current study, I sequenced only ERG11 alleles from isolates exhibiting decreased 
susceptibilities to fluconazole. It is most likely that mutations in ERG11 occur in both 
azole-susceptible and resistant isolates that do not affect azole resistance. Another 
possibility is that mutations may arise in conjunction with mutations creating azole 
resistance that also affect fitness. Previous work has shown that specific ERG11 
mutations affect fitness and catalytic activity of the enzyme (166, 201). Further 
investigation of how ERG11 mutations affect fitness is warranted. 
 
One isolate contained a Q21L amino acid substitution in one ERG11 allele with a 
wild-type ERG11 allele. In membrane bound lanosterol demethylases, the far N-terminal 
region acts as a transmembrane portion of the enzyme that anchors this enzyme to the 
endoplasmic reticulum (38). This is the only mutation that I recovered in the far N-
terminal region, and it was expressed with a wild-type allele. When expressed in SC5314, 
I did not observe a change in any azole susceptibilities at 48 hours. This data suggests 
that mutations occurring near the putative transmembrane region of the enzyme may not 
interfere with enzyme-substrate interaction. 
 
Clearly, the susceptibility of clinical isolates is a product of the interplay of multiple 
mechanisms of resistance. Mutations in the ERG11 genes have been shown to be a 
significant and prevalent mechanism of resistance in C. albicans. Notably, 19 clinical 
isolates carried ERG11 mutations in addition to Upc2 GOF mutations. It is probable that 
the combination of these two mechanisms have a combinatorial effect on azole 
susceptibility. Our data clearly demonstrate that many ERG11 mutations result in 
fluconazole resistance, but most are not as significant when tested against voriconazole or 
itraconazole. Itraconazole, in particular seems less effected by ERG11 mutations which 
produce significant resistance to fluconazole. Despite this general observation, I have 
identified a specific combination of amino acid substitutions that significantly reduce 
itraconazole and voriconazole susceptibility. The association of clinically derived 
mutations in ERG11 resulting in decreased azole susceptibility are of clinical importance. 
In this study, I limited our characterization to specific mutant ERG11 alleles. Further 
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characterization of clinically derived ERG11 mutant alleles to azole resistance is needed 
help guide antifungal pharmacotherapy and assist with future antifungal development. 
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CHAPTER 5.    DISCUSSION AND CONCLUSIONS 
 
 
GENERAL DISSERTATION OVERVIEW 
 
In Chapter 2, I describe the characterization of known resistance mechanisms in a 
large group of clinical C. albicans isolates that were enriched for decreased fluconazole 
susceptibility. A transcriptional profile for each isolate was created for genes known to 
cause azole resistance such as ERG11, CDR1, CDR2 and MDR1. Stratified into groups 
based on fluconazole susceptible vs. resistant phenotypes (MIC ≥ 8), transcription 
profiles of genes known in azole resistance were then compared. 
 
As CDR1 and CDR2 are transcriptionally co-regulated by Tac1, it was not surprising 
to observe the coordinate expression of these transporters. Increased expression of CDR1 
was observed in 77% of isolates with increased resistance to fluconazole as opposed to 
the overexpression of MDR1, which encompassed only 21%. There was no correlation 
between transcriptional expression of the ABC transporters and the MFS transporter 
MDR1 in this group. This observation may be due to specific fitness costs associated with 
the overexpression of both these transporters in one isolate. In 2012, Sasse et al 
systematically investigated the effects of GOF mutations in the transcriptional regulators 
MRR1, TAC1, UPC2, and also mutations in ERG11, on associated fitness costs in C. 
albicans (166). In this work, the authors demonstrated that although combinations of 
mechanisms of drug resistance resulted in a step-wise acquisition of high level resistance, 
there was also an associated decrease in fitness when tested in non-selective conditions in 
vitro and in vivo. Mutations associated with the greatest decrease in fitness were the 
combination of a GOF mutation in TAC1 and MRR1 in isolates constructed to carry two 
mechanisms of resistance. The addition of a GOF UPC2 allele resulted in a further 
decrease in fitness. In the absence of any compensatory mutations that might arise in a 
clinical isolate, this work demonstrated that loss of the wild-type regulation of gene 
expression is associated with a decrease in fitness. I believe these fitness costs may 
explain why simultaneous overexpression of MDR1 and CDR1/CDR2 are not observed in 
this group of clinical isolates. 
 
In addition to efflux transporter expression, I also measured the transcriptional profile 
of ERG11, whose gene product is the target of azole antifungals. These data showed 
increased expression of ERG11 occurred in 75% of our clinical isolate collection. For 
those that overexpressed ERG11 when compared to fluconazole-susceptible isolates, I 
sequenced a known regulator of ergosterol biosynthesis UPC2. Previous to this study, 
only three distinct UPC2 GOF mutations had been identified to occur clinically. Our 
sequenced data introduced five previously undescribed GOF mutations in UPC2 and also 
established that these mutations occurred frequently in azole-resistant isolates.  
 
As has been described for activating mutations in zinc-cluster transcription factors in 
S. cerevisiae, all of the mutations observed in this study occurred in the C-terminal 
putative activation domain of CaUPC2. In C. albicans, UPC2 is orthologous to UPC2 
and ECM22 in S. cerevisiae, which regulate ergosterol biosynthesis and uptake of 
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exogenous sterols. Both transcription factors are localized to the intracellular membrane 
of the endoplasmic reticulum but under sterol-depleted activating conditions, they 
localize around the nucleus (115). Gain-of-function mutations have been identified in 
both ScUPC2 and ScECM22 and in each instance, mutations identified occur in the C-
terminal activation domain (197). There are two theories that describe how GOF 
mutations result in constitutive activation of UPC2. First, mutations in the C-terminus 
may interfere with the transmembrane region of the protein resulting in constitutive 
localization to the nucleus and constitutive activation of target genes. The second theory 
is that mutations in the C-terminal area could relieve Upc2 of a repressor that would 
otherwise keep Upc2 in an inactive state in non-activating conditions (177). 
 
The most widely characterized zinc-cluster transcription factor in yeast is Gal4. Gal4 
regulates genes involved in the transport and metabolism of galactose (20). As has been 
shown in UPC2 localization studies in S. cerevisiae, Gal4 is localized to the cytoplasm 
and upon activation, is directed towards and imported into the nucleus. Gal4 is inhibited 
by repressor protein Gal80 in the absence of galactose. Previous work has shown that the 
carboxy-terminal 28 amino acids are responsible for the sequence specific interaction 
between these two proteins (161). A single amino acid substitution in this region is 
sufficient to constitutively activate target genes by relieving interaction of Gal4 with 
Gal80 (161). Notably, a mutation in Gal80 has been shown to compensate for a GOF 
mutation in Gal4, resulting in a wild-type phenotype. Adding another level of regulation 
in Gal4 activation is the detection of mutant Gal3 proteins that show altered Gal80-
binding characteristics and result in constitutive activation of Gal4 (14).  
 
A repressor protein for UPC2 or ECM22 has not been identified in either S. 
cerevisiae or in C. albicans but it is plausible that these mutations interfere with this 
interaction. In addition to relief of a repressor, post-transcriptional modifications occur 
with Gal4 by the phosphorylation of a series of C-terminal serine residues which are 
thought to “fine tune” activation and may regulate ubiquitin degradation (160). 
Activating mutations observed in CaUpc2 have not been shown to occur on any serine 
residues but using an online phosphorylation site identifier 
(http://www.cbs.dtu.dk/services/NetPhos/), highlights potential phosphorylation sites 
identified at positions S469, S533 and S575. 
 
In strains constructed to carry a GOF allele in UPC2, I observed that homozygous 
replacement of the GOF UPC2 allele showed a greater effect on azole susceptibility than 
mutations expressed with a wild-type allele. This is consistent to what is observed in 
GOF mutations in TAC1 and MRR1. When comparing genome-wide transcriptional 
analysis of four distinct UPC2 GOF mutations I observed a core set of genes to be 
upregulated. Expectedly, among these genes were those involved in oxidoreductase 
activity and those involved in ergosterol biosynthesis. 
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Summary and discussion of Chapter 3 
 
In Chapter 3 I explored the hypothesis that mutations in NDT80 might result in 
overexpression of ERG11 in azole resistant isolates that do not carry mutations in UPC2. 
Ndt80 is a transcriptional regulator that in C. albicans has been shown to regulate ERG11 
expression. ERG11 is a direct target of Ndt80 and its disruption results in reduced ERG11 
expression and increased azole susceptibility. Clinical isolates 945 and1619 are 
genetically matched isolates comprised of a susceptible and resistant constituent, in 
which the resistant isolate overexpresses ERG11 and does not carry mutations in UPC2. I 
therefore sequenced NDT80 in both isolates and found several mutations to be present. 
Suspecting these mutations as being the cause of ERG11 overexpression in these isolates, 
I expressed mutant NDT80 alleles derived from the fluconazole-susceptible and –resistant 
isolates in SC5314. I did not observe a change in fluconazole resistance or ERG11 
expression in strains carrying mutant NDT80 alleles. While this does not preclude the 
involvement of mutations in NDT80 in azole resistance, such mutations do not explain 
the overexpression of ERG11 in these clinical isolates. 
 
 
Summary and discussion of Chapter 4 
 
In Chapter 4, I characterized clinically derived mutations in the ERG11 gene and their 
effects on the activity of a panel of structurally different azole antifungals. I was able to 
demonstrate that distinct amino acid substitutions in Erg11 produced a variable increase 
in resistance to fluconazole, itraconazole and voriconazole. I also observed trends to 
placement of the resulting amino acid substitutions in the enzyme and the level of 
resulting resistance to fluconazole. 
 
Both voriconazole and itraconazole susceptibilities were not as affected by mutations 
in ERG11 when compared to fluconazole. It is likely that structural differences resulting 
in stronger binding of newer generation azoles make them less vulnerable to the effects of 
ERG11 mutations. Itraconazole seemed to be the least susceptible to ERG11 mutations, 
with only the F145L + Y132F combination resulting in a significant increase in MIC. 
Although itraconazole retains its activity against ERG11 mutations and previous work 
has shown that itraconazole is not a substrate for Mdr1 efflux transport, the utility of this 
agent in the treatment of invasive candidiasis is wanting due to its erratic bioavailability 
and the lack of an intravenous formulation. 
 
As discussed earlier, despite the low sequence homology of Cyp51 enzymes between 
species, the secondary structure is highly conserved and specific amino acid positions are 
conserved within fungal organisms and even between kingdoms. Its logical that as these 
positions are conserved between species, their role in the structure and function of Cyp51 
likely important. In this collection, we observed and characterized mutations occurring 
both in conserved and non-conserved positions in the Cyp51 sequence. A general 
observation was that amino acid substitutions occurring in conserved positions resulted in 
fluconazole resistance. The exception to this observation was the Q21L substitution, 
which is conserved in fungal species yet did not result in increased MICs to azoles. 
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Likewise, amino acid substitutions occurring in non-conserved positions, such as E266D 
did not affect fluconazole susceptibility and are not associated with azole-resistant 
isolates in this study or in previous publications (122). Over 150 missense mutations in 
ERG11 have been documented in the literature and characterizing mutations as I have by 
constructing strains that carry these mutations is laborious and slow. Generally, mutations 
characterized in this study that result in a change in azole resistance are those that arise in 
clinically resistant isolates and are in conserved positions in the Cyp51 enzyme. As 
sequencing can now be efficiently and cost-effectively performed on a large scale, 
correlating mutations to azole resistance can be done statistically in the future once 
sufficient data is available.  
 
Although several homology models for fungal Cyp51 structures have been published, 
a crystal structure for this enzyme is not public. Many publications on fungal Cyp51 
structure cite the difficulty of obtaining a crystal for membrane bound enzymes. Despite 
this difficulty, X-ray structures for 25 membrane bound Cyp51 enzymes are available, 
including that for humans(38). As Cyp51 for C. albicans, as well as other fungal species, 
is the most important and exploited target for antifungals, the addition of a CaCyp51 
crystal structure would aid in the development of better azole antifungals.  
 
 
DISCUSSION OF METHODS 
 
The studies discussed in this dissertation describe the use of a variety of molecular 
techniques to quantify gene transcription involved in mechanisms of resistance and the 
construction of strains that carry mutant genes derived from resistant isolates in a wild-
type background strain. With these constructed strains, I was able to specifically identify 
the specific contribution to azole resistance and to identify key determinants of azole 
resistance in this species. 
 
 
Gene-quantification 
 
To quantify genes involved in azole resistance, I used quantitative real-time PCR 
(RT-PCR), which is the standard method of gene quantification. This method has several 
advantages over other methods of gene quantification due to its increased sensitivity and 
quantitative capabilities. To quantify gene expression, I used the Comparative Ct (2-∆∆Ct) 
method. Using this model, I can calculate changes in gene expression as a relative fold 
difference between an experimental and a calibrator sample. This method requires similar 
amplification kinetics of both the target and reference gene because different efficiencies 
will generate errors with this method. Therefore, for each gene measured, a validation 
assay using serial dilutions of cDNA target are assayed for each gene of interest and the 
results are plotted with the log-input concentration for each dilution on the x-axis, and the 
difference for Ct dilution on the y-axis. This particular collection was comprised of a 
large number of unrelated clinical isolates. Most expression experiments of this nature 
are performed with genetically match-paired isolates that differ only in azole-
susceptibility phenotypes. As none of our isolates are related, I averaged the gene 
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expression data from azole susceptible isolates to compared expression of genes of 
interest to our resistant isolates.  
 
Studies have shown that genes involved in azole resistance are regulated at the 
transcriptional level in response to azole drugs, and not to gene duplication events (105). 
Although transcription of specific genes is correlated with azole resistance, using 
methods that only quantify RNA could be a limitation to this work. Manoharlal et al. 
demonstrated that in addition to increased transcription initiation of CDR1, CDR1 mRNA 
stability half-life was threefold higher in an azole-resistant strain when compared to an 
azole-susceptible counterpart (112). Although correlating gene expression with resistance 
in C. albicans is standard in the literature, this technique neglects regulation that could 
occur post-transcriptionally or post-translationally that could be contributing to an azole-
resistant phenotype. 
 
 
Genetic manipulation in C. albicans 
 
The SAT1-flipper technique was utilized to perform targeted gene inactivation and 
replacement. The SAT1 flipping strategy allows for genetic manipulation to occur in 
prototrophic C. albicans strains using a dominant drug selection marker that is recyclable, 
which is important in diploid species(156). This method uses a CaSAT1-selectable 
marker which enables resistance to the aminoglycoside nourseothricin and also a CaFLP 
gene, which encodes a site-specific recombinase for cassette excision and selection 
marker recycling. Previous to the technique, targeted gene disruption occurred in specific 
auxotrophic background strains using nutritional markers for the selection of 
transformants. However, use of auxotrophic markers made it difficult to interpret mutant 
phenotypes as these genes were shown to modulate processes such as virulence.  
 
Although the SAT1 flipper method has resolved difficulties associated with the use of 
auxotrophic strains, there are other complications associated with genetic manipulation of 
C. albicans. As stated in the introduction, genetic plasticity in the C. albicans genome is 
well described and development of aneuploidy and chromosomal rearrangements occur 
readily under a wide variety of events including antifungal drug exposure. Aneuploidies 
of selected chromosomes are not uncommon in laboratory strains (96, 172). 
Chromosomal aneuploidies and truncations have been described in laboratory strains as a 
result of genetic modification like what is described in this dissertation. It is clear that 
detection of chromosomal ploidy is important in this species. As we do not have a cot-
effective mechanism to routinely detect this in our lab, I have constructed duplicates of 
each strain to ensure reproducibility of the phenotypes I have observed in these mutant 
strains. 
 
 
Measuring antifungal susceptibility 
 
To measure antifungal susceptibility, we used a modified version of the Clinical 
Laboratory and Standards Institute microbroth dilution method. The modification of this 
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protocol is the addition of 2% dextrose to RPMI media, which has been observed to 
decrease the amount of trailing associated with azole fungistatic activity in this species. 
Reducing the amount of trailing is important for interpretation of data. In addition to 
standard broth dilution methods, we occasionally used azole treated E-test strips 
(Biomerieux) as these interpretations of MICs are less subjective. At times, instead of 
RPMI, we test azole susceptibilities in rich YPD media in order reveal smaller changes 
resulting from certain genes. Potential drawbacks of using YPD media for susceptibility 
testing are that media varies based on preparation and one cannot make associations of 
susceptibility to clinical breakpoints, as those are performed in RPMI. 
 
The ability to incorporate exogenous sterols into the fungal cell membrane has been 
shown for S. cerevisiae and C. glabrata but has not yet been shown for C. albicans. If 
this process occurs, it may be that testing MICs in media without exogenous sterols may 
underrepresent resistance phenotypes. If a particular isolate has an increased ability to 
incorporate sterols from the environment, inhibition of ergosterol synthesis could be 
bypassed. As yeast extract is a component of YPD, this may be partly contributing the 
increased growth and higher MICs resulting from susceptibility testing in this media.  
 
 
OVERALL THEME AND CONCLUSIONS 
 
Throughout the research presented in this dissertation, there is one recurring theme 
which deserves attention. The work presented here is the largest comparison of resistance 
mechanisms that have been defined in a group of azole-resistant clinical isolates of C. 
albicans. Prior to this work, the primary focus of azole resistance was on efflux 
transporters CDR1, CDR2 and MDR1. It was not surprising that overexpression of efflux 
transporters was well represented in this collection. Notably, expression data in this work 
revealed the considerable involvement of ERG11 overexpression which had previously 
taken a back seat to the involvement of efflux transporters. Overexpression of ERG11 
seems to be something specific for C. albicans, as smaller population studies have not 
shown increased ERG11 expression to be prevalent in C. glabrata or C. dubliniensis. 
Also in this group, we defined the significance of individual mutant ERG11 alleles on 
azole resistance. Numerous sequencing data has demonstrated ERG11 is highly tolerant 
of mutations in both azole-susceptible and resistant isolates. These data corroborated with 
sequencing data for this collection. Large scale phenotypic characterization of these 
mutations done in this work demonstrated ERG11 mutations were a prevalent contributor 
to azole resistance in C. albicans. 
 
 
FUTURE DIRECTIONS 
 
The long term goal of our research is to improve the treatment of Candida infections 
by understanding the molecular basis of azole resistance. Ultimately, part of goal will be 
to develop improved options for the treatment of candidiasis. Currently, there are only 4 
systemic therapies available for the treatment of fungal disease. Despite the increasing 
need for new antifungal classes to treat candidiasis, antifungal drug discovery is limited 
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by the detection of novel and specific antifungal targets. The azole class of antifungals is 
presently our only oral option for the treatment of systemic disease but as shown in this 
work, there are clinical isolates that have become highly resistant to these agents. In 
Chapter 4, I investigated several mutations in ERG11, some of which caused an increase 
in voriconazole and itraconazole susceptibility to the susceptible dose-dependent range. 
In this study, I was only able to characterize a subset ERG11 alleles observed, but there 
are probably specific mutant alleles, like those which contain 3 or 4 amino acid 
substitutions, which may confer a greater effect on azole resistance. The more 
information obtained on ERG11 mutations and their specific effect azole resistance may 
shed light on how to better target Erg11 either by construction of improved members of 
the azole class or by development of a new compound. 
 
Although my contribution to characterizing ERG11-mediated azole resistance in C. 
albicans is nearly complete, there are areas in this project that warrant further 
exploration. I present here some future directions made possible from the groundwork 
prepared by these data. 
 
 
Whole genome sequencing to investigate UPC-independent mechanisms of ERG11-
overexpression  
 
Our lab and others have observed ERG11 overexpression in isolates that do not 
contain GOF mutations in UPC2. In Chapter 3, I investigated the role of mutant NDT80 
alleles derived from resistant isolates in ERG11 overexpression but was unable to 
demonstrate a role for this transcription factor in regulating azole resistance. The 
mechanism of ERG11 overexpression in these isolates remains unknown. The strategy of 
targeted gene sequencing based on genome-wide expression data or educated guesses are 
time consuming and largely yield negative results. As there are potentially several genes 
involved in azole resistance that have not been identified, investigations of this nature can 
now be undertaken on a genome-wide scale.  
 
As transcription factors have played a primary role in many key drug resistance and 
pathogenic processes, exploring mutations that occur in these genes containing missense 
polymorphisms in resistant isolates will be an obvious and fruitful choice to investigate 
further. As someone who has spent considerable time exploring sequencing data of this 
type, I have further suggestions of possible genes and pathways to explore in future 
studies. 
 
First, I recommend that in addition to mutations in ERG11, polymorphisms occurring 
in other components of the ergosterol biosynthesis pathway be explored. Studies have 
already shown that azole- and amphotericin B- resistant species of Candida display 
alternate sterol profiles. Additionally, as microarray data show an increased expression of 
genes important to ergosterol biosynthesis in response to chemical inhibition, I suspect 
that decreased ergosterol production resulting from mutations in the ERG pathway may 
also result in increased ERG11 expression. 
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A next generation sequencing study performed in a series of clinical C. glabrata 
isolates has already identified a gene mutation that arises after FKS mutations that result 
in ameliorating fitness costs of echinocandin resistance (178). As similar fitness defects 
occur in azole-resistant C. albicans strains, detection of genes that restore fitness in 
clinical isolates would represent an additional mechanism of resistance in this species. 
 
In the future, proteins required for pathogenicity in fungus may be considered a 
potential drug targeting strategy. One unit of chromatin is defined as 146bp of DNA 
wrapped around a histone complex comprised of two histone H2A-H2B dimers and one 
histone (H3-H4)2 tetramer(103). Histone proteins play a role in tightly packaging DNA 
into nucleosomes and association to a tightly wound chromatin is associated with gene 
silencing. Data from genome-wide transcription profiles suggest that wide-spread 
transcriptional networks are activated in response to antifungals and pathogenesis, which 
suggests some level of chromatin regulating events (175). Specific histone modifications 
result in either the relaxing of the histone tail permitting access of transcriptional 
machinery to coding genes or tightening of the histone complex resulting in gene 
silencing. The role of various histone modification enzymes have already been 
investigated regarding pathogenesis and even antifungal resistance in Candida species as 
nicely reviewed by Lopes de Rosa and Kaufman (84). Identification of mutations that 
modulate chromatin structure in resistant isolates would further delineate drug resistance 
mechanisms and perhaps identify future drug targets. 
 
 
Employing genotypic testing as a tool to guide antifungal therapy 
 
As mentioned earlier, the CLSI guidelines have been recently modified for both 
azoles and echinocandins. Newer clinical breakpoints take into account species specific 
epidemiological cutoff values (ECV), resulting in species specific breakpoints to help 
guide therapy. Revising these breakpoints may allow us to detect Candida species and 
isolates that are a risk for the development of resistance. Although recent data show that 
C. albicans as a species remains largely susceptible to the azole class, this work 
demonstrates that azole resistance does arise in clinical isolates. As a means to quickly 
and efficiently guide treatment as well as to track resistance patterns in Candida species, 
genotypic data could potentially play a large role in guiding antifungal treatment in the 
future. 
 
As an example of this type of analysis, Shields et. al described the relationship 
between echinocandin MICs and patient responses to therapy in C. glabrata (176). 
Authors extracted information from medical records (prior echinocandin exposure, 
duration of treatment, patient outcomes) and tied this with microbiologic data such as 
caspofungin susceptibilities and occurrence of FKS mutations. This study produced a 
paradigm defining a method-specific caspofungin susceptibility threshold that was 
sensitive and specific enough to detect the presence of FKS mutations in C. glabrata. Of 
direct clinical importance, authors also identified prior echinocandin use and caspofungin 
MIC over the defined threshold (MIC > 0.25 µg/mL for E test) as the most sensitive 
predictors of treatment outcomes. 
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In C. albicans, azole resistance in clinical isolates is multifactorial but there is 
extensive data defining key mutations in genes resulting in a resistant phenotype. In a 
similar manner, it would be significant to use these data to further define treatment 
paradigms in an effort to detect resistant organisms and to improve patient outcomes. 
 
 
  
84 
LIST OF REFERENCES 
 
 
1. 1981. Centers for Disease Control and Prevention. Pneumocystis pneumonia--Los 
Angeles. MMWR Morb Mortal Wkly Rep 30:250-2. 
2. Achkar, J. M., and B. C. Fries. 2010. Candida infections of the genitourinary 
tract. Clin Microbiol Rev 23:253-73. 
3. Agvald-Ohman, C., L. Klingspor, H. Hjelmqvist, and C. Edlund. 2008. 
Invasive candidiasis in long-term patients at a multidisciplinary intensive care 
unit: Candida colonization index, risk factors, treatment and outcome. Scand J 
Infect Dis 40:145-53. 
4. Alonso-Monge, R., F. Navarro-Garcia, G. Molero, R. Diez-Orejas, M. Gustin, 
J. Pla, M. Sanchez, and C. Nombela. 1999. Role of the mitogen-activated 
protein kinase Hog1p in morphogenesis and virulence of Candida albicans. J 
Bacteriol 181:3058-68. 
5. Alvarez-Rueda, N., A. Fleury, F. Morio, F. Pagniez, L. Gastinel, and P. Le 
Pape. 2011. Amino acid substitutions at the major insertion loop of Candida 
albicans sterol 14alpha-demethylase are involved in fluconazole resistance. PLoS 
One 6:e21239. 
6. Ampel, N. M. 1996. Emerging disease issues and fungal pathogens associated 
with HIV infection. Emerg Infect Dis 2:109-16. 
7. Anderson, M. R., K. Klink, and A. Cohrssen. 2004. Evaluation of vaginal 
complaints. JAMA 291:1368-79. 
8. Andes, D., and M. van Ogtrop. 2000. In vivo characterization of the 
pharmacodynamics of flucytosine in a neutropenic murine disseminated 
candidiasis model. Antimicrob Agents Chemother 44:938-42. 
9. Ashley, E. D., R. Drew, M. Johnson, R. Danna, D. Dabrowski, V. Walker, M. 
Prasad, B. Alexander, G. Papadopoulos, and J. Perfect. 2012. Cost of Invasive 
Fungal Infections in the Era of New Diagnostics and Expanded Treatment 
Options. Pharmacotherapy. 
10. Barnett, J. A. 2004. A history of research on yeasts 8: taxonomy. Yeast 21:1141-
93. 
11. Beernaert, L. A., F. Pasmans, L. Van Waeyenberghe, F. Haesebrouck, and A. 
Martel. 2010. Aspergillus infections in birds: a review. Avian Pathol 39:325-31. 
12. Bennett, R. J., and A. D. Johnson. 2003. Completion of a parasexual cycle in 
Candida albicans by induced chromosome loss in tetraploid strains. EMBO J 
22:2505-15. 
13. Bhaumik, S. R., T. Raha, D. P. Aiello, and M. R. Green. 2004. In vivo target of 
a transcriptional activator revealed by fluorescence resonance energy transfer. 
Genes Dev 18:333-43. 
14. Blank, T. E., M. P. Woods, C. M. Lebo, P. Xin, and J. E. Hopper. 1997. Novel 
Gal3 proteins showing altered Gal80p binding cause constitutive transcription of 
Gal4p-activated genes in Saccharomyces cerevisiae. Mol Cell Biol 17:2566-75. 
15. Brammer, K. W., A. J. Coakley, S. G. Jezequel, and M. H. Tarbit. 1991. The 
disposition and metabolism of [14C]fluconazole in humans. Drug Metab Dispos 
19:764-7. 
  
85 
16. Brammer, K. W., P. R. Farrow, and J. K. Faulkner. 1990. Pharmacokinetics 
and tissue penetration of fluconazole in humans. Rev Infect Dis 12 Suppl 3:S318-
26. 
17. Bruno, V. M., and A. P. Mitchell. 2005. Regulation of azole drug susceptibility 
by Candida albicans protein kinase CK2. Mol Microbiol 56:559-73. 
18. Butler, G., M. D. Rasmussen, M. F. Lin, M. A. Santos, S. Sakthikumar, C. A. 
Munro, E. Rheinbay, M. Grabherr, A. Forche, J. L. Reedy, I. Agrafioti, M. 
B. Arnaud, S. Bates, A. J. Brown, S. Brunke, M. C. Costanzo, D. A. 
Fitzpatrick, P. W. de Groot, D. Harris, L. L. Hoyer, B. Hube, F. M. Klis, C. 
Kodira, N. Lennard, M. E. Logue, R. Martin, A. M. Neiman, E. Nikolaou, M. 
A. Quail, J. Quinn, M. C. Santos, F. F. Schmitzberger, G. Sherlock, P. Shah, 
K. A. Silverstein, M. S. Skrzypek, D. Soll, R. Staggs, I. Stansfield, M. P. 
Stumpf, P. E. Sudbery, T. Srikantha, Q. Zeng, J. Berman, M. Berriman, J. 
Heitman, N. A. Gow, M. C. Lorenz, B. W. Birren, M. Kellis, and C. A. 
Cuomo. 2009. Evolution of pathogenicity and sexual reproduction in eight 
Candida genomes. Nature 459:657-62. 
19. Casadevall, A. 2012. Fungi and the rise of mammals. PLoS Pathog 8:e1002808. 
20. Chan, C. K., and D. A. Jans. 1999. Synergy of importin alpha recognition and 
DNA binding by the yeast transcriptional activator GAL4. FEBS Lett 462:221-4. 
21. Chen, C. G., Y. L. Yang, H. I. Shih, C. L. Su, and H. J. Lo. 2004. CaNdt80 is 
involved in drug resistance in Candida albicans by regulating CDR1. Antimicrob 
Agents Chemother 48:4505-12. 
22. Coste, A., V. Turner, F. Ischer, J. Morschhauser, A. Forche, A. Selmecki, J. 
Berman, J. Bille, and D. Sanglard. 2006. A mutation in Tac1p, a transcription 
factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at 
chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 
172:2139-56. 
23. Coste, A. T., M. Karababa, F. Ischer, J. Bille, and D. Sanglard. 2004. TAC1, 
transcriptional activator of CDR genes, is a new transcription factor involved in 
the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot 
Cell 3:1639-52. 
24. Cournia, Z., G. M. Ullmann, and J. C. Smith. 2007. Differential effects of 
cholesterol, ergosterol and lanosterol on a dipalmitoyl phosphatidylcholine 
membrane: a molecular dynamics simulation study. J Phys Chem B 111:1786-
801. 
25. Courtney, R., E. Radwanski, J. Lim, and M. Laughlin. 2004. 
Pharmacokinetics of posaconazole coadministered with antacid in fasting or 
nonfasting healthy men. Antimicrob Agents Chemother 48:804-8. 
26. Courtney, R., Sansone-Parsons, A., Devlin, D., Soni, P., Laughlin, M., Simon, 
J. 2004. P-Glycoprotein (P-gp) expression and gentype: exploratory analysis of 
posaconazole (POS) in healthy volunteers. . Intrsci Conf Antimicrob Agents 
Chemother Abstract A-40. 
27. Courtney, R., D. Wexler, E. Radwanski, J. Lim, and M. Laughlin. 2004. 
Effect of food on the relative bioavailability of two oral formulations of 
posaconazole in healthy adults. Br J Clin Pharmacol 57:218-22. 
  
86 
28. Crowley, J. H., F. W. Leak, Jr., K. V. Shianna, S. Tove, and L. W. Parks. 
1998. A mutation in a purported regulatory gene affects control of sterol uptake in 
Saccharomyces cerevisiae. J Bacteriol 180:4177-83. 
29. Crump, J. A., and P. J. Collignon. 2000. Intravascular catheter-associated 
infections. Eur J Clin Microbiol Infect Dis 19:1-8. 
30. Cryan, P. M., C. U. Meteyer, D. S. Blehert, J. M. Lorch, D. M. Reeder, G. G. 
Turner, J. Webb, M. Behr, M. Verant, R. E. Russell, and K. T. Castle. 2013. 
Electrolyte depletion in white-nose syndrome bats. J Wildl Dis 49:398-402. 
31. Cryan, P. M., C. U. Meteyer, J. G. Boyles, and D. S. Blehert. 2013. White-nose 
syndrome in bats: illuminating the darkness. BMC Biol 11:47. 
32. Csank, C., K. Schroppel, E. Leberer, D. Harcus, O. Mohamed, S. Meloche, D. 
Y. Thomas, and M. Whiteway. 1998. Roles of the Candida albicans mitogen-
activated protein kinase homolog, Cek1p, in hyphal development and systemic 
candidiasis. Infect Immun 66:2713-21. 
33. Dalle, F., B. Wachtler, C. L'Ollivier, G. Holland, N. Bannert, D. Wilson, C. 
Labruere, A. Bonnin, and B. Hube. Cellular interactions of Candida albicans 
with human oral epithelial cells and enterocytes. Cell Microbiol 12:248-71. 
34. Davies, B. S., and J. Rine. 2006. A role for sterol levels in oxygen sensing in 
Saccharomyces cerevisiae. Genetics 174:191-201. 
35. de Leon, E. M., S. J. Jacober, J. D. Sobel, and B. Foxman. 2002. Prevalence 
and risk factors for vaginal Candida colonization in women with type 1 and type 2 
diabetes. BMC Infect Dis 2:1. 
36. de Micheli, M., J. Bille, C. Schueller, and D. Sanglard. 2002. A common drug-
responsive element mediates the upregulation of the Candida albicans ABC 
transporters CDR1 and CDR2, two genes involved in antifungal drug resistance. 
Mol Microbiol 43:1197-214. 
37. Delgado, A. C., R. de Jesus Pedro, F. H. Aoki, M. R. Resende, P. Trabasso, A. 
L. Colombo, M. S. de Oliveira, Y. Mikami, and M. L. Moretti. 2009. Clinical 
and microbiological assessment of patients with a long-term diagnosis of human 
immunodeficiency virus infection and Candida oral colonization. Clin Microbiol 
Infect 15:364-71. 
38. Denisov, I. G., A. Y. Shih, and S. G. Sligar. 2012. Structural differences 
between soluble and membrane bound cytochrome P450s. J Inorg Biochem 
108:150-8. 
39. Deray, G. 2002. Amphotericin B nephrotoxicity. J Antimicrob Chemother 49 
Suppl 1:37-41. 
40. Desta, Z., X. Zhao, J. G. Shin, and D. A. Flockhart. 2002. Clinical significance 
of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 
41:913-58. 
41. Diez-Orejas, R., G. Molero, F. Navarro-Garcia, J. Pla, C. Nombela, and M. 
Sanchez-Perez. 1997. Reduced virulence of Candida albicans MKC1 mutants: a 
role for mitogen-activated protein kinase in pathogenesis. Infect Immun 65:833-7. 
42. Dore, G. J., and D. A. Cooper. 2006. HAART's first decade: success brings 
further challenges. Lancet 368:427-8. 
 
  
87 
43. Dunkel, N., J. Blass, P. D. Rogers, and J. Morschhauser. 2008. Mutations in 
the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are 
the main cause of MDR1 overexpression in fluconazole-resistant Candida 
albicans strains. Mol Microbiol 69:827-40. 
44. Dunkel, N., T. T. Liu, K. S. Barker, R. Homayouni, J. Morschhauser, and P. 
D. Rogers. 2008. A gain-of-function mutation in the transcription factor Upc2p 
causes upregulation of ergosterol biosynthesis genes and increased fluconazole 
resistance in a clinical Candida albicans isolate. Eukaryot Cell 7:1180-90. 
45. Ezzet, F., D. Wexler, R. Courtney, G. Krishna, J. Lim, and M. Laughlin. 
2005. Oral bioavailability of posaconazole in fasted healthy subjects: comparison 
between three regimens and basis for clinical dosage recommendations. Clin 
Pharmacokinet 44:211-20. 
46. Fanning, S., and A. P. Mitchell. Fungal biofilms. PLoS Pathog 8:e1002585. 
47. Feigal, D. W., M. H. Katz, D. Greenspan, J. Westenhouse, W. Winkelstein, 
Jr., W. Lang, M. Samuel, S. P. Buchbinder, N. A. Hessol, A. R. Lifson, and et 
al. 1991. The prevalence of oral lesions in HIV-infected homosexual and bisexual 
men: three San Francisco epidemiological cohorts. AIDS 5:519-25. 
48. Finkel, J. S., and A. P. Mitchell. Genetic control of Candida albicans biofilm 
development. Nat Rev Microbiol 9:109-18. 
49. Fisher, J. F., C. L. Newman, and J. D. Sobel. 1995. Yeast in the urine: solutions 
for a budding problem. Clin Infect Dis 20:183-9. 
50. Flowers, S. A., K. S. Barker, E. L. Berkow, G. Toner, S. G. Chadwick, S. E. 
Gygax, J. Morschhauser, and P. D. Rogers. 2012. Gain-of-function mutations 
in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical 
isolates of Candida albicans. Eukaryot Cell 11:1289-99. 
51. Forche, A., K. Alby, D. Schaefer, A. D. Johnson, J. Berman, and R. J. 
Bennett. 2008. The parasexual cycle in Candida albicans provides an alternative 
pathway to meiosis for the formation of recombinant strains. PLoS Biol 6:e110. 
52. Forche, A., P. T. Magee, A. Selmecki, J. Berman, and G. May. 2009. 
Evolution in Candida albicans populations during a single passage through a 
mouse host. Genetics 182:799-811. 
53. Franz, R., M. Ruhnke, and J. Morschhauser. 1999. Molecular aspects of 
fluconazole resistance development in Candida albicans. Mycoses 42:453-8. 
54. Frohner, I. E., C. Bourgeois, K. Yatsyk, O. Majer, and K. Kuchler. 2009. 
Candida albicans cell surface superoxide dismutases degrade host-derived 
reactive oxygen species to escape innate immune surveillance. Mol Microbiol 
71:240-52. 
55. Gao, C., L. Wang, E. Milgrom, and W. C. Shen. 2004. On the mechanism of 
constitutive Pdr1 activator-mediated PDR5 transcription in Saccharomyces 
cerevisiae: evidence for enhanced recruitment of coactivators and altered 
nucleosome structures. J Biol Chem 279:42677-86. 
56. Garaizar, J., S. Brena, J. Bikandi, A. Rementeria, and J. Ponton. 2006. Use of 
DNA microarray technology and gene expression profiles to investigate the 
pathogenesis, cell biology, antifungal susceptibility and diagnosis of Candida 
albicans. FEMS Yeast Res 6:987-98. 
  
88 
57. Garey, K. W., M. Rege, M. P. Pai, D. E. Mingo, K. J. Suda, R. S. Turpin, and 
D. T. Bearden. 2006. Time to initiation of fluconazole therapy impacts mortality 
in patients with candidemia: a multi-institutional study. Clin Infect Dis 43:25-31. 
58. Ghannoum, M. A., R. J. Jurevic, P. K. Mukherjee, F. Cui, M. Sikaroodi, A. 
Naqvi, and P. M. Gillevet. 2010. Characterization of the oral fungal microbiome 
(mycobiome) in healthy individuals. PLoS Pathog 6:e1000713. 
59. Ghannoum, M. A., and L. B. Rice. 1999. Antifungal agents: mode of action, 
mechanisms of resistance, and correlation of these mechanisms with bacterial 
resistance. Clin Microbiol Rev 12:501-17. 
60. Ghosal, A., N. Hapangama, Y. Yuan, J. Achanfuo-Yeboah, R. Iannucci, S. 
Chowdhury, K. Alton, J. E. Patrick, and S. Zbaida. 2004. Identification of 
human UDP-glucuronosyltransferase enzyme(s) responsible for the 
glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 32:314-20. 
61. Ghosh, S., D. H. Navarathna, D. D. Roberts, J. T. Cooper, A. L. Atkin, T. M. 
Petro, and K. W. Nickerson. 2009. Arginine-induced germ tube formation in 
Candida albicans is essential for escape from murine macrophage line RAW 
264.7. Infect Immun 77:1596-605. 
62. Gow, N. A., and B. Hube. Importance of the Candida albicans cell wall during 
commensalism and infection. Curr Opin Microbiol 15:406-12. 
63. Gray, K. C., D. S. Palacios, I. Dailey, M. M. Endo, B. E. Uno, B. C. Wilcock, 
and M. D. Burke. 2012. Amphotericin primarily kills yeast by simply binding 
ergosterol. Proc Natl Acad Sci U S A 109:2234-9. 
64. Gray, R. R., A. J. Tatem, J. A. Johnson, A. V. Alekseyenko, O. G. Pybus, M. 
A. Suchard, and M. Salemi. 2011. Testing spatiotemporal hypothesis of 
bacterial evolution using methicillin-resistant Staphylococcus aureus ST239 
genome-wide data within a bayesian framework. Mol Biol Evol 28:1593-603. 
65. Groll, A. H., J. C. Gea-Banacloche, A. Glasmacher, G. Just-Nuebling, G. 
Maschmeyer, and T. J. Walsh. 2003. Clinical pharmacology of antifungal 
compounds. Infect Dis Clin North Am 17:159-91, ix. 
66. Heilmann, C. J., S. Schneider, K. S. Barker, P. D. Rogers, and J. 
Morschhauser. 2010. An A643T mutation in the transcription factor Upc2p 
causes constitutive ERG11 upregulation and increased fluconazole resistance in 
Candida albicans. Antimicrob Agents Chemother 54:353-9. 
67. Hepworth, S. R., H. Friesen, and J. Segall. 1998. NDT80 and the meiotic 
recombination checkpoint regulate expression of middle sporulation-specific 
genes in Saccharomyces cerevisiae. Mol Cell Biol 18:5750-61. 
68. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J. 
W. Oestmann, W. V. Kern, K. A. Marr, P. Ribaud, O. Lortholary, R. 
Sylvester, R. H. Rubin, J. R. Wingard, P. Stark, C. Durand, D. Caillot, E. 
Thiel, P. H. Chandrasekar, M. R. Hodges, H. T. Schlamm, P. F. Troke, and 
B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of 
invasive aspergillosis. N Engl J Med 347:408-15. 
69. Hernday, A. D., S. M. Noble, Q. M. Mitrovich, and A. D. Johnson. Genetics 
and molecular biology in Candida albicans. Methods Enzymol 470:737-58. 
 
  
89 
70. Hickman, M. A., G. Zeng, A. Forche, M. P. Hirakawa, D. Abbey, B. D. 
Harrison, Y. M. Wang, C. H. Su, R. J. Bennett, Y. Wang, and J. Berman. The 
'obligate diploid' Candida albicans forms mating-competent haploids. Nature 
494:55-9. 
71. Hollenbach, E. 2008. To treat or not to treat--critically ill patients with 
candiduria. Mycoses 51 Suppl 2:12-24. 
72. Holubar, K., and N. Wikonkal. 2010. David Gruby 1810-1898: unveiling of a 
portrait bust in his birthplace. Skinmed 8:294-5. 
73. Hoot, S. J., R. P. Brown, B. G. Oliver, and T. C. White. 2010. The UPC2 
promoter in Candida albicans contains two cis-acting elements that bind directly 
to Upc2p, resulting in transcriptional autoregulation. Eukaryot Cell 9:1354-62. 
74. Hoot, S. J., A. R. Smith, R. P. Brown, and T. C. White. 2011. An A643V 
amino acid substitution in Upc2p contributes to azole resistance in well-
characterized clinical isolates of Candida albicans. Antimicrob Agents Chemother 
55:940-2. 
75. Huh, W. K., J. V. Falvo, L. C. Gerke, A. S. Carroll, R. W. Howson, J. S. 
Weissman, and E. K. O'Shea. 2003. Global analysis of protein localization in 
budding yeast. Nature 425:686-91. 
76. Hull, C. M., and A. D. Johnson. 1999. Identification of a mating type-like locus 
in the asexual pathogenic yeast Candida albicans. Science 285:1271-5. 
77. Hwang, C. S., G. E. Rhie, J. H. Oh, W. K. Huh, H. S. Yim, and S. O. Kang. 
2002. Copper- and zinc-containing superoxide dismutase (Cu/ZnSOD) is required 
for the protection of Candida albicans against oxidative stresses and the 
expression of its full virulence. Microbiology 148:3705-13. 
78. Isoherranen, N., K. L. Kunze, K. E. Allen, W. L. Nelson, and K. E. Thummel. 
2004. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 
32:1121-31. 
79. Jacobsen, I. D., D. Wilson, B. Wachtler, S. Brunke, J. R. Naglik, and B. 
Hube. Candida albicans dimorphism as a therapeutic target. Expert Rev Anti 
Infect Ther 10:85-93. 
80. Johnson, A. 2003. The biology of mating in Candida albicans. Nat Rev Microbiol 
1:106-16. 
81. Johnson, L. B., and C. A. Kauffman. 2003. Voriconazole: a new triazole 
antifungal agent. Clin Infect Dis 36:630-7. 
82. Jones, T., N. A. Federspiel, H. Chibana, J. Dungan, S. Kalman, B. B. Magee, 
G. Newport, Y. R. Thorstenson, N. Agabian, P. T. Magee, R. W. Davis, and 
S. Scherer. 2004. The diploid genome sequence of Candida albicans. Proc Natl 
Acad Sci U S A 101:7329-34. 
83. Kadosh, D., and K. Struhl. 1997. Repression by Ume6 involves recruitment of a 
complex containing Sin3 corepressor and Rpd3 histone deacetylase to target 
promoters. Cell 89:365-71. 
84. Kaufman, D. A. 2012. "Getting to Zero": preventing invasive Candida infections 
and eliminating infection-related mortality and morbidity in extremely preterm 
infants. Early Hum Dev 88 Suppl 2:S45-9. 
  
90 
85. Kelly, S. L., D. C. Lamb, and D. E. Kelly. 1999. Y132H substitution in Candida 
albicans sterol 14alpha-demethylase confers fluconazole resistance by preventing 
binding to haem. FEMS Microbiol Lett 180:171-5. 
86. Kelly, S. L., D. C. Lamb, J. Loeffler, H. Einsele, and D. E. Kelly. 1999. The 
G464S amino acid substitution in Candida albicans sterol 14alpha-demethylase 
causes fluconazole resistance in the clinic through reduced affinity. Biochem 
Biophys Res Commun 262:174-9. 
87. Kirk, P. 2008. Dictionary of the Fungi, 10th ed. CAB International, Wallingford. 
88. Klein, R. S., C. A. Harris, C. B. Small, B. Moll, M. Lesser, and G. H. 
Friedland. 1984. Oral candidiasis in high-risk patients as the initial manifestation 
of the acquired immunodeficiency syndrome. N Engl J Med 311:354-8. 
89. Klepser, M. E., E. J. Wolfe, R. N. Jones, C. H. Nightingale, and M. A. Pfaller. 
1997. Antifungal pharmacodynamic characteristics of fluconazole and 
amphotericin B tested against Candida albicans. Antimicrob Agents Chemother 
41:1392-5. 
90. Kontoyiannis, D. P., and R. E. Lewis. 2002. Antifungal drug resistance of 
pathogenic fungi. Lancet 359:1135-44. 
91. Krieter, P., B. Flannery, T. Musick, M. Gohdes, M. Martinho, and R. 
Courtney. 2004. Disposition of posaconazole following single-dose oral 
administration in healthy subjects. Antimicrob Agents Chemother 48:3543-51. 
92. Kuse, E. R., P. Chetchotisakd, C. A. da Cunha, M. Ruhnke, C. Barrios, D. 
Raghunadharao, J. S. Sekhon, A. Freire, V. Ramasubramanian, I. Demeyer, 
M. Nucci, A. Leelarasamee, F. Jacobs, J. Decruyenaere, D. Pittet, A. J. 
Ullmann, L. Ostrosky-Zeichner, O. Lortholary, S. Koblinger, H. Diekmann-
Berndt, and O. A. Cornely. 2007. Micafungin versus liposomal amphotericin B 
for candidaemia and invasive candidosis: a phase III randomised double-blind 
trial. Lancet 369:1519-27. 
93. Kvaal, C., S. A. Lachke, T. Srikantha, K. Daniels, J. McCoy, and D. R. Soll. 
1999. Misexpression of the opaque-phase-specific gene PEP1 (SAP1) in the white 
phase of Candida albicans confers increased virulence in a mouse model of 
cutaneous infection. Infect Immun 67:6652-62. 
94. Kvaal, C. A., T. Srikantha, and D. R. Soll. 1997. Misexpression of the white-
phase-specific gene WH11 in the opaque phase of Candida albicans affects 
switching and virulence. Infect Immun 65:4468-75. 
95. Lamb, D. C., L. Lei, A. G. Warrilow, G. I. Lepesheva, J. G. Mullins, M. R. 
Waterman, and S. L. Kelly. 2009. The first virally encoded cytochrome p450. J 
Virol 83:8266-9. 
96. Lenardon, M. D., and A. Nantel. 2012. Rapid detection of aneuploidy following 
the generation of mutants in Candida albicans. Methods Mol Biol 845:41-9. 
97. Leon, C., S. Ruiz-Santana, P. Saavedra, B. Almirante, J. Nolla-Salas, F. 
Alvarez-Lerma, J. Garnacho-Montero, and M. A. Leon. 2006. A bedside 
scoring system ("Candida score") for early antifungal treatment in nonneutropenic 
critically ill patients with Candida colonization. Crit Care Med 34:730-7. 
98. Lepesheva, G. I., and M. R. Waterman. 2004. CYP51--the omnipotent P450. 
Mol Cell Endocrinol 215:165-70. 
  
91 
99. Li, F., L. Wu, B. Cao, Y. Zhang, X. Li, and Y. Liu. 2013. Surveillance of the 
prevalence, antibiotic susceptibility, and genotypic characterization of invasive 
candidiasis in a teaching hospital in China between 2006 to 2011. BMC Infect Dis 
13:353. 
100. Lin, H. X., and K. A. White. 2004. A complex network of RNA-RNA 
interactions controls subgenomic mRNA transcription in a tombusvirus. EMBO J 
23:3365-74. 
101. Lo, H. J., J. R. Kohler, B. DiDomenico, D. Loebenberg, A. Cacciapuoti, and 
G. R. Fink. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell 90:939-
49. 
102. Lohr, D., P. Venkov, and J. Zlatanova. 1995. Transcriptional regulation in the 
yeast GAL gene family: a complex genetic network. FASEB J 9:777-87. 
103. Lopes da Rosa, J., and P. D. Kaufman. 2012. Chromatin-mediated Candida 
albicans virulence. Biochim Biophys Acta 1819:349-55. 
104. Lopez-Ribot, J. L. 2005. Candida albicans biofilms: more than filamentation. 
Curr Biol 15:R453-5. 
105. Lopez-Ribot, J. L., R. K. McAtee, L. N. Lee, W. R. Kirkpatrick, T. C. White, 
D. Sanglard, and T. F. Patterson. 1998. Distinct patterns of gene expression 
associated with development of fluconazole resistance in serial candida albicans 
isolates from human immunodeficiency virus-infected patients with 
oropharyngeal candidiasis. Antimicrob Agents Chemother 42:2932-7. 
106. Lorenz, M. C., J. A. Bender, and G. R. Fink. 2004. Transcriptional response of 
Candida albicans upon internalization by macrophages. Eukaryot Cell 3:1076-87. 
107. Lutsar, I., S. Roffey, and P. Troke. 2003. Voriconazole concentrations in the 
cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised 
patients. Clin Infect Dis 37:728-32. 
108. MacPherson, S., B. Akache, S. Weber, X. De Deken, M. Raymond, and B. 
Turcotte. 2005. Candida albicans zinc cluster protein Upc2p confers resistance to 
antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob 
Agents Chemother 49:1745-52. 
109. MacPherson, S., M. Larochelle, and B. Turcotte. 2006. A fungal family of 
transcriptional regulators: the zinc cluster proteins. Microbiol Mol Biol Rev 
70:583-604. 
110. Manavathu, E. K., J. L. Cutright, and P. H. Chandrasekar. 1998. Organism-
dependent fungicidal activities of azoles. Antimicrob Agents Chemother 42:3018-
21. 
111. Manavathu, E. K., S. Kallakuri, M. T. Arganoza, and J. A. Vazquez. 1999. 
Amino acid variations of cytochrome P-450 lanosterol 14 alpha-demethylase 
(CYP51A1) from fluconazoleresistant clinical isolates of Candida albicans. Rev 
Iberoam Micol 16:198-203. 
112. Manoharlal, R., N. A. Gaur, S. L. Panwar, J. Morschhauser, and R. Prasad. 
2008. Transcriptional activation and increased mRNA stability contribute to 
overexpression of CDR1 in azole-resistant Candida albicans. Antimicrob Agents 
Chemother 52:1481-92. 
 
  
92 
113. Mansfield, B. E., H. N. Oltean, B. G. Oliver, S. J. Hoot, S. E. Leyde, L. 
Hedstrom, and T. C. White. 2010. Azole drugs are imported by facilitated 
diffusion in Candida albicans and other pathogenic fungi. PLoS Pathog 
6:e1001126. 
114. Marichal, P., L. Koymans, S. Willemsens, D. Bellens, P. Verhasselt, W. 
Luyten, M. Borgers, F. C. Ramaekers, F. C. Odds, and H. V. Bossche. 1999. 
Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, 
Cyp51p) to azole resistance in Candida albicans. Microbiology 145 ( Pt 10):2701-
13. 
115. Marie, C., S. Leyde, and T. C. White. 2008. Cytoplasmic localization of sterol 
transcription factors Upc2p and Ecm22p in S. cerevisiae. Fungal Genet Biol 
45:1430-8. 
116. Martchenko, M., A. M. Alarco, D. Harcus, and M. Whiteway. 2004. 
Superoxide dismutases in Candida albicans: transcriptional regulation and 
functional characterization of the hyphal-induced SOD5 gene. Mol Biol Cell 
15:456-67. 
117. Mayer, F. L., D. Wilson, and B. Hube. 2013. Candida albicans pathogenicity 
mechanisms. Virulence 4:119-28. 
118. McNeil, M. M., S. L. Nash, R. A. Hajjeh, M. A. Phelan, L. A. Conn, B. D. 
Plikaytis, and D. W. Warnock. 2001. Trends in mortality due to invasive 
mycotic diseases in the United States, 1980-1997. Clin Infect Dis 33:641-7. 
119. Miyazaki, Y., A. Geber, H. Miyazaki, D. Falconer, T. Parkinson, C. 
Hitchcock, B. Grimberg, K. Nyswaner, and J. E. Bennett. 1999. Cloning, 
sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol 
desaturase gene) in Candida albicans. Gene 236:43-51. 
120. Mogavero, S., A. Tavanti, S. Senesi, P. D. Rogers, and J. Morschhauser. 
2011. Differential requirement of the transcription factor Mcm1 for activation of 
the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and 
Cap1. Antimicrob Agents Chemother 55:2061-6. 
121. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, 
J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. 
Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J 
Med 347:2020-9. 
122. Morio, F., C. Loge, B. Besse, C. Hennequin, and P. Le Pape. 2010. Screening 
for amino acid substitutions in the Candida albicans Erg11 protein of azole-
susceptible and azole-resistant clinical isolates: new substitutions and a review of 
the literature. Diagn Microbiol Infect Dis 66:373-84. 
123. Morio, F., F. Pagniez, C. Lacroix, M. Miegeville, and P. Le Pape. 2012. 
Amino acid substitutions in the Candida albicans sterol Delta5,6-desaturase 
(Erg3p) confer azole resistance: characterization of two novel mutants with 
impaired virulence. J Antimicrob Chemother 67:2131-8. 
124. Morrow, C. A., and J. A. Fraser. 2013. Ploidy variation as an adaptive 
mechanism in human pathogenic fungi. Semin Cell Dev Biol 24:339-46. 
125. Morschhauser, J. 2002. The genetic basis of fluconazole resistance development 
in Candida albicans. Biochim Biophys Acta 1587:240-8. 
  
93 
126. Morschhauser, J. Regulation of white-opaque switching in Candida albicans. 
Med Microbiol Immunol 199:165-72. 
127. Morschhauser, J., K. S. Barker, T. T. Liu, B. W. J. Bla, R. Homayouni, and 
P. D. Rogers. 2007. The transcription factor Mrr1p controls expression of the 
MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS 
Pathog 3:e164. 
128. Muratani, M., C. Kung, K. M. Shokat, and W. P. Tansey. 2005. The F box 
protein Dsg1/Mdm30 is a transcriptional coactivator that stimulates Gal4 turnover 
and cotranscriptional mRNA processing. Cell 120:887-99. 
129. Naglik, J. R., D. L. Moyes, B. Wachtler, and B. Hube. Candida albicans 
interactions with epithelial cells and mucosal immunity. Microbes Infect 13:963-
76. 
130. Nelson, D. R. 1999. Cytochrome P450 and the individuality of species. Arch 
Biochem Biophys 369:1-10. 
131. Niwa, T., T. Shiraga, and A. Takagi. 2005. Effect of antifungal drugs on 
cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver 
microsomes. Biol Pharm Bull 28:1805-8. 
132. Noble, S. M., S. French, L. A. Kohn, V. Chen, and A. D. Johnson. Systematic 
screens of a Candida albicans homozygous deletion library decouple 
morphogenetic switching and pathogenicity. Nat Genet 42:590-8. 
133. Odds, F. C., M. E. Bougnoux, D. J. Shaw, J. M. Bain, A. D. Davidson, D. 
Diogo, M. D. Jacobsen, M. Lecomte, S. Y. Li, A. Tavanti, M. C. Maiden, N. 
A. Gow, and C. d'Enfert. 2007. Molecular phylogenetics of Candida albicans. 
Eukaryot Cell 6:1041-52. 
134. Odds, F. C., A. D. Davidson, M. D. Jacobsen, A. Tavanti, J. A. Whyte, C. C. 
Kibbler, D. H. Ellis, M. C. Maiden, D. J. Shaw, and N. A. Gow. 2006. Candida 
albicans strain maintenance, replacement, and microvariation demonstrated by 
multilocus sequence typing. J Clin Microbiol 44:3647-58. 
135. Oliver, B. G., J. L. Song, J. H. Choiniere, and T. C. White. 2007. cis-Acting 
elements within the Candida albicans ERG11 promoter mediate the azole 
response through transcription factor Upc2p. Eukaryot Cell 6:2231-9. 
136. Orozco, A. S., L. M. Higginbotham, C. A. Hitchcock, T. Parkinson, D. 
Falconer, A. S. Ibrahim, M. A. Ghannoum, and S. G. Filler. 1998. Mechanism 
of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 
42:2645-9. 
137. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, 
H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. 
Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 
bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 
47:3149-54. 
138. Oude Lashof, A. M., J. D. Sobel, M. Ruhnke, P. G. Pappas, C. Viscoli, H. T. 
Schlamm, J. H. Rex, and B. J. Kullberg. 2012. Safety and tolerability of 
voriconazole in patients with baseline renal insufficiency and candidemia. 
Antimicrob Agents Chemother 56:3133-7. 
 
  
94 
139. Pappas, P. G., C. A. Kauffman, D. Andes, D. K. Benjamin, Jr., T. F. 
Calandra, J. E. Edwards, Jr., S. G. Filler, J. F. Fisher, B. J. Kullberg, L. 
Ostrosky-Zeichner, A. C. Reboli, J. H. Rex, T. J. Walsh, and J. D. Sobel. 
2009. Clinical practice guidelines for the management of candidiasis: 2009 update 
by the Infectious Diseases Society of America. Clin Infect Dis 48:503-35. 
140. Patel, P. K., J. E. Erlandsen, W. R. Kirkpatrick, D. K. Berg, S. D. 
Westbrook, C. Louden, J. E. Cornell, G. R. Thompson, A. C. Vallor, B. L. 
Wickes, N. P. Wiederhold, S. W. Redding, and T. F. Patterson. 2012. The 
Changing Epidemiology of Oropharyngeal Candidiasis in Patients with 
HIV/AIDS in the Era of Antiretroviral Therapy. AIDS Res Treat 2012:262471. 
141. Peng, G., and J. E. Hopper. 2002. Gene activation by interaction of an inhibitor 
with a cytoplasmic signaling protein. Proc Natl Acad Sci U S A 99:8548-53. 
142. Perea, S., J. L. Lopez-Ribot, W. R. Kirkpatrick, R. K. McAtee, R. A. 
Santillan, M. Martinez, D. Calabrese, D. Sanglard, and T. F. Patterson. 2001. 
Prevalence of molecular mechanisms of resistance to azole antifungal agents in 
Candida albicans strains displaying high-level fluconazole resistance isolated 
from human immunodeficiency virus-infected patients. Antimicrob Agents 
Chemother 45:2676-84. 
143. Pfaller, M., D. Neofytos, D. Diekema, N. Azie, H. U. Meier-Kriesche, S. P. 
Quan, and D. Horn. 2012. Epidemiology and outcomes of candidemia in 3648 
patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) 
registry, 2004-2008. Diagn Microbiol Infect Dis 74:323-31. 
144. Pfaller, M. A. 2012. Antifungal drug resistance: mechanisms, epidemiology, and 
consequences for treatment. Am J Med 125:S3-13. 
145. Pfaller, M. A., D. Andes, D. J. Diekema, A. Espinel-Ingroff, and D. Sheehan. 
2010. Wild-type MIC distributions, epidemiological cutoff values and species-
specific clinical breakpoints for fluconazole and Candida: time for harmonization 
of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 13:180-
95. 
146. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. 
Diekema. 2005. In vitro activities of anidulafungin against more than 2,500 
clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J 
Clin Microbiol 43:5425-7. 
147. Pfaller, M. A., D. J. Diekema, S. A. Messer, R. J. Hollis, and R. N. Jones. 
2003. In vitro activities of caspofungin compared with those of fluconazole and 
itraconazole against 3,959 clinical isolates of Candida spp., including 157 
fluconazole-resistant isolates. Antimicrob Agents Chemother 47:1068-71. 
148. Pfaller, M. A., S. A. Messer, L. Boyken, R. J. Hollis, C. Rice, S. Tendolkar, 
and D. J. Diekema. 2004. In vitro activities of voriconazole, posaconazole, and 
fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus 
neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal 
surveillance program. Diagn Microbiol Infect Dis 48:201-5. 
149. Pfaller, M. A., S. A. Messer, R. J. Hollis, and R. N. Jones. 2001. In vitro 
activities of posaconazole (Sch 56592) compared with those of itraconazole and 
fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus 
neoformans. Antimicrob Agents Chemother 45:2862-4. 
  
95 
150. Pittet, D., M. Monod, P. M. Suter, E. Frenk, and R. Auckenthaler. 1994. 
Candida colonization and subsequent infections in critically ill surgical patients. 
Ann Surg 220:751-8. 
151. Poirier, J. M., and G. Cheymol. 1998. Optimisation of itraconazole therapy 
using target drug concentrations. Clin Pharmacokinet 35:461-73. 
152. Prasad, R., P. De Wergifosse, A. Goffeau, and E. Balzi. 1995. Molecular 
cloning and characterization of a novel gene of Candida albicans, CDR1, 
conferring multiple resistance to drugs and antifungals. Curr Genet 27:320-9. 
153. Rangel-Frausto, M. S., T. Wiblin, H. M. Blumberg, L. Saiman, J. Patterson, 
M. Rinaldi, M. Pfaller, J. E. Edwards, Jr., W. Jarvis, J. Dawson, and R. P. 
Wenzel. 1999. National epidemiology of mycoses survey (NEMIS): variations in 
rates of bloodstream infections due to Candida species in seven surgical intensive 
care units and six neonatal intensive care units. Clin Infect Dis 29:253-8. 
154. Reboli, A. C., C. Rotstein, P. G. Pappas, S. W. Chapman, D. H. Kett, D. 
Kumar, R. Betts, M. Wible, B. P. Goldstein, J. Schranz, D. S. Krause, and T. 
J. Walsh. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N 
Engl J Med 356:2472-82. 
155. Redding, S., J. Smith, G. Farinacci, M. Rinaldi, A. Fothergill, J. Rhine-
Chalberg, and M. Pfaller. 1994. Resistance of Candida albicans to fluconazole 
during treatment of oropharyngeal candidiasis in a patient with AIDS: 
documentation by in vitro susceptibility testing and DNA subtype analysis. Clin 
Infect Dis 18:240-2. 
156. Reuss, O., A. Vik, R. Kolter, and J. Morschhauser. 2004. The SAT1 flipper, an 
optimized tool for gene disruption in Candida albicans. Gene 341:119-27. 
157. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida 
species to fluconazole. Antimicrob Agents Chemother 39:1-8. 
158. Rogers, P. D., and K. S. Barker. 2002. Evaluation of differential gene 
expression in fluconazole-susceptible and -resistant isolates of Candida albicans 
by cDNA microarray analysis. Antimicrob Agents Chemother 46:3412-7. 
159. Saag, M. S., R. J. Graybill, R. A. Larsen, P. G. Pappas, J. R. Perfect, W. G. 
Powderly, J. D. Sobel, and W. E. Dismukes. 2000. Practice guidelines for the 
management of cryptococcal disease. Infectious Diseases Society of America. 
Clin Infect Dis 30:710-8. 
160. Sadowski, I., C. Costa, and R. Dhanawansa. 1996. Phosphorylation of Ga14p at 
a single C-terminal residue is necessary for galactose-inducible transcription. Mol 
Cell Biol 16:4879-87. 
161. Salmeron, J. M., Jr., K. K. Leuther, and S. A. Johnston. 1990. GAL4 
mutations that separate the transcriptional activation and GAL80-interactive 
functions of the yeast GAL4 protein. Genetics 125:21-7. 
162. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1998. Amino acid 
substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase 
(CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to 
resistance to azole antifungal agents. Antimicrob Agents Chemother 42:241-53. 
163. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1997. Cloning of Candida 
albicans genes conferring resistance to azole antifungal agents: characterization of 
CDR2, a new multidrug ABC transporter gene. Microbiology 143 ( Pt 2):405-16. 
  
96 
164. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1996. Susceptibilities of 
Candida albicans multidrug transporter mutants to various antifungal agents and 
other metabolic inhibitors. Antimicrob Agents Chemother 40:2300-5. 
165. Sanglard, D., K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille. 
1995. Mechanisms of resistance to azole antifungal agents in Candida albicans 
isolates from AIDS patients involve specific multidrug transporters. Antimicrob 
Agents Chemother 39:2378-86. 
166. Sasse, C., N. Dunkel, T. Schafer, S. Schneider, F. Dierolf, K. Ohlsen, and J. 
Morschhauser. 2012. The stepwise acquisition of fluconazole resistance 
mutations causes a gradual loss of fitness in Candida albicans. Mol Microbiol 
86:539-56. 
167. Sasse, C., M. Hasenberg, M. Weyler, M. Gunzer, and J. Morschhauser. 2013. 
White-opaque switching of Candida albicans allows immune evasion in an 
environment-dependent fashion. Eukaryot Cell 12:50-8. 
168. Schillig, R., and J. Morschhauser. 2013. Analysis of a fungus-specific 
transcription factor family, the Candida albicans zinc cluster proteins, by artificial 
activation. Mol Microbiol. 
169. Schubert, S., K. S. Barker, S. Znaidi, S. Schneider, F. Dierolf, N. Dunkel, M. 
Aid, G. Boucher, P. D. Rogers, M. Raymond, and J. Morschhauser. 2011. 
Regulation of efflux pump expression and drug resistance by the transcription 
factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob Agents 
Chemother 55:2212-23. 
170. Sellam, A., C. Askew, E. Epp, F. Tebbji, A. Mullick, M. Whiteway, and A. 
Nantel. 2010. Role of transcription factor CaNdt80p in cell separation, hyphal 
growth, and virulence in Candida albicans. Eukaryot Cell 9:634-44. 
171. Sellam, A., F. Tebbji, and A. Nantel. 2009. Role of Ndt80p in sterol metabolism 
regulation and azole resistance in Candida albicans. Eukaryot Cell 8:1174-83. 
172. Selmecki, A., S. Bergmann, and J. Berman. 2005. Comparative genome 
hybridization reveals widespread aneuploidy in Candida albicans laboratory 
strains. Mol Microbiol 55:1553-65. 
173. Selmecki, A., A. Forche, and J. Berman. 2006. Aneuploidy and isochromosome 
formation in drug-resistant Candida albicans. Science 313:367-70. 
174. Selmecki, A. M., K. Dulmage, L. E. Cowen, J. B. Anderson, and J. Berman. 
2009. Acquisition of aneuploidy provides increased fitness during the evolution of 
antifungal drug resistance. PLoS Genet 5:e1000705. 
175. Shapiro, R. S., N. Robbins, and L. E. Cowen. 2011. Regulatory circuitry 
governing fungal development, drug resistance, and disease. Microbiol Mol Biol 
Rev 75:213-67. 
176. Shields, R. K., M. H. Nguyen, E. G. Press, C. L. Updike, and C. J. Clancy. 
2013. Caspofungin MICs correlate with treatment outcomes among patients with 
Candida glabrata invasive candidiasis and prior echinocandin exposure. 
Antimicrob Agents Chemother 57:3528-35. 
177. Silver, P. M., B. G. Oliver, and T. C. White. 2004. Role of Candida albicans 
transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot 
Cell 3:1391-7. 
  
97 
178. Singh-Babak, S. D., T. Babak, S. Diezmann, J. A. Hill, J. L. Xie, Y. L. Chen, 
S. M. Poutanen, R. P. Rennie, J. Heitman, and L. E. Cowen. Global analysis 
of the evolution and mechanism of echinocandin resistance in Candida glabrata. 
PLoS Pathog 8:e1002718. 
179. Soll, D. R., and C. Pujol. 2003. Candida albicans clades. FEMS Immunol Med 
Microbiol 39:1-7. 
180. Soustre, J., M. H. Rodier, S. Imbert-Bouyer, G. Daniault, and C. Imbert. 
2004. Caspofungin modulates in vitro adherence of Candida albicans to plastic 
coated with extracellular matrix proteins. J Antimicrob Chemother 53:522-5. 
181. Spinillo, A., E. Capuzzo, R. Gulminetti, P. Marone, L. Colonna, and G. 
Piazzi. 1997. Prevalence of and risk factors for fungal vaginitis caused by non-
albicans species. Am J Obstet Gynecol 176:138-41. 
182. Staab, J. F., and P. Sundstrom. 2003. URA3 as a selectable marker for 
disruption and virulence assessment of Candida albicans genes. Trends Microbiol 
11:69-73. 
183. Sugita, T., and T. Nakase. 1999. Non-universal usage of the leucine CUG codon 
and the molecular phylogeny of the genus Candida. Syst Appl Microbiol 22:79-
86. 
184. Sun, J. N., N. V. Solis, Q. T. Phan, J. S. Bajwa, H. Kashleva, A. Thompson, 
Y. Liu, A. Dongari-Bagtzoglou, M. Edgerton, and S. G. Filler. Host cell 
invasion and virulence mediated by Candida albicans Ssa1. PLoS Pathog 
6:e1001181. 
185. Talibi, D., and M. Raymond. 1999. Isolation of a putative Candida albicans 
transcriptional regulator involved in pleiotropic drug resistance by functional 
complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiae. J 
Bacteriol 181:231-40. 
186. Templeton, I. E., K. E. Thummel, E. D. Kharasch, K. L. Kunze, C. Hoffer, 
W. L. Nelson, and N. Isoherranen. 2008. Contribution of itraconazole 
metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 83:77-85. 
187. Thaler, F., B. Bernard, M. Tod, C. P. Jedynak, O. Petitjean, P. Derome, and 
P. Loirat. 1995. Fluconazole penetration in cerebral parenchyma in humans at 
steady state. Antimicrob Agents Chemother 39:1154-6. 
188. Thompson, G. R., 3rd, P. K. Patel, W. R. Kirkpatrick, S. D. Westbrook, D. 
Berg, J. Erlandsen, S. W. Redding, and T. F. Patterson. 2010. Oropharyngeal 
candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol 
Oral Radiol Endod 109:488-95. 
189. Tsao, S., F. Rahkhoodaee, and M. Raymond. 2009. Relative contributions of 
the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole 
resistance. Antimicrob Agents Chemother 53:1344-52. 
190. Uchaipichat, V., L. K. Winner, P. I. Mackenzie, D. J. Elliot, J. A. Williams, 
and J. O. Miners. 2006. Quantitative prediction of in vivo inhibitory interactions 
involving glucuronidated drugs from in vitro data: the effect of fluconazole on 
zidovudine glucuronidation. Br J Clin Pharmacol 61:427-39. 
 
 
  
98 
191. Uppuluri, P., A. K. Chaturvedi, A. Srinivasan, M. Banerjee, A. K. 
Ramasubramaniam, J. R. Kohler, D. Kadosh, and J. L. Lopez-Ribot. 
Dispersion as an important step in the Candida albicans biofilm developmental 
cycle. PLoS Pathog 6:e1000828. 
192. Vajda, V., and S. McLoughlin. 2004. Fungal proliferation at the Cretaceous-
Tertiary boundary. Science 303:1489. 
193. Vale-Silva, L. A., A. T. Coste, F. Ischer, J. E. Parker, S. L. Kelly, E. Pinto, 
and D. Sanglard. 2012. Azole resistance by loss of function of the sterol 
Delta(5),(6)-desaturase gene (ERG3) in Candida albicans does not necessarily 
decrease virulence. Antimicrob Agents Chemother 56:1960-8. 
194. Vermes, A., H. J. Guchelaar, and J. Dankert. 2000. Flucytosine: a review of its 
pharmacology, clinical indications, pharmacokinetics, toxicity and drug 
interactions. J Antimicrob Chemother 46:171-9. 
195. Vermitsky, J. P., M. J. Self, S. G. Chadwick, J. P. Trama, M. E. Adelson, E. 
Mordechai, and S. E. Gygax. 2008. Survey of vaginal-flora Candida species 
isolates from women of different age groups by use of species-specific PCR 
detection. J Clin Microbiol 46:1501-3. 
196. Viale, P. 2009. Candida colonization and candiduria in critically ill patients in the 
intensive care unit. Drugs 69 Suppl 1:51-7. 
197. Vik, A., and J. Rine. 2001. Upc2p and Ecm22p, dual regulators of sterol 
biosynthesis in Saccharomyces cerevisiae. Mol Cell Biol 21:6395-405. 
198. Vincent, J. L., J. Rello, J. Marshall, E. Silva, A. Anzueto, C. D. Martin, R. 
Moreno, J. Lipman, C. Gomersall, Y. Sakr, and K. Reinhart. 2009. 
International study of the prevalence and outcomes of infection in intensive care 
units. JAMA 302:2323-9. 
199. Wang, J. S., Y. L. Yang, C. J. Wu, K. J. Ouyang, K. Y. Tseng, C. G. Chen, H. 
Wang, and H. J. Lo. 2006. The DNA-binding domain of CaNdt80p is required to 
activate CDR1 involved in drug resistance in Candida albicans. J Med Microbiol 
55:1403-11. 
200. Warrilow, A. G., C. M. Martel, J. E. Parker, N. Melo, D. C. Lamb, W. D. 
Nes, D. E. Kelly, and S. L. Kelly. 2010. Azole binding properties of Candida 
albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother 
54:4235-45. 
201. Warrilow, A. G., J. G. Mullins, C. M. Hull, J. E. Parker, D. C. Lamb, D. E. 
Kelly, and S. L. Kelly. 2012. S279 point mutations in Candida albicans Sterol 
14-alpha demethylase (CYP51) reduce in vitro inhibition by fluconazole. 
Antimicrob Agents Chemother 56:2099-107. 
202. Weiss, J., M. M. Ten Hoevel, J. Burhenne, I. Walter-Sack, M. M. Hoffmann, 
J. Rengelshausen, W. E. Haefeli, and G. Mikus. 2009. CYP2C19 genotype is a 
major factor contributing to the highly variable pharmacokinetics of voriconazole. 
J Clin Pharmacol 49:196-204. 
203. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and 
molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 
11:382-402. 
  
99 
204. Wille, M. P., T. Guimaraes, G. H. Furtado, and A. L. Colombo. 2013. 
Historical trends in the epidemiology of candidaemia: analysis of an 11-year 
period in a tertiary care hospital in Brazil. Mem Inst Oswaldo Cruz 108. 
205. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. 
B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis 
of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 
39:309-17. 
206. Wu, Y., R. J. Reece, and M. Ptashne. 1996. Quantitation of putative activator-
target affinities predicts transcriptional activating potentials. EMBO J 15:3951-
63. 
207. Wysong, D. R., L. Christin, A. M. Sugar, P. W. Robbins, and R. D. Diamond. 
1998. Cloning and sequencing of a Candida albicans catalase gene and effects of 
disruption of this gene. Infect Immun 66:1953-61. 
208. Xiao, L., V. Madison, A. S. Chau, D. Loebenberg, R. E. Palermo, and P. M. 
McNicholas. 2004. Three-dimensional models of wild-type and mutated forms of 
cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and 
Candida albicans provide insights into posaconazole binding. Antimicrob Agents 
Chemother 48:568-74. 
209. Yoshida, Y. 1988. Cytochrome P450 of fungi: primary target for azole antifungal 
agents. Curr Top Med Mycol 2:388-418. 
210. Yoshida, Y., Y. Aoyama, M. Noshiro, and O. Gotoh. 2000. Sterol 14-
demethylase P450 (CYP51) provides a breakthrough for the discussion on the 
evolution of cytochrome P450 gene superfamily. Biochem Biophys Res Commun 
273:799-804. 
211. Zaas, A. K., and B. D. Alexander. 2005. Echinocandins: role in antifungal 
therapy, 2005. Expert Opin Pharmacother 6:1657-68. 
212. Zhu, W., and S. G. Filler. Interactions of Candida albicans with epithelial cells. 
Cell Microbiol 12:273-82. 
213. Zimmermann, T., R. A. Yeates, M. Albrecht, H. Laufen, and A. Wildfeuer. 
1994. Influence of concomitant food intake on the gastrointestinal absorption of 
fluconazole and itraconazole in Japanese subjects. Int J Clin Pharmacol Res 
14:87-93. 
214. Zimmermann, T., R. A. Yeates, H. Laufen, G. Pfaff, and A. Wildfeuer. 1994. 
Influence of concomitant food intake on the oral absorption of two triazole 
antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 46:147-50. 
215. Zimmermann, T., R. A. Yeates, K. D. Riedel, P. Lach, and H. Laufen. 1994. 
The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of 
omeprazole. Int J Clin Pharmacol Ther 32:491-6. 
216. Znaidi, S., X. De Deken, S. Weber, T. Rigby, A. Nantel, and M. Raymond. 
2007. The zinc cluster transcription factor Tac1p regulates PDR16 expression in 
Candida albicans. Mol Microbiol 66:440-52. 
217. Znaidi, S., S. Weber, O. Z. Al-Abdin, P. Bomme, S. Saidane, S. Drouin, S. 
Lemieux, X. De Deken, F. Robert, and M. Raymond. 2008. Genomewide 
location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and 
azole drug resistance. Eukaryot Cell 7:836-47. 
 
  
100 
APPENDIX A.    C. ALBICANS STRAINS TABLE 
  
Strain # Modified strain identification Source if known Relevant characteristics or genotypea Source UPC2 polymorphisms observed (amino acid substitutions) 
Clinical isolates 
SC5314 SC5314 UPC2-1/ UPC2-2 ATCC 
20644.082 1 FLUS isolate University of Iowa 
20205.043 2 Blood FLUS isolate University of Iowa 
20339.016 3 Esophogeal FLUS isolate University of Iowa G1791A (M597I) 
20389.007 4 FLUS isolate University of Iowa 
20646.057 5 Blood FLUS isolate University of Iowa 
20313.046 6 Throat FLUS isolate University of Iowa 
20510.016 7 Abdom.Fluid FLUS isolate University of Iowa 
20464.007 8 Sput FLUS isolate University of Iowa 
20646.057 9 Blood FLUS isolate University of Iowa 
20324.046 10 Blood FLUS isolate University of Iowa C449T (P150L);  A817G (T273A) 
20512.088 11 FLUR isolate University of Iowa 
20512.089 12 FLUR isolate University of Iowa 
20533.031 13 FLUR isolate University of Iowa G1927A (A643T) 
20637.057 14 Blood FLUR isolate University of Iowa 
20513.024 15 FLUR isolate University of Iowa G1434C (W478C) 
20288.098 16 FLUR isolate University of Iowa 
20642.062 17 FLUR isolate University of Iowa 
20513.009 18 FLUR isolate University of Iowa 
20513.01 19 FLUR isolate University of Iowa G910A (G304R) 
20513.011 20 FLUR isolate University of Iowa G910A (G304R) 
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Appendix A.      Continued. 
     
Strain # Modified strain identification Source if known Relevant characteristics or genotypea Source UPC2 polymorphisms observed (amino acid substitutions) 
20513.016 21 FLUR isolate University of Iowa G1943A (G648D) 
20245.061 22 Abdom.Fluid FLUR isolate University of Iowa 
20323.066 23 Throat FLUR isolate University of Iowa 
20339.013 24 Esophogeal FLUR isolate University of Iowa 
20339.027 25 Oral FLUR isolate University of Iowa G1942A (G648S) 
20339.063 26 Esophogeal FLUR isolate University of Iowa 
20513.025 27 FLUR isolate University of Iowa  G1434C(W478C) 
20513.026 28 FLUR isolate University of Iowa 
20408.049 29 Tissue FLUR isolate University of Iowa 
20531.041 30 Blood FLUR isolate University of Iowa C1928T (A643V) 
20628.078 31 FLUR isolate University of Iowa 
20288.080 32 Tissue FLUR isolate University of Iowa 
20323.052 33 Throat FLUR isolate University of Iowa 
20339.014 34 Esophogeal FLUR isolate University of Iowa 
20339.028 35 Esophogeal FLUR isolate University of Iowa G1942A (G648S) 
20339.044 36 Oropharynx FLUR isolate University of Iowa A1925T (Y642F) 
20339.045 37 Buccal FLUR isolate University of Iowa A1925T (Y642F) 
20339.027 38 Oral FLUR isolate University of Iowa G1943A (G648D) 
20339.062 39 Esophogeal FLUR isolate University of Iowa 
20408.059 40 Blood FLUR isolate University of Iowa 
20348.024 41 Sputum FLUR isolate University of Iowa 
20512.090 42 FLUR isolate University of Iowa 
20339.003 43 Buccal FLUR isolate University of Iowa 
20339.025 44 Oral FLUR isolate University of Iowa 
  
102 
Appendix A.      Continued. 
     
Strain # Modified strain identification Source if known Relevant characteristics or genotypea Source UPC2 polymorphisms observed (amino acid substitutions) 
20339.048 45 Esophogeal FLUR isolate University of Iowa C1937T (A646V) 
20339.064 46 Esophogeal FLUR isolate University of Iowa 
20339.072 47 Esophogeal FLUR isolate University of Iowa G1943A (G648D) 
20512.099 48 FLUR isolate University of Iowa 
20377.041 49 Pleural Fl FLUR isolate University of Iowa 
20323.080 50 Throat FLUR isolate University of Iowa 
20339.008 51 Oral FLUR isolate University of Iowa 
20339.058 52 Esophogeal FLUR isolate University of Iowa G1943A (G648D) 
20672.028 53 Blood FLUR isolate University of Iowa 
20495.091 54 Abscess FLUR isolate University of Iowa 
C406T (P136S), A671G (N224S), A749G (N250S), T1952C 
(M651T) 
20513.014 55 FLUR isolate University of Iowa G1942A (G648S) 
20513.021 56 FLUR isolate University of Iowa G1942A (G648S) 
20513.022 57 FLUR isolate University of Iowa G1942A (G648S) 
20513.023 58 FLUR isolate University of Iowa G1942A (G648S) 
20430.009 59 Blood FLUR isolate University of Iowa G1943A (G648D) 
20288.030 60 Tissue FLUR isolate University of Iowa 
20323.083 61 Throat FLUR isolate University of Iowa 
20339.006 62 Oral FLUR isolate University of Iowa 
20339.011 63 Esophogeal FLUR isolate University of Iowa 
20339.015 64 Oral FLUR isolate University of Iowa 
20339.020 65 Oropharynx FLUR isolate University of Iowa G1942A (G648S) 
20339.021 66 Oropharynx FLUR isolate University of Iowa 
20339.022 67 Oropharynx FLUR isolate University of Iowa G1942A (G648S) 
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Appendix A.      Continued. 
     
Strain # Modified strain identification Source if known Relevant characteristics or genotypea Source UPC2 polymorphisms observed (amino acid substitutions) 
20339.030 68 Oropharynx FLUR isolate University of Iowa  A817G (T273A), C1928T (A643V) 
20339.032 69 Oropharynx FLUR isolate University of Iowa G1942A (G648S) 
20339.049 70 Esophogeal FLUR isolate University of Iowa C1937T (A646V) 
20339.070 71 Oral FLUR isolate University of Iowa G1943A (G648D) 
20513.02 72 FLUR isolate University of Iowa 
FLUS; fluconazole susceptible.  FLUR; fluconazole resistant 
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APPENDIX B.    GENES UPREGULATED IN STRAINS CARRYING UPC2 GOF ALLELES BY AT LEAST 1.5 FOLD 
 
Change in fold expressiona 
G648S G648D Y642F A643V 
CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
ANP1 orf19.3622 1.9 1.5 1.5 1.2 1.3 1.4 1.1 1.0 contributes_to alpha-1,6-mannosyltransferase activity (IEA) 
FRE9 orf19.3538 2.1 1.5 1.2 1.4 1.0 1.3 1.2 1.7 ferric-chelate reductase activity (IEA) 
GST1 orf19.3121 7.8 2.0 38.0 1.2 16.4 0.9 13.5 0.9 transcription corepressor activity (IEA) 
IFC1 orf19.3746 1.9 1.8 0.9 0.9 1.3 0.7 1.2 0.8 oligopeptide transporter activity (IGI, ISS) 
LTE1 orf19.2238 18.2 2.0 9.8 0.5 19.1 1.3 10.1 0.8 guanyl-nucleotide exchange factor activity (IEA) 
NBP35 orf19.747 1.8 1.5 2.1 1.4 1.6 1.0 2.1 1.2 nucleotide binding (NAS)|4 iron, 4 sulfur cluster binding (IEA) 
PHO114 orf19.4584 1.7 1.6 2.2 1.4 1.8 0.9 2.0 1.3 acid phosphatase activity (IEA) 
PLB1 orf19.689 1.6 2.0 1.9 1.2 1.3 1.1 1.4 1.1 lysophospholipase activity (IDA, IMP, ISS) 
PLB4 orf19.1443 1.6 1.5 2.0 1.3 1.4 1.3 1.5 1.3 lysophospholipase activity (ISS) 
PRR2 orf19.1341 1.5 2.5 2.9 1.1 0.9 0.9 1.1 1.6  receptor signaling protein serine/threonine kinase activity (IEA) 
RBT1 orf19.1327 1.9 1.6 1.2 1.1 1.6 1.9 1.1 1.2 
SMC3 orf19.262 1.5 1.7 1.3 0.9 1.8 0.8 1.4 0.7 ATPase activity (IEA) 
SUA72 orf19.3519 1.5 1.7 2.3 0.8 1.3 1.0 1.7 1.2 general RNA polymerase II transcription factor activity (IEA) 
ZRT1 orf19.3112 1.5 1.6 1.6 1.4 1.1 0.8 1.2 1.0 low-affinity zinc ion transmembrane transporter activity (IEA) 
orf19.11618 1.5 1.6 1.6 0.7 0.9 1.0 1.8 0.8 
orf19.1768 1.6 1.7 1.3 1.0 1.6 1.1 1.6 0.9 
orf19.302 1.7 1.5 1.3 1.1 1.0 0.7 1.4 1.2 contributes_to Rab guanyl-nucleotide exchange factor activity (IEA) 
orf19.3156 2.1 1.5 1.9 1.0 1.7 1.0 1.5 1.0 
orf19.3813 1.5 1.8 2.7 1.4 1.4 1.0 2.4 1.1 
orf19.3926 1.6 15.1 1.2 5.6 0.7 8.9 0.3 1.0 endoribonuclease activity (IEA) 
orf19.3976 1.5 2.0 0.8 0.9 1.6 1.0 1.5 1.0 structural constituent of cytoskeleton (IEA) 
orf19.4276 1.8 2.5 2.2 0.6 1.8 1.7 1.2 1.0 
orf19.4711 3.8 1.7 4.9 1.4 1.7 1.0 3.7 0.9 
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  Change in fold expressiona  
  G648S G648D Y642F A643V  
CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
orf19.4735 1.5 1.6 1.5 1.1 1.2 0.8 1.4 0.8 
orf19.4923 1.5 2.4 1.4 1.9 1.1 1.1 1.3 1.9 sugar transmembrane transporter activity (ISS) 
orf19.5693 1.5 1.5 1.6 1.4 1.1 1.4 1.3 1.4 GPI-anchor transamidase activity (IEA) 
orf19.6351 1.7 1.7 1.3 1.4 2.4 0.9 1.5 1.0 
orf19.6899 1.6 2.5 0.6 0.4 0.7 0.9 0.3 0.4 
orf19.6950 1.5 2.2 0.9 1.0 1.5 1.2 1.1 1.0 
orf19.6979 1.8 1.5 2.2 0.9 1.6 1.1 1.3 1.0 
orf19.6982 1.7 1.5 1.4 1.3 1.7 1.1 1.4 1.1 
orf19.7193 1.7 1.5 1.0 1.1 1.3 0.8 1.0 0.8 
orf19.7303 3.5 2.8 1.8 0.7 1.4 1.2 3.8 1.3 
orf19.911 2.3 1.6 1.8 1.2 1.4 1.2 1.9 0.9 ubiquitin-protein ligase activity (IEA) 
orf19.980 1.7 1.5 1.9 1.3 0.8 1.3 0.8 1.1 
ADO1 orf19.5591 1.4 1.3 1.6 1.6 1.4 1.5 1.5 1.4 adenosine kinase activity (IEA) 
AMS1 orf19.2768 1.1 2.8 4.2 2.0 1.3 0.8 1.3 1.3 alpha-mannosidase activity (IEA) 
ASR1 orf19.2344 0.6 3.2 2.1 1.8 0.6 1.0 0.9 1.2 
BUD16 orf19.1828 2.5 0.9 2.7 1.5 2.1 0.8 2.1 0.9 
CAS1 orf19.1135 1.1 1.2 1.5 1.5 1.2 1.0 1.4 1.5 
CAT1 orf19.6229 1.2 1.7 1.7 1.8 1.3 1.5 1.4 1.8 catalase activity (IDA, IMP, ISS)|protein binding (IDA) 
CAT2 orf19.4591 1.1 1.4 1.5 1.6 1.1 1.1 1.5 1.4 
CAT8 orf19.5097 1.6 0.7 2.0 2.1 1.0 1.1 2.4 1.1 
CDC23 orf19.6437 1.1 1.1 1.6 1.5 1.3 1.1 1.5 1.4 protein binding (IEA)|ubiquitin-protein ligase activity (IEA) 
CTA4 orf19.7374 1.4 1.3 2.0 1.6 1.7 1.4 1.9 1.3 transcription activator activity (IDA, IGI) 
CYB2 orf19.5000 1.1 1.3 1.8 1.5 1.2 0.9 1.5 1.1 L-lactate dehydrogenase (cytochrome) activity (NAS) 
DAL9 orf19.6956 0.9 1.6 2.0 1.6 0.9 1.2 1.3 1.7 anion:cation symporter activity (ISS)  
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  Change in fold expressiona  
  G648S G648D Y642F A643V  
CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
ECM29 orf19.6773  1.1 1.2 1.5 1.5 1.3 1.0 1.2 1.2 
ERG10 orf19.1591 1.2 1.5 2.0 1.7 1.1 1.0 1.7 1.4 acetyl-CoA C-acyltransferase activity (IEA) 
ERG10 orf19.1591 1.3 1.5 1.6 1.6 1.4 1.7 1.4 1.8 acetyl-CoA C-acyltransferase activity (IEA) 
FGR16 orf19.2303 2.4 1.1 1.8 1.5 1.7 1.0 2.1 1.2 
FGR34 orf19.7579 1.0 1.4 1.5 1.5 1.0 0.9 1.2 1.2 
FMO2 orf19.859 1.3 1.8 2.5 1.9 0.6 0.7 1.5 1.2 
FRP2 orf19.7112 0.8 1.4 1.6 1.5 1.1 1.1 1.1 1.3 ferric-chelate reductase activity (IEA) 
GAP2 orf19.6993 0.6 1.5 2.2 1.7 0.6 0.7 1.1 1.6 L-proline transmembrane transporter activity (IEA) 
GAT1 orf19.1275 0.7 1.8 1.6 2.0 0.5 1.0 0.9 2.7 specific RNA polymerase II transcription factor activity (IMP, ISS) 
GDH3 orf19.4716 1.0 1.6 1.9 1.6 1.0 1.3 1.2 1.6 glutamate dehydrogenase (NADP+) activity (IEA) 
GPD1 orf19.1756 1.1 1.3 1.7 1.5 1.2 1.0 1.5 1.4 glycerol-3-phosphate dehydrogenase (NAD+) activity (IEA) 
GRE2 orf19.3150 0.9 1.5 1.7 1.5 1.0 1.2 1.2 1.4 oxidoreductase activity (NAS) 
GST1 orf19.3121 0.8 1.1 2.4 1.6 1.1 1.6 1.0 1.4 transcription corepressor activity (IEA) 
HIS5 orf19.4177 1.3 1.5 1.5 1.5 1.0 0.8 1.7 1.2 histidinol-phosphate transaminase activity (IEA) 
HOS3 orf19.2772 1.1 1.1 1.6 1.5 1.3 0.9 1.4 1.2 histone deacetylase activity (ISS) 
HSX11 orf19.4592 2.0 1.4 2.4 1.6 1.9 1.1 2.1 1.2 ceramide glucosyltransferase activity (IDA, IGI, IMP) 
HXK1 orf19.2154 1.3 1.4 1.6 1.6 0.9 1.0 1.3 1.5 N-acetylglucosamine kinase activity (IDA, IMP)|hexokinase activity (ISS) 
IFR1 orf19.1763 1.1 3.3 4.0 1.9 1.6 1.1 2.1 1.4 
IFU5 orf19.2568 1.1 1.7 2.2 1.7 1.1 1.2 1.3 1.6 
INO4 orf19.837.1  1.1 1.0 1.6 1.7 1.4 1.1 1.7 1.2 
INP51 orf19.1373 1.9 1.0 2.5 1.5 1.7 0.8 2.6 1.3 inositol-polyphosphate 5-phosphatase activity (IEA) 
KNS1 orf19.4979 0.7 1.8 2.0 2.2 0.9 0.8 1.4 2.1 protein serine/threonine kinase activity (IEA) 
LEU2 orf19.7080 1.0 1.5 1.5 1.5 0.9 1.2 1.1 1.3 3-isopropylmalate dehydrogenase activity (IDA, IGI, NAS) 
LIP8 orf19.1345 1.4 1.9 1.6 1.6 0.8 1.5 1.3 2.0 lipase activity (IDA) 
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  Change in fold expressiona  
  G648S G648D Y642F A643V  
CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
MIT1 orf19.4077 1.2 1.1 2.2 1.9 1.4 1.0 1.8 1.3 mannosyltransferase activity (IMP) 
MLS1 orf19.4833 0.8 2.1 1.9 1.5 0.8 1.0 1.0 1.3 malate synthase activity (ISS) 
MUQ1 orf19.2107 0.9 1.5 1.6 1.5 1.1 1.1 1.3 1.4 choline-phosphate cytidylyltransferase activity (IEA) 
NAG6 orf19.2151 1.2 1.3 1.7 1.5 1.1 1.1 1.4 1.3 GTP binding (ISS) 
NCE4 orf19.5320 1.2 0.8 1.8 1.6 1.6 0.8 2.0 1.1 
NUF2 orf19.1941 1.1 1.1 1.6 1.5 1.4 0.8 1.6 1.1 structural constituent of cytoskeleton (IEA) 
OYE32 orf19.3131 1.0 2.5 2.3 1.7 1.0 1.2 1.3 1.8 NADPH dehydrogenase activity (IEA) 
PAN1 orf19.886 1.1 1.8 1.8 1.9 1.0 1.3 1.3 1.7 cytoskeletal adaptor activity (IEA)|protein binding, bridging (IEA) 
PDC12 orf19.4608 2.3 1.3 3.8 1.5 3.0 1.0 3.3 1.0 
PDK2 orf19.7281 0.9 1.3 1.5 1.6 1.0 0.8 1.2 1.3 
PEP7 orf19.5662 1.5 1.1 1.9 1.7 1.7 0.8 1.6 1.4 phosphatidylinositol 3-phosphate binding (IEA) 
PGA60 orf19.5588 0.8 4.6 1.7 2.4 1.0 0.2 1.0 5.0 
PLB5 orf19.5102 0.9 1.6 1.9 1.5 0.8 0.9 1.2 1.5 phospholipase A2 activity (IMP)|lysophospholipase activity (ISS) 
PLD1 orf19.1161 1.3 1.2 1.8 1.5 1.3 1.1 1.7 1.4 phospholipase D activity (IMP, ISS) 
POT1-2 orf19.2046 1.1 1.5 1.5 1.7 1.2 1.0 1.5 1.3 acetyl-CoA C-acyltransferase activity (IEA) 
PPH3 orf19.4378  1.2 1.2 1.5 1.5 1.2 1.0 1.8 1.4 
PRR2 orf19.1341 1.7 1.4 3.3 1.5 0.6 1.9 2.7 0.8  receptor signaling protein serine/threonine kinase activity (IEA) 
RAD10 orf19.2469 1.7 1.2 1.5 1.5 1.7 1.1 1.6 1.1 DNA strand annealing activity (ISA) 
RAD14 orf19.6517 1.0 1.5 1.6 1.6 0.9 1.0 1.2 1.7 damaged DNA binding (IEA)|zinc ion binding (IEA) 
RAM1 orf19.5046 1.0 0.9 1.5 1.5 1.0 1.0 0.9 1.0 protein farnesyltransferase activity (IEA) 
RDH54 orf19.5367 1.5 1.2 1.7 1.6 1.2 0.9 1.6 1.1 DNA topoisomerase activity (IEA)|DNA translocase activity (IEA) 
RGA2 orf19.4593 1.2 1.2 1.6 1.6 1.4 1.1 1.4 1.4 Rho GTPase activator activity (IDA)|signal transducer activity (IEA) 
RGS2 orf19.695 0.9 0.8 1.5 2.6 0.7 0.5 1.0 1.6 
RIB1 orf19.2862 1.3 1.3 1.8 1.5 1.3 1.1 1.7 1.4 cyclohydrolase activity (IEA) 
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  Change in fold expressiona  
  G648S G648D Y642F A643V  
CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
RPN10 orf19.4102 1.3 1.2 1.5 1.6 1.4 1.2 1.5 1.3 endopeptidase activity (IEA)|protein binding, bridging (IEA) 
RVS162 orf19.6349 1.1 1.7 1.8 1.5 1.2 0.9 1.7 1.3 cytoskeletal protein binding (IEA) 
SKN7 orf19.971 1.2 1.5 1.7 1.7 1.1 1.0 1.3 1.5 two-component response regulator activity (ISS) 
SMP2 orf19.1462 1.1 1.0 1.7 1.5 1.4 0.9 1.6 1.1 phosphatidate phosphatase activity (IEA) 
SNF3 orf19.5962 1.5 1.1 1.9 1.5 1.5 1.1 1.9 1.4 glucose transmembrane transporter activity (ISS) 
SNZ1 orf19.2947 1.0 1.6 1.7 1.9 1.3 1.4 1.3 1.6 protein binding (IEA) 
SSP96 orf19.5145 0.9 1.9 1.5 2.3 1.3 1.2 1.3 2.1 
SVF1 orf19.6068 1.3 1.1 1.9 1.6 1.5 1.1 1.5 1.4 
TUP1 orf19.6109 1.2 1.7 1.7 1.6 1.0 1.3 1.3 1.4 transcription repressor activity (IGI, IMP, ISS) 
UBC15 orf19.5337 1.4 1.4 1.8 1.5 1.3 1.0 1.7 1.4 
UGA1 orf19.802 1.2 1.8 1.8 1.5 1.1 1.1 1.4 1.3 4-aminobutyrate transaminase activity (IEA) 
VPS2 orf19.945 1.3 1.7 2.1 1.9 1.6 1.3 1.8 1.4 
XYL2 orf19.7676 0.8 2.0 1.9 1.6 0.8 1.1 1.2 1.6 L-iditol 2-dehydrogenase activity (IEA) 
YAF9 orf19.5501 0.9 1.5 1.5 1.5 0.7 1.1 1.7 1.3 contributes_to histone acetyltransferase activity (IC) 
orf19.1070 1.0 1.2 3.9 2.2 1.2 0.9 1.7 1.2 
orf19.1191 1.1 1.3 1.6 1.5 1.1 1.0 1.5 1.4 contributes_to ubiquitin-protein ligase activity (IEA) 
orf19.1314 1.3 0.9 1.6 1.7 1.4 1.0 2.0 1.4 
orf19.1364 1.2 1.4 2.0 1.6 1.1 0.9 1.5 1.2 
orf19.1369 1.1 1.7 1.9 1.6 0.9 1.2 0.9 1.4 
orf19.1392 1.5 1.2 1.5 1.7 1.9 1.0 2.0 1.3 chaperone binding (IEA)|protein disulfide isomerase activity (IEA) 
orf19.1395 1.2 1.9 1.5 1.8 1.3 0.7 0.9 1.8 inorganic phosphate transmembrane transporter activity (IEA) 
orf19.1406 1.0 1.0 2.1 1.5 1.1 0.7 1.8 0.9 
orf19.1421 1.0 1.8 1.7 1.5 1.1 1.0 1.2 1.3 ureidoglycolate hydrolase activity (IEA) 
orf19.1434 1.0 1.0 1.9 1.7 1.0 1.0 1.3 1.0 kinase activator activity (IEA)|protein binding (IEA) 
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orf19.1482 1.0 1.4 1.6 1.8 0.9 1.0 1.3 1.4 
orf19.1496 1.3 1.1 1.6 1.6 1.2 0.8 1.3 1.4 transcription factor activity (ISS) 
orf19.1667 1.3 1.8 1.5 1.8 1.3 1.7 1.1 1.7 helicase activity (IEA) 
orf19.1723 0.9 1.4 1.5 1.5 1.0 1.1 1.3 1.4 
orf19.1728 1.1 5.8 2.1 3.3 1.0 0.2 0.4 1.6 
orf19.1730 1.1 1.0 1.6 1.7 1.5 1.0 1.4 1.3 
orf19.1776 2.6 1.1 3.1 2.1 4.0 1.1 4.3 1.3 
orf19.190 1.2 1.1 1.5 1.6 1.3 0.7 1.1 1.0 
orf19.1917 1.3 1.5 1.9 1.5 1.2 1.2 1.4 1.5 
orf19.192 1.3 1.4 1.6 1.8 1.2 0.9 1.4 1.4 
orf19.2009 2.1 1.0 2.6 1.6 2.8 0.8 2.6 1.3 protein binding (IEA) 
orf19.2065 1.1 1.6 1.9 1.5 1.3 1.1 1.4 1.6 allantoicase activity (IEA) 
orf19.2204.2 1.5 1.2 2.4 1.5 1.3 1.3 1.9 1.4 GTPase activity (ISS)|signal transducer activity (IDA) 
orf19.225 1.1 1.4 2.0 1.6 1.3 1.0 1.2 1.2 
orf19.2257 1.2 1.3 1.5 1.6 1.3 1.2 1.4 1.3 
orf19.2262 0.9 1.9 1.9 1.7 0.9 1.0 1.3 1.6 AU-rich element binding (IEA) 
orf19.2313 1.3 1.6 1.7 1.7 0.9 1.0 1.4 1.7 
orf19.2346 1.6 1.0 2.0 1.5 1.7 0.8 1.7 1.2 
orf19.2411 1.1 1.3 1.5 1.7 1.3 1.1 1.5 1.4 SNAP receptor activity (IEA) 
orf19.2496 1.0 1.3 1.7 1.7 0.8 1.6 1.4 1.4 
orf19.2565 1.1 1.3 1.5 1.6 0.8 0.9 1.3 1.5 phosphatidylinositol 3-phosphate binding (IEA) 
orf19.268 0.9 1.4 1.8 1.5 1.0 0.7 1.3 1.5 
orf19.2710 1.5 1.0 2.8 1.5 2.1 0.8 2.4 1.1 enzyme activator activity (IEA) 
orf19.273 1.2 1.2 1.8 1.5 1.2 1.3 1.4 1.4 
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orf19.2740 1.3 1.6 1.5 1.5 1.1 1.1 1.1 1.4 
orf19.2755 1.6 0.9 2.0 1.6 2.0 0.9 1.6 0.7 endopeptidase activity (IEA) 
orf19.2791 1.1 1.6 1.7 1.5 1.0 1.0 1.3 1.4 myosin I binding (IEA) 
orf19.2888 1.4 0.7 1.8 1.6 2.2 0.8 2.6 1.0 
orf19.2905 1.1 1.6 1.8 2.1 1.5 1.2 1.3 1.6 
orf19.2913 1.1 1.1 1.6 1.5 1.1 1.0 1.4 1.3 
orf19.2974 1.2 1.1 1.5 1.5 1.6 1.1 1.7 1.3 palmitoyltransferase activity (IEA) 
orf19.3151 0.8 1.4 1.5 1.5 1.1 0.9 1.6 1.1 oxidoreductase activity (NAS) 
orf19.3214 1.2 1.5 2.5 2.3 1.3 1.1 1.7 1.1 
orf19.3215 1.3 1.6 1.8 1.5 1.2 1.0 1.5 1.2 
orf19.3407 1.3 1.4 1.5 1.6 1.4 1.0 1.5 1.2 transcription factor activity (ISS) 
orf19.3411 1.4 1.1 1.7 1.5 1.3 1.0 1.8 1.4 
orf19.345 1.6 1.3 1.5 1.7 1.4 1.6 1.4 1.3 succinate-semialdehyde dehydrogenase [NAD(P)+] activity (IEA) 
orf19.3536 1.4 1.2 1.7 1.7 1.4 1.2 1.6 1.4 acetylglucosaminyltransferase activity (IEA) 
orf19.3631 1.6 1.4 1.5 1.5 1.7 1.2 1.0 1.3 
orf19.3658 1.0 1.5 1.5 1.8 1.0 1.3 1.4 1.5 
orf19.3661 1.3 1.4 1.7 1.7 1.6 1.1 1.4 1.4 ubiquitin-specific protease activity (IEA) 
orf19.3679 1.0 1.7 2.2 1.5 1.0 0.9 1.5 1.4 
orf19.3804 1.3 1.2 1.9 1.7 1.4 1.2 1.5 1.4 
orf19.3806 1.4 1.2 2.0 1.5 2.0 0.9 2.0 1.4 
orf19.3814 1.1 1.4 1.8 1.7 1.1 0.8 1.6 1.4 
orf19.393 1.3 1.2 1.8 1.5 1.3 1.0 1.8 1.4 
orf19.3939 2.2 1.1 2.1 1.5 2.5 1.1 2.4 1.2 
orf19.3984 1.0 1.0 1.6 1.8 1.3 0.8 1.3 1.2 
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orf19.4061 1.5 1.2 1.8 1.5 1.2 1.0 2.1 1.3 
orf19.4206 1.3 1.2 2.2 2.2 1.6 1.0 1.9 1.4 crossover junction endodeoxyribonuclease activity (IEA) 
orf19.4229 0.4 1.8 2.0 1.6 0.8 1.1 0.9 1.4 bis(5'-adenosyl)-hexaphosphatase activity (IEA) 
orf19.4246 1.4 1.3 2.2 1.5 1.6 1.2 1.9 1.4 
orf19.4357 1.6 1.2 2.1 1.5 1.5 1.0 1.7 1.2 misfolded protein binding (IEA) 
orf19.4390 0.8 1.4 1.7 1.6 0.9 0.9 1.2 1.4 
orf19.4503 1.4 1.1 1.8 1.5 1.5 1.3 2.0 1.3 
orf19.4583 2.3 1.1 1.9 1.6 1.8 1.2 2.0 0.8 transporter activity (IEA) 
orf19.4691 1.2 1.4 2.5 2.0 0.9 0.8 1.0 1.3 
orf19.4726 1.3 1.2 2.0 1.5 1.6 1.2 1.8 1.4 calcium ion binding (IEA)|enzyme activator activity (IEA) 
orf19.4731 1.4 1.0 1.8 1.6 1.7 1.1 1.9 1.4 
orf19.4791 1.2 1.8 2.3 1.6 1.0 0.7 1.5 1.1 
orf19.4807 1.2 1.1 1.5 1.5 1.0 0.9 1.3 1.2 inorganic diphosphatase activity (IEA) 
orf19.4894 1.0 1.9 1.6 1.5 1.0 1.0 1.2 1.3 0.0 
orf19.4983 1.6 1.2 1.6 1.6 2.0 1.0 1.7 1.2 0.0 
orf19.5008.1 0.9 1.1 1.5 1.9 1.1 0.8 1.3 1.0 structural constituent of cytoskeleton (IEA) 
orf19.5014 1.1 1.1 1.5 1.6 1.0 0.9 1.2 1.2 0.0 
orf19.5095 1.1 1.4 2.2 1.9 1.1 1.0 1.4 1.4 oxysterol binding (IEA)|sterol carrier activity (IEA) 
orf19.5169 0.8 1.9 2.4 2.0 1.5 1.4 0.6 1.6 amidase activity (IEA) 
orf19.52 1.0 1.3 1.5 1.6 1.1 1.1 1.4 1.3 0.0 
orf19.5236.1 1.2 1.0 1.5 1.5 1.5 1.0 1.7 1.3 dehydrodolichyl diphosphate synthase activity (IEA) 
orf19.5253 1.1 1.1 1.6 1.5 1.5 1.0 1.9 1.4 protein kinase activity (IEA) 
orf19.5270 1.1 1.4 2.0 1.5 0.8 0.4 1.9 1.3 
orf19.5342 1.0 1.5 1.6 1.5 1.0 1.1 1.3 1.3 
  
112 
Appendix B.     Continued. 
          
  Change in fold expressiona  
  G648S G648D Y642F A643V  
CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
orf19.5345 1.3 1.4 1.6 1.6 1.2 1.2 1.6 1.3 protein binding, bridging (IEA) 
orf19.537 1.8 1.3 1.9 1.6 1.7 1.4 2.5 1.4 
orf19.5547 3.1 0.9 1.7 1.6 5.7 1.3 3.4 0.9 
orf19.5620 1.2 1.7 1.6 1.5 1.2 1.4 1.3 1.6 
orf19.5773 1.4 1.5 2.0 1.5 1.4 1.3 1.6 1.4 dipeptidyl-peptidase activity (IEA) 
orf19.5784 1.0 1.8 1.7 1.5 0.9 0.7 1.1 1.7 
orf19.5812 1.2 1.1 1.6 1.5 1.3 1.2 1.5 1.4 
orf19.5862 0.5 2.8 2.4 1.7 0.9 0.9 1.7 0.7 arginase activity (IEA) 
orf19.5881 1.4 1.2 2.1 1.6 1.4 0.9 1.7 1.1 voltage-gated chloride channel activity (IEA) 
orf19.589 1.2 1.3 2.0 1.6 1.3 1.2 1.6 1.4 GTPase activity (ISS)|GTP binding (IEA) 
orf19.5935 1.3 2.5 1.8 1.7 1.2 1.1 1.4 1.2 
orf19.5952 1.1 1.0 1.6 1.6 1.1 0.9 1.1 1.6 
orf19.5961 0.9 1.2 1.5 1.5 1.3 0.9 1.5 1.3 
orf19.6045 1.2 1.2 1.6 1.5 1.1 1.1 1.4 1.4 phosphatidylserine decarboxylase activity (IEA) 
orf19.6187 1.3 1.6 1.7 1.6 1.4 1.2 1.4 1.3 
orf19.6196 0.8 1.6 1.7 1.6 1.0 0.9 1.2 1.7 
orf19.6200 1.3 1.3 2.7 1.7 1.6 0.8 2.1 1.4 
orf19.6268 1.7 1.1 1.8 1.5 2.0 1.1 1.8 1.2 
orf19.6357 2.2 1.2 2.0 1.6 2.1 1.2 2.6 1.4 
orf19.6460 1.5 1.0 1.7 1.5 1.6 0.8 1.7 1.1 ATPase activity (IEA)|protein heterodimerization activity (IEA) 
orf19.6462 0.9 1.0 1.5 2.1 1.2 1.1 1.2 1.4 
orf19.6498 1.3 1.1 1.8 1.5 1.4 1.0 1.8 1.4 
orf19.6552 1.4 1.2 1.5 1.5 1.5 1.1 1.6 1.2 thiol oxidase activity (IEA) 
orf19.6556 1.1 1.1 1.7 1.5 1.1 0.9 1.0 0.9 
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orf19.6569 1.9 1.1 2.1 1.7 1.5 1.1 2.6 1.3 
orf19.6601 0.9 1.6 2.8 1.6 1.1 0.7 1.4 1.2 
orf19.6709 1.0 1.4 1.6 1.6 0.8 1.1 1.3 1.3 
orf19.6754 0.9 1.2 1.5 1.5 1.1 1.1 1.3 1.3 
orf19.6867 1.2 1.5 1.7 1.7 1.5 1.2 1.5 1.4 
orf19.6883 1.1 1.3 1.7 1.6 1.3 1.3 1.4 1.5 cholesterol binding (IEA 
orf19.6900 1.2 1.5 1.7 1.7 1.4 1.1 1.4 1.3 
orf19.6905 1.1 1.1 1.5 1.5 1.3 1.0 1.4 1.3 
orf19.7061 2.0 1.0 2.0 1.5 2.1 1.4 2.3 1.3 ATPase activity (IEA) 
orf19.711 0.9 2.0 1.6 2.0 0.8 1.4 1.1 1.2 
orf19.7179 1.3 1.1 1.5 1.5 1.4 1.0 1.7 1.4 
orf19.7225 1.2 1.1 2.1 1.5 1.0 0.9 1.8 1.3 
orf19.7229 1.1 1.5 1.8 1.8 1.2 1.1 1.4 1.5 
orf19.7260 0.8 2.0 1.5 2.2 0.7 1.4 0.9 1.7 
orf19.7265 1.1 1.6 1.6 1.7 1.2 1.3 1.2 1.5 
orf19.7267 1.5 1.4 1.5 1.6 1.4 1.2 1.4 1.3 
orf19.7288 1.1 1.4 1.6 1.5 1.1 0.9 1.4 1.4 
orf19.7328 1.3 1.5 1.9 1.6 1.5 1.3 1.3 1.5 
orf19.7365 1.2 1.0 1.7 1.5 1.1 0.9 1.1 0.9 
orf19.7449 1.3 1.2 1.8 1.7 1.5 1.3 1.9 1.3 
orf19.7507 0.9 1.3 1.6 1.7 1.3 0.8 1.1 1.3 
orf19.751 1.2 2.6 1.6 1.9 1.0 1.7 1.3 2.6 
orf19.7538 1.2 1.5 1.5 1.7 1.2 1.2 1.4 1.5 DNA helicase activity (IEA) 
orf19.834 1.5 1.1 1.9 1.5 1.5 1.2 1.7 1.0 carbohydrate binding (IEA) 
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orf19.91 1.2 0.9 1.5 1.5 1.2 1.0 1.5 1.3 
orf19.6356 2.2 0.8 1.4 1.1 1.9 1.6 1.2 1.0  RNA splicing factor activity, transesterification mechanism (IEA) 
CMP1 orf19.6033 1.4 1.2 1.2 1.8 1.7 1.5 1.1 1.3 calcium-dependent protein serine/threonine phosphatase activity (ISS) 
PHO13 orf19.1405 1.4 0.8 1.3 1.5 1.6 1.5 1.4 1.4 4-nitrophenylphosphatase activity (IEA)|alkaline phosphatase activity (IEA) 
YST1 orf19.6975 2.1 1.2 1.5 0.4 2.4 1.5 0.8 1.6 structural constituent of ribosome (IGI) 
orf19.6589 2.2 0.9 1.4 1.3 2.1 1.5 1.7 1.2 rRNA binding (IEA) 
orf19.5291 1.5 0.9 1.7 1.2 1.6 1.5 1.3 1.4 
FOX2 orf19.1288  1.3 1.3 1.5 1.3 1.0 1.1 1.6 1.5 nucleotide binding 
ANT1 orf19.6254 1.3 1.2 1.2 1.6 1.2 1.4 1.5 1.6 adenine nucleotide transmembrane transporter activity (IEA) 
BMT8 orf19.860 1.0 1.4 1.6 1.3 1.0 0.8 1.5 2.0 
CDC45 orf19.1988 1.6 1.2 1.7 1.3 1.6 1.0 1.5 1.5 DNA replication origin binding (IEA)|chromatin binding (IEA) 
DEF1 orf19.7561 1.2 1.4 1.7 1.2 1.1 1.1 1.5 1.6 
GAL1 orf19.3670 1.3 1.1 1.2 1.4 1.5 1.0 2.0 1.6 galactokinase activity (IGI, NAS)|transcription activator activity (IEA) 
GAL10 orf19.3672 1.0 1.3 1.1 1.5 1.3 1.1 1.6 1.6 UDP-glucose 4-epimerase activity (IGI)|aldose 1-epimerase activity (IEA) 
HAP31 orf19.517 1.3 1.0 1.3 1.8 1.5 1.2 1.7 1.5 transcription factor activity (NAS)|transcription activator activity (IEA) 
HGT17 orf19.4682 0.7 0.8 1.5 1.2 0.8 0.9 2.3 2.2 glucose transmembrane transporter activity (ISS) 
HGT20 orf19.1587 1.0 1.2 1.2 1.5 0.9 1.1 1.6 1.8 glucose transmembrane transporter activity (ISS) 
HOS1 orf19.4411 1.1 0.9 1.5 1.4 1.3 1.2 1.7 1.5 histone deacetylase activity (ISS) 
INO1 orf19.7585 1.2 0.6 1.4 1.5 1.7 1.2 2.5 1.6 inositol-3-phosphate synthase activity (IGI, ISS) 
PEX5 orf19.5640 1.0 1.0 1.3 1.5 1.1 1.0 1.6 1.5 peroxisome matrix targeting signal-1 binding (IEA)|protein binding, bridging (IEA) 
RBT5 orf19.5636 1.3 1.5 1.2 1.8 1.4 1.8 1.8 2.0 heme binding (IDA, IMP) 
SOD6 orf19.2108 1.2 0.9 1.2 1.5 1.6 0.8 2.4 1.6 superoxide dismutase activity (ISS) 
STF2 orf19.2107.1 1.0 1.3 1.3 1.5 1.2 1.1 1.6 1.5 
SUR2 orf19.5818 1.0 1.1 1.4 1.1 1.2 1.1 1.5 1.6 sphingosine hydroxylase activity (IEA) 
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VAM3 orf19.5875 1.0 1.5 1.1 1.8 1.1 1.0 1.5 1.7 
ZCF11 orf19.2423 1.0 1.2 1.3 1.9 0.9 1.2 1.5 2.0 sequence-specific DNA binding (IEA) 
ZCF14 orf19.2647 1.3 1.4 1.1 1.4 1.0 1.5 1.6 1.6 transcription factor activity (ISS) 
orf19.1412 1.4 1.1 1.4 1.5 1.4 1.0 1.8 1.5 
orf19.1881 1.4 1.2 2.2 1.4 1.3 1.3 2.1 1.8 1-acylglycerol-3-phosphate O-acyltransferase activity (IEA) 
orf19.1940 1.0 1.2 1.3 1.9 1.2 1.2 1.5 1.7 
orf19.2286 1.4 1.2 1.6 1.4 1.5 1.3 1.6 1.5 deoxyhypusine monooxygenase activity (IEA) 
orf19.2313 1.4 1.6 1.4 2.3 0.9 0.8 1.7 1.8 
orf19.314 1.1 1.2 1.5 1.4 1.4 1.3 1.6 1.6 transcription repressor activity (IEA) 
orf19.3434 1.6 1.1 1.4 1.3 1.6 1.3 2.1 1.6 
orf19.3877 1.3 1.4 1.5 1.0 1.1 1.2 1.6 1.6 
orf19.3937 1.4 1.6 1.1 1.4 1.4 0.9 1.8 1.6 
orf19.4174 1.1 1.3 1.4 1.5 0.9 1.1 1.5 1.6 nucleoside transmembrane transporter activity (IEA) 
orf19.4504 1.4 1.3 1.5 1.4 1.2 0.8 2.1 1.7 alcohol dehydrogenase (NAD) activity (IEA) 
orf19.4595 1.0 1.3 1.3 1.3 1.1 0.9 1.5 1.5 
orf19.4726 1.4 1.1 2.4 1.3 1.9 0.8 2.4 1.6 calcium ion binding (IEA)|enzyme activator activity (IEA) 
orf19.516 1.1 1.1 1.2 1.4 1.0 1.2 1.5 1.5 
orf19.5237 1.2 1.2 1.4 1.7 1.6 1.1 1.7 1.8 
orf19.5282 1.2 1.2 1.3 1.7 1.4 1.4 1.5 1.5 
orf19.5319 1.7 1.4 1.6 1.1 2.1 0.9 1.7 1.6 single-stranded DNA binding (IEA) 
orf19.540 0.9 1.2 1.7 1.4 1.1 0.7 1.7 1.8 
orf19.5523 1.0 1.0 1.2 1.2 1.3 0.9 1.6 1.5 
orf19.6031 1.1 1.2 2.4 1.4 1.6 1.0 1.7 1.6 phosphatidylinositol 3-phosphate binding (IEA)|protein binding (IEA) 
orf19.6393 1.0 1.2 1.4 1.2 1.3 1.0 1.9 1.5 ARF GTPase activator activity (IEA) 
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orf19.6690 0.9 1.5 2.0 1.4 1.0 0.9 1.5 1.5 
orf19.676 1.1 1.2 1.4 1.3 1.1 0.8 1.6 1.5 structural constituent of cytoskeleton (IEA) 
orf19.6816 1.0 1.0 1.3 1.6 1.2 1.1 1.6 1.5 aldehyde reductase activity (IEA) 
orf19.6852 1.0 1.1 1.4 1.6 1.3 1.2 1.6 1.5 
orf19.6973 1.1 1.3 1.7 1.3 1.2 0.8 1.5 1.5 ATP-dependent peptidase activity (IEA) 
orf19.7444 1.2 1.6 1.3 1.2 2.0 0.9 2.4 1.6 
orf19.7459 1.3 0.9 1.4 1.3 1.4 1.1 1.6 1.5 
orf19.89 0.9 1.3 1.4 1.6 1.2 1.0 1.7 1.5 peroxisome matrix targeting signal-2 binding (IEA) 
orf19.897 1.1 1.2 1.5 1.4 1.1 1.0 1.8 1.5 protein binding (IEA) 
orf19.910 1.1 1.2 1.1 1.4 1.1 1.0 1.5 1.6 
BNR1 orf19.7537 1.6 1.5 2.3 1.5 1.3 1.2 1.8 1.4 cytoskeletal protein binding (IDA) 
MUC1 orf19.4183 1.5 1.5 2.5 1.5 1.5 1.1 1.7 1.3 
USO6 orf19.6967 1.7 1.5 2.7 1.6 1.8 0.9 2.0 1.0 
orf19.6148 1.5 17.0 3.5 19.0 1.9 7.7 0.9 5.5 structural constituent of cytoskeleton (IEA) 
orf19.6501 1.6 19.2 3.0 18.4 1.4 9.0 1.0 8.1 
orf19.6790 1.5 1.5 2.8 1.5 1.6 0.7 1.3 0.9 mRNA binding (IEA) 
orf19.2400 1.5 1.9 1.6 2.0 1.8 1.3 1.4 1.4 
orf19.3461 1.5 1.6 2.1 2.0 1.4 1.3 1.4 2.1 
orf19.4330 1.7 2.0 2.3 1.9 1.7 1.5 1.4 1.8 
orf19.6308 1.5 1.5 1.8 1.5 1.4 0.8 1.5 1.0 
orf19.6920 2.0 1.8 2.7 2.1 1.6 1.4 1.5 0.9 
orf19.2006 2.5 1.6 2.8 2.1 3.4 0.9 1.8 0.9 
orf19.2204.2 1.5 1.5 2.1 1.8 1.7 1.4 1.8 1.4 * GTPase activity 
orf19.4168 1.6 1.7 1.6 1.7 2.3 1.4 1.9 1.1 ribonuclease MRP activity (IEA) 
  
117 
Appendix B.     Continued. 
          
  Change in fold expressiona  
  G648S G648D Y642F A643V  
CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
orf19.5772 1.8 1.5 1.7 1.6 1.9 1.2 1.9 1.1 
orf19.5295 1.6 2.1 2.5 1.6 0.9 0.9 1.9 1.3 
orf19.641 1.8 1.5 2.2 1.6 1.7 1.3 2.0 1.3 
orf19.1297 2.2 1.6 2.5 1.8 1.3 1.5 2.2 1.4 
orf19.5426 1.7 1.9 2.6 1.9 1.5 0.9 2.3 1.4 triglyceride lipase activity (IEA) 
orf19.3437 2.5 2.3 2.5 1.9 0.2 1.0 2.3 1.3 
orf19.1444 2.0 1.7 4.4 1.9 2.9 1.6 2.6 1.4  phosphatidylinositol-4,5-bisphosphate binding 
orf19.3607 3.8 10.1 3.2 15.1 1.4 6.4 0.4 13.9 
ARG81 orf19.4766 1.7 1.5 1.9 1.6 2.0 1.0 1.7 1.2 transcription factor activity (ISS)|transcription cofactor activity (IEA) 
BIO2 orf19.2593 1.6 1.8 3.0 1.6 1.3 1.0 1.5 1.3 biotin synthase activity (NAS) 
BNR1 orf19.7537 1.6 1.5 2.3 1.5 1.3 1.2 1.8 1.4 cytoskeletal protein binding (IDA)|cytoskeletal regulatory protein binding (IEA) 
USO6 orf19.6967 1.7 1.5 2.7 1.6 1.8 0.9 2.0 1.0 
orf19.6501 1.6 19.2 3.0 18.4 1.4 9.0 1.0 8.1 
orf19.3461 1.5 1.6 2.1 2.0 1.4 1.3 1.4 2.1 
orf19.2400 1.5 1.9 1.6 2.0 1.8 1.3 1.4 1.4 
orf19.5295 1.6 2.1 2.5 1.6 0.9 0.9 1.9 1.3 
orf19.641 1.8 1.5 2.2 1.6 1.7 1.3 2.0 1.3 
orf19.5772 1.8 1.5 1.7 1.6 1.9 1.2 1.9 1.1 
orf19.4168 1.6 1.7 1.6 1.7 2.3 1.4 1.9 1.1 ribonuclease MRP activity (IEA) 
orf19.3998 1.5 1.6 3.7 1.6 2.0 0.6 1.9 1.1 
orf19.6308 1.5 1.5 1.8 1.5 1.4 0.8 1.5 1.0 
orf19.2006 2.5 1.6 2.8 2.1 3.4 0.9 1.8 0.9 
orf19.6920 2.0 1.8 2.7 2.1 1.6 1.4 1.5 0.9 
orf19.6790 1.5 1.5 2.8 1.5 1.6 0.7 1.3 0.9 mRNA binding (IEA) 
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CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
RBT1 orf19.1327 1.9 1.6 1.2 1.1 1.6 1.9 1.1 1.2 
orf19.3851 1.5 1.6 2.1 1.1 0.9 0.9 1.6 1.6 
ALD6 orf19.742 2.6 3.2 1.4 1.2 1.7 0.7 1.8 1.5 aldehyde dehydrogenase (NAD) activity (IEA) 
orf19.136 1.6 1.5 1.3 1.3 1.0 1.1 1.6 1.5 drug transporter activity (ISS)|multidrug efflux pump activity (IEA) 
CIRT4B orf19.2839 1.9 1.7 2.9 1.3 1.4 0.5 3.4 1.5 
CAG1 orf19.4015 1.2 2.1 1.7 1.5 1.7 1.7 1.2 1.4 GTPase activity (IGI)|guanyl nucleotide binding (ISS) 
FGR23 orf19.1616 0.7 2.5 1.5 2.4 1.7 1.5 1.2 2.3 
orf19.345 2.1 1.4 1.6 1.8 2.3 1.5 1.9 1.3 succinate-semialdehyde dehydrogenase [NAD(P)+] activity (IEA) 
orf19.6805 1.8 1.3 2.8 1.6 2.1 1.5 1.5 1.0 
orf19.2650.1 1.4 1.2 1.7 1.6 1.8 1.6 1.3 1.1 structural constituent of ribosome (IEA) 
orf19.6023 1.3 1.6 2.2 1.5 1.7 1.8 1.3 1.5 drug transmembrane transport 
orf19.6311 1.0 4.2 3.9 4.5 2.1 1.7 1.4 1.2 
HGT20 orf19.1587 1.3 1.1 1.5 1.6 1.0 1.0 1.8 1.8 glucose transmembrane transporter activity (ISS) 
HGT3 orf19.4356 1.1 1.5 2.5 1.7 1.0 1.0 1.9 1.7 glucose transmembrane transporter activity (ISS) 
HYR1 orf19.4975 1.3 1.3 1.7 1.5 1.2 1.0 1.8 1.5 
IFC3 orf19.3749  1.1 1.7 5.9 3.6 1.3 1.2 3.6 3.4 oligopeptide transmembrane transporter activity 
IHD1 orf19.5760 1.3 1.8 1.7 1.9 1.2 1.7 1.7 2.0 
IRS4 orf19.6953 1.3 1.4 1.9 1.6 1.5 1.3 1.7 1.5 
LAP3 orf19.539 1.1 2.0 2.6 2.0 1.2 1.0 1.8 2.0 aminopeptidase activity (NAS) 
MEP1 orf19.1614 1.1 2.2 6.6 4.5 1.2 1.1 2.9 3.5 ammonium transmembrane transporter activity (IGI) 
MET13 orf19.2887 1.4 1.3 1.8 1.6 1.3 1.3 1.6 1.5 
MSO1 orf19.5248 1.3 1.3 3.0 2.9 2.1 1.3 2.9 2.3 
ORC3 orf19.6942 1.4 1.2 1.8 1.6 1.4 1.2 1.8 1.6 DNA replication origin binding (IEA)|chromatin binding (IEA) 
PGA10 orf19.5674 1.3 2.2 2.1 2.8 1.4 2.1 1.7 2.6 heme binding (IDA, IGI) 
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PLB4 orf19.1443 1.4 1.9 2.0 1.9 1.2 1.3 1.5 1.5 lysophospholipase activity (ISS) 
POS5 orf19.6800 1.1 1.5 2.2 2.1 1.4 0.9 1.9 1.9 NADH kinase activity (IEA) 
PTC4 orf19.6638 0.9 1.1 1.6 1.7 1.2 1.0 1.5 1.5 protein serine/threonine phosphatase activity (IEA) 
PTC6 orf19.3705 1.7 1.3 2.1 2.1 1.7 1.2 2.3 1.9 protein serine/threonine phosphatase activity (IDA) 
RAD57 orf19.2174 1.3 1.3 2.3 1.7 1.6 1.1 1.9 1.5 protein heterodimerization activity (IEA) 
RPN4 orf19.1069 1.4 1.1 2.0 2.2 1.5 1.3 1.7 1.6 sequence-specific DNA binding (IDA)|transcription factor activity (ISS) 
SAP5 orf19.5585 1.0 2.3 1.9 2.9 0.9 0.8 1.9 2.8 aspartic-type endopeptidase activity (IDA, ISS)|drug binding (IDA,ISS) 
SCT2 orf19.5815 1.5 1.1 2.5 1.7 1.3 1.2 1.8 1.5 
SOD6 orf19.2108 1.9 1.2 1.9 2.1 1.6 1.1 2.6 1.7 superoxide dismutase activity (ISS) 
UBA4 orf19.2324 1.5 1.0 1.5 1.7 1.6 1.1 1.9 1.6 URM1 activating enzyme activity (IEA) 
VAM3 orf19.5875 0.9 1.5 1.6 1.7 1.5 1.0 1.5 2.0 
VPS51 orf19.5568 1.2 1.3 2.0 1.7 1.9 1.0 2.0 1.5 
VRP1 orf19.2190 1.0 2.3 2.2 2.4 1.2 1.2 1.6 2.1 actin binding (IEA) 
YPT31 orf19.2622 1.5 1.2 2.0 1.6 1.7 1.4 1.9 1.5 GTPase activity (IEA) 
ZCF21 orf19.4166 1.8 1.2 2.2 1.9 1.6 1.3 2.1 1.6 
orf19.90 1.3 1.1 4.9 3.4 1.9 1.1 3.9 2.3 
orf19.2515 1.4 4.0 9.4 4.5 1.8 1.3 3.6 3.2 
orf19.5205 1.3 1.6 2.5 2.7 1.5 0.9 3.4 2.5 
orf19.4031 1.6 1.4 3.3 2.4 2.0 1.2 3.4 2.2 
orf19.6027 1.3 1.3 1.5 1.6 2.1 1.0 3.3 1.5 
orf19.7578 1.2 1.7 2.7 2.2 1.5 1.0 3.1 2.3 protein transporter activity (IEA) 
orf19.7457 1.4 1.6 2.3 2.7 1.7 1.2 2.7 1.8 
orf19.4897 1.9 1.3 2.7 2.2 2.3 1.4 2.7 1.8 phosphatidylinositol transporter activity (IEA) 
orf19.3318 1.5 1.2 3.1 2.0 1.6 1.0 2.6 1.6 
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CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
orf19.5777 1.2 2.1 3.5 3.6 1.3 1.6 2.6 2.9 
orf19.5535 1.4 1.7 2.2 2.6 1.4 1.9 2.5 2.9 anion:cation symporter activity (ISS)|pantothenate transporter activity (IEA) 
orf19.5727 1.2 1.5 2.7 2.4 1.4 1.2 2.5 2.0 
orf19.3544 1.1 1.9 3.5 1.6 1.1 1.0 2.4 1.9 
orf19.5275 1.4 1.3 3.0 2.2 2.7 1.4 2.4 1.8 ATPase activator activity (IEA) 
orf19.951 1.3 1.4 2.1 2.6 1.8 1.1 2.4 1.5 
orf19.288 1.6 1.2 2.7 2.4 1.7 1.4 2.4 1.8 methylenetetrahydrofolate reductase (NADPH) activity (IEA) 
orf19.1985 1.6 1.4 2.4 2.1 1.6 1.3 2.3 2.2 * protein phosphorylation 
orf19.4287 1.1 2.1 3.2 3.7 1.1 1.3 2.3 3.0 (R,R)-butanediol dehydrogenase activity (IEA) 
orf19.910 1.7 1.2 1.7 1.7 1.9 1.3 2.3 1.7 
orf19.1277 1.2 2.1 2.2 2.3 1.5 1.3 2.3 1.9 
orf19.2943 1.5 1.0 2.4 2.3 1.7 0.9 2.3 1.7 amino acid transmembrane transporter activity (IEA) 
orf19.1592 1.9 1.2 2.1 1.6 2.0 1.3 2.2 1.5 
orf19.996 1.3 1.3 2.5 1.9 1.9 1.1 2.2 1.7 adenylate cyclase activity (IEA) 
orf19.1698 1.7 1.3 2.3 1.5 1.6 1.0 2.2 1.7 
orf19.4723 1.5 1.2 1.7 1.6 1.4 1.2 2.2 1.5 FMN adenylyltransferase activity (IEA) 
orf19.2691 1.0 2.8 3.8 4.1 0.9 1.3 2.2 3.2 
orf19.7347 1.5 1.1 1.9 1.6 1.6 1.2 2.1 1.7 ubiquitin-protein ligase activity (ISS) 
orf19.35 1.3 1.1 2.1 1.9 1.4 1.1 2.1 1.6 
orf19.89 1.2 1.0 1.6 1.9 1.3 1.0 2.1 1.6 peroxisome matrix targeting signal-2 binding (IEA) 
orf19.4711 1.2 1.3 2.1 2.1 1.4 1.2 2.1 1.8 
orf19.3135 1.3 1.2 2.0 1.8 1.3 1.0 2.1 1.7 protein binding, bridging (IEA) 
orf19.296 0.9 2.4 3.4 2.3 0.9 1.0 2.1 2.2 
orf19.6912 1.4 1.1 2.5 1.6 1.5 1.1 2.1 1.7 choline kinase activity (IEA) 
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orf19.1857 1.7 1.2 2.2 1.6 1.9 1.0 2.1 1.5 histone acetyltransferase activity (IEA) 
orf19.2026 1.2 1.1 1.7 1.7 1.5 1.0 2.1 1.6 ubiquitin-specific protease activity (IEA) 
orf19.2703 1.2 1.1 2.1 1.7 1.1 1.1 2.1 1.6 
orf19.6624 1.6 1.3 1.9 1.8 1.2 1.2 2.1 1.5 
orf19.5601 1.2 1.5 2.9 2.4 1.4 1.0 2.1 1.7 
orf19.5492 1.2 1.0 2.0 1.8 1.4 1.2 2.1 1.5 mRNA binding (IEA) 
orf19.7131 1.4 1.8 2.9 1.9 1.3 1.3 2.0 1.6 gamma-butyrobetaine dioxygenase activity (IMP) 
orf19.6557 1.8 1.4 2.4 1.5 1.7 1.1 2.0 1.9 
orf19.7567 1.4 1.8 3.7 2.7 1.7 1.2 2.0 2.0 
orf19.3881 1.2 1.3 2.2 2.0 1.2 1.0 2.0 1.7 
orf19.5249 1.2 1.4 2.6 1.9 1.6 1.1 2.0 1.5 
orf19.3734 1.2 1.3 2.0 1.9 1.4 1.1 2.0 1.7 
orf19.5114 1.0 1.4 2.0 2.2 1.1 1.1 2.0 1.6 phosphatidylinositol 3-phosphate binding (IEA)|protein binding (IEA) 
orf19.4658 1.6 1.4 3.3 2.6 1.7 1.3 2.0 1.5 
orf19.6057 1.4 1.3 1.9 2.2 1.5 1.4 2.0 1.9 3-methyl-2-oxobutanoate hydroxymethyltransferase activity (IEA) 
orf19.1162.1 1.1 1.3 2.4 1.6 1.3 1.1 1.9 1.7 
orf19.719 1.1 1.5 1.7 2.4 1.3 1.2 1.9 1.8 ubiquitin-protein ligase activity (IEA) 
orf19.6148 1.4 1.9 4.5 3.0 1.8 1.4 1.9 1.8 structural constituent of cytoskeleton (IEA) 
orf19.6626 1.2 1.3 1.9 2.2 1.4 1.4 1.9 1.8 
orf19.6411 1.3 1.4 2.4 2.3 1.3 1.3 1.9 1.8 enzyme activator activity (IEA) 
orf19.4292 1.2 1.1 1.8 1.8 1.4 1.1 1.9 1.5 SNAP receptor activity (IEA) 
orf19.6832 1.2 1.3 1.8 1.8 1.4 1.1 1.9 1.6 
orf19.1306 1.2 0.9 2.2 2.1 1.4 1.3 1.9 1.8 
orf19.775 1.1 1.6 2.4 2.1 1.3 1.1 1.8 1.6 
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orf19.2278 1.4 1.6 2.5 2.2 1.6 1.4 1.8 1.7 
orf19.5125 1.1 1.8 2.4 1.6 1.1 0.8 1.8 1.5 
orf19.5711 1.4 1.4 2.1 1.5 1.4 1.2 1.8 1.7 phosphatidylinositol transporter activity (IEA) 
orf19.1424 1.1 1.6 2.1 2.2 1.1 1.5 1.8 1.9 oxalate transmembrane transporter activity (ISS) 
orf19.4699 1.0 2.2 2.1 2.5 1.2 1.3 1.8 2.0 phospholipase activity (ISS)|triglyceride lipase activity (IEA) 
orf19.5925 1.3 1.1 1.5 1.6 1.7 1.0 1.8 1.8 
orf19.577 1.2 1.4 2.3 1.8 1.2 1.1 1.8 1.7 
orf19.6194 1.1 1.5 1.8 1.7 1.3 1.1 1.8 1.5 
orf19.5459 1.3 2.0 1.9 1.6 1.2 1.8 1.7 1.8 
orf19.7092 1.3 1.2 2.0 1.7 1.4 1.1 1.7 1.5 
orf19.346 1.2 1.6 2.0 1.8 1.1 1.0 1.7 1.6 L-alanine:2-oxoglutarate aminotransferase activity (IEA) 
orf19.5751 1.2 1.2 2.0 2.4 1.4 1.3 1.7 1.5 
orf19.3058 1.3 1.4 1.9 2.0 1.3 1.3 1.7 1.9 
orf19.6816 1.0 1.1 1.5 1.7 1.2 1.1 1.7 1.6 aldehyde reductase activity (IEA) 
orf19.5752 1.1 1.3 1.8 2.0 1.2 1.2 1.7 1.7 contributes_to ubiquitin-protein ligase activity (IEA) 
orf19.6043 1.3 1.5 2.5 1.9 1.7 1.3 1.7 1.8 D-lactate dehydrogenase (cytochrome) activity (IEA) 
orf19.2558 1.3 1.3 1.5 2.1 1.4 1.6 1.7 1.9 
orf19.2050 0.9 1.6 1.9 1.9 1.0 1.1 1.7 2.0 sterol esterase activity (IEA) 
orf19.3615 1.3 1.6 2.3 2.9 1.5 1.3 1.7 1.9 
orf19.3991 1.3 1.2 1.7 1.6 1.3 1.3 1.7 1.5 
orf19.6850 1.1 1.3 1.7 1.7 1.2 1.1 1.7 1.7 transcription factor activity (ISS)|ubiquitin-protein ligase activity (IEA) 
orf19.3508 0.8 2.0 2.2 2.0 1.0 1.2 1.7 2.3 
orf19.135 1.4 1.2 2.1 1.6 1.7 1.0 1.7 1.5 protein binding (IEA) 
orf19.3815 1.4 1.1 1.5 1.8 1.4 1.0 1.7 1.6 ubiquitin-specific protease activity (IEA) 
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orf19.1630 1.5 1.1 1.6 1.6 1.3 1.3 1.7 1.5 
orf19.3910 0.9 2.2 2.9 2.4 0.8 0.6 1.7 1.7 
orf19.1433 1.1 1.4 1.8 2.0 1.3 1.1 1.6 1.6 
orf19.6102 1.2 1.4 1.9 1.8 1.3 1.3 1.6 1.8 specific RNA polymerase II transcription factor activity (IEA) 
orf19.467 1.3 2.0 2.8 1.7 1.3 1.1 1.6 1.6 
orf19.6860 1.2 1.4 1.6 1.8 1.2 1.3 1.6 1.6 CDP-diacylglycerol-inositol 3-phosphatidyltransferase activity (IEA) 
orf19.1307 1.0 2.9 3.2 1.7 0.8 1.2 1.6 2.1 
orf19.6838 1.1 1.8 1.9 2.0 1.1 1.3 1.6 2.0 2,4-dienoyl-CoA reductase (NADPH) activity (IEA) 
orf19.1162 1.2 1.5 1.7 1.6 1.3 1.4 1.6 1.7 
orf19.1940 1.0 1.4 1.6 2.1 1.2 1.3 1.6 1.8 
orf19.4865 1.2 1.2 1.5 1.6 1.2 1.3 1.6 1.7 phosphatidylinositol-3,5-bisphosphate 5-phosphatase activity (IEA) 
orf19.6003 1.6 1.3 2.2 1.7 1.6 0.8 1.6 1.5 
orf19.3659 1.1 1.2 1.6 1.7 1.3 1.2 1.6 1.6 
orf19.5614 0.9 2.6 2.4 3.1 0.9 2.0 1.6 2.3 ribonuclease H activity (IEA) 
orf19.7459 1.2 0.9 1.5 1.5 1.3 1.2 1.6 1.6 
orf19.2838 0.7 1.5 1.5 1.6 0.8 0.8 1.6 1.9 
orf19.2163 1.0 1.7 1.8 1.9 1.1 1.2 1.6 1.6 
orf19.417 1.4 1.4 1.6 1.8 1.3 1.5 1.6 1.6 metallochaperone activity (IEA)|transporter activity (IEA) 
orf19.3973 0.9 2.0 2.1 2.1 1.0 1.1 1.6 2.0 
orf19.5953 1.4 1.2 1.5 1.9 1.3 1.4 1.5 1.7 sequence-specific DNA binding (IEA)|transcription factor activity (IEA) 
orf19.4127 1.1 1.2 1.5 1.7 1.3 1.2 1.5 1.5 
orf19.4055 0.7 1.1 1.5 1.5 0.9 0.7 1.5 1.6 
orf19.3021 0.8 1.5 1.9 2.0 1.4 1.0 1.5 1.7 
orf19.5943 1.3 1.2 1.6 1.6 1.2 1.0 1.5 1.5 
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orf19.7038 1.1 1.4 1.8 1.8 1.1 1.0 1.5 1.5 phosphatidylinositol 3-phosphate binding (IEA) 
orf19.6443 1.2 1.9 2.1 1.9 1.2 1.2 1.5 1.7 dodecenoyl-CoA delta-isomerase activity (IEA) 
orf19.3233 1.2 1.2 1.9 1.5 1.2 1.2 1.5 1.6 protein binding (IEA) 
orf19.6995 1.0 1.1 1.9 1.6 0.6 0.9 1.5 1.6 
orf19.5236 1.2 1.4 1.5 1.5 1.3 1.0 1.5 1.7 dehydrodolichyl diphosphate synthase activity (IEA) 
orf19.6469 1.1 1.5 1.7 1.7 1.1 1.2 1.5 1.7 * RNA-directed DNA polymerase activity 
orf19.6440 1.1 1.2 1.7 1.5 1.0 0.9 1.5 1.5 ubiquitin-protein ligase activity (IEA) 
orf19.278 1.4 1.6 1.6 1.9 1.4 1.2 1.5 1.7 
orf19.827 1.4 1.9 1.9 2.9 1.3 1.4 1.5 1.8 
orf19.4070 1.2 1.6 1.7 1.6 1.3 1.2 1.5 1.7 
orf19.5239 1.0 1.8 2.4 2.1 1.8 1.0 1.5 1.5 
orf19.6048 0.8 1.3 1.5 1.5 0.8 1.0 1.5 1.6 dolichyl-phosphate-mannose-protein mannosyltransferase activity (IEA) 
ALS1 orf19.5741 2.6 0.9 1.3 2.2 2.8 2.3 3.4 2.1 protein binding (IDA)|cell adhesion molecule binding (IEA) 
IFM3 orf19.2176 1.6 1.4 1.4 1.4 1.6 1.7 1.8 1.8 
MSO1 orf19.5248 1.3 1.4 2.7 3.0 1.6 1.5 2.9 2.2 
orf19.4041 1.8 1.3 1.2 2.4 1.9 1.5 3.2 2.3 ubiquitin-protein ligase activity (IEA) 
orf19.1050 1.3 2.5 0.8 3.2 1.9 2.9 1.6 1.9 
orf19.2016 1.1 1.5 1.3 2.1 1.5 1.7 1.5 1.6 protein binding, bridging (IEA) 
COQ4 orf19.3008 1.7 1.4 2.6 2.8 1.8 1.5 2.9 2.3 
DAL1 orf19.5454 2.1 1.3 1.8 2.3 2.8 2.4 2.8 1.9 
DAP1 orf19.489 1.3 2.0 3.0 3.9 1.8 2.0 2.7 2.8 heme binding (IEA) 
ERG11 orf19.922 1.6 1.4 1.8 1.6 1.7 1.6 1.7 1.7 drug binding (IDA, ISS)|sterol 14-demethylase activity (IDA) 
ERG6 orf19.1631 1.6 1.4 2.1 1.5 1.8 1.8 1.7 1.9 sterol 24-C-methyltransferase activity (IGI, IMP, ISS) 
ERG7 orf19.1570 1.4 1.6 2.4 2.1 1.6 1.7 2.4 2.7 lanosterol synthase activity (IGI, ISS) 
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ERG9 orf19.3616 1.5 1.3 2.0 1.7 1.7 1.5 1.8 1.8 farnesyl-diphosphate farnesyltransferase activity (ISS) 
EXG2 orf19.2952 2.0 1.4 2.4 2.4 2.0 1.5 2.4 1.9 glucan 1,3-beta-glucosidase activity (IDA, IGI, IMP) 
IPK2 orf19.1377 2.1 1.2 3.0 2.2 2.5 1.5 3.7 2.1 inositol 1,3,4,5,6-pentakisphosphate kinase activity (IEA) 
PGA10 orf19.5674 1.4 2.3 1.8 2.4 1.6 2.2 1.6 2.5 heme binding (IDA, IGI) 
SLD1 orf19.260 1.6 1.4 1.9 2.0 1.7 1.6 1.9 1.8 
SNO1 orf19.2948 1.4 1.4 2.4 2.0 1.8 1.5 2.3 1.9 imidazoleglycerol-phosphate synthase activity (IEA) 
orf19.692 1.3 2.7 2.2 3.4 1.7 1.8 3.0 4.1 
orf19.1344 4.7 1.3 2.9 1.8 3.2 2.5 3.5 2.1 
orf19.7504 2.2 1.4 4.0 2.4 2.4 1.8 2.6 1.8 
orf19.2175 1.5 1.3 1.5 1.6 1.8 1.6 1.8 1.7 
orf19.2452 2.2 1.3 2.1 1.9 2.2 1.5 2.7 1.7 
orf19.4167 1.9 0.7 2.2 2.2 2.8 1.7 2.9 1.7 
orf19.4690 1.2 5.0 11.3 10.3 1.9 2.4 3.4 6.7 manganese ion transmembrane transporter activity (IEA) 
orf19.3921 1.6 1.2 2.8 2.2 1.6 1.5 2.0 1.7 
orf19.633 1.7 1.0 2.3 2.3 1.9 1.6 2.8 1.9 
orf19.4459 1.6 1.2 3.5 3.5 2.1 1.7 2.4 2.0 
orf19.6753 1.4 1.5 3.3 1.5 1.8 1.5 2.9 2.0 
orf19.6558 1.7 1.4 1.7 1.7 1.7 1.5 1.8 1.5 GTPase activator activity (IEA) 
orf19.633 1.7 1.0 2.3 2.3 1.9 1.6 2.8 1.9 
orf19.6558 1.7 1.4 1.7 1.7 1.7 1.5 1.8 1.5 GTPase activator activity (IEA) 
orf19.2296 2.2 2.4 3.6 1.2 1.7 1.9 2.7 1.9 
orf19.6342 1.9 3.9 3.3 9.3 0.6 4.7 2.5 9.9 
ARO9 orf19.1237 1.5 3.4 5.8 4.2 1.5 1.9 2.1 2.8 aromatic-amino-acid:2-oxoglutarate aminotransferase activity (ISS) 
CAG1 orf19.4015 2.4 1.6 2.7 1.5 1.4 0.9 2.1 1.5 GTPase activity (IGI)|guanyl nucleotide binding (ISS) 
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CAN1 orf19.97 1.6 1.7 5.5 3.2 1.2 1.1 2.5 2.4 amino acid binding  
CDR11 orf19.919 1.8 2.1 4.1 4.9 1.4 1.5 2.3 4.2 ATP binding (ISS) 
CNH1 orf19.367 2.3 1.9 2.8 2.3 1.9 1.3 2.4 1.8 Candida albicans Na+/H+ antiporter 
ENT3 orf19.1553 2.1 1.9 2.2 2.1 2.0 1.4 1.5 1.9 
HAP31 orf19.517 1.5 1.7 2.3 2.4 1.8 1.4 2.0 1.9 transcription factor activity (NAS)|transcription activator activity (IEA) 
HAP42 orf19.1481 1.6 1.5 3.6 2.3 2.2 1.0 2.1 1.5 
IFR1 orf19.1763 1.6 3.3 6.8 2.9 1.9 1.1 2.6 2.4 
LIG4 orf19.5798 1.7 1.5 3.3 2.4 1.9 1.2 2.6 1.9 DNA ligase activity (IGI, ISS)|DNA ligase (ATP) activity (IEA) 
PXP2 orf19.1655 1.5 2.5 3.5 3.3 0.8 1.3 2.0 2.2 acyl-CoA oxidase activity (ISS) 
UGA6 orf19.5820 1.7 1.9 3.7 1.5 1.7 1.0 3.0 1.8 amino acid transmembrane transporter activity 
ZCF11 orf19.2423 1.7 1.5 2.8 2.5 2.1 1.4 2.9 2.3 sequence-specific DNA binding (IEA) 
orf19.4191.1 1.5 1.5 3.2 2.9 1.9 1.4 3.5 3.1 ubiquitin-ubiquitin ligase activity (IEA) 
orf19.2836 2.5 1.7 5.3 3.4 2.0 1.3 5.7 3.0 
orf19.6970 1.8 1.9 3.8 3.8 2.6 1.4 4.7 2.8 
orf19.3848 2.4 1.8 6.3 3.5 2.0 1.1 6.4 2.8 
orf19.5799 1.7 2.0 3.4 2.4 1.5 1.5 2.4 2.6 
orf19.6986 2.4 1.8 2.5 2.2 2.8 1.2 2.6 2.2 
orf19.1881 1.5 1.6 2.4 2.2 1.5 1.5 2.4 2.1 1-acylglycerol-3-phosphate O-acyltransferase activity (IEA) 
orf19.4763 1.6 2.0 2.7 3.1 1.7 1.1 2.3 2.0 
orf19.1964 1.5 2.0 1.6 2.1 1.2 1.9 1.6 2.0 
orf19.5644 1.9 1.6 3.1 2.2 1.7 1.2 2.6 1.9 
orf19.4982 1.7 1.6 3.0 2.0 1.9 1.1 2.7 1.8 
orf19.5037 3.1 1.5 2.3 2.0 2.0 1.2 2.7 1.8 
orf19.541 1.6 1.6 1.7 1.9 1.6 1.2 2.2 1.7 
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orf19.4170 2.3 1.7 2.8 2.5 2.9 1.3 4.2 1.7 structural constituent of cell wall (IEA) 
orf19.5426 2.0 1.9 3.0 1.8 1.6 1.2 2.1 1.7 triglyceride lipase activity (IEA) 
orf19.7380 1.5 2.1 2.4 2.3 1.3 1.2 1.6 1.6 
orf19.6797 1.5 2.1 1.5 1.8 1.1 1.7 1.8 1.8 
orf19.4657 2.1 1.5 2.8 2.0 2.1 1.4 2.5 1.6 contributes_to phosphoprotein phosphatase activity (IEA) 
orf19.1504 1.6 1.6 2.7 1.6 1.8 1.0 3.0 1.6 
orf19.7345 1.7 1.6 2.1 2.0 1.8 1.1 2.6 1.6 ATP binding (IEA) 
orf19.4346  1.6 1.6 2.4 1.8 1.6 0.9 2.1 1.5  protein anchor 
orf19.4589 1.5 1.5 1.8 1.6 1.3 1.3 1.7 1.5 amine oxidase activity (IEA) 
orf19.2607 1.7 1.5 2.2 1.7 2.0 1.3 1.8 1.5 
orf19.6348 1.7 2.0 2.0 2.2 1.5 1.2 2.4 1.5 
PRM9 orf19.2508 14.1 2.9 15.1 1.6 13.3 2.6 13.7 1.2 
orf19.1444 2.0 1.7 4.4 1.9 2.9 1.6 2.6 1.4  phosphatidylinositol-4,5-bisphosphate binding 
orf19.4330 1.7 2.0 2.3 1.9 1.7 1.5 1.4 1.8 
ARO9 orf19.1237 1.5 3.4 5.8 4.2 1.5 1.9 2.1 2.8 aromatic-amino-acid:2-oxoglutarate aminotransferase activity (ISS) 
BTS1 orf19.6674 2.0 2.5 6.8 6.4 2.6 2.0 5.0 4.1 farnesyltranstransferase activity (IEA) 
BUL1 orf19.5094 1.9 1.9 4.1 3.1 2.5 1.8 2.1 1.9 
COQ4 orf19.3008 1.5 1.5 2.3 2.8 1.9 1.6 2.6 2.5 
DDR48 orf19.4082 2.2 4.3 5.8 4.7 2.7 2.9 3.4 4.3 
ERG1 orf19.406 1.8 1.8 2.7 2.3 2.2 2.0 2.3 2.3 squalene monooxygenase activity (IDA, IMP)|drug binding (IEA) 
ERG2 orf19.6026 1.7 1.5 2.3 1.9 1.9 1.9 2.1 2.0 C-8 sterol isomerase activity (IGI, IMP) 
ERG24 orf19.1598 1.7 1.7 2.3 2.1 1.7 1.8 2.1 2.3 delta14-sterol reductase activity (IGI, ISS) 
ERG26 orf19.2909 1.7 1.6 2.7 2.6 2.2 2.0 2.7 2.7 C-3 sterol dehydrogenase (C-4 sterol decarboxylase) activity (IGI, ISS) 
ERG27 orf19.3240 1.8 2.1 3.3 3.4 2.2 2.2 3.1 3.2 3-keto sterol reductase activity (IGI, IMP) 
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ERG7 orf19.1570 1.5 1.6 2.8 2.1 1.8 1.6 2.7 2.4 lanosterol synthase activity (IGI, ISS) 
FMA1 orf19.6837 1.8 3.2 2.7 5.3 1.5 3.3 1.7 3.0 nucleotide binding, oxidoreductase activity 
FRP1 orf19.5634 5.4 5.7 17.3 17.5 8.1 5.9 16.3 14.7 ferric-chelate reductase activity (IEA, IMP) 
FTH1 orf19.4802 2.6 2.6 5.3 5.2 2.3 1.9 6.6 5.2 
GYP1 orf19.3811 1.6 1.6 3.7 3.5 1.8 1.5 3.7 3.4 Rab GTPase activator activity (IEA) 
HEM14 orf19.4747 2.1 1.6 3.6 3.0 2.2 1.8 2.9 2.3 oxygen-dependent protoporphyrinogen oxidase activity (ISS) 
HXT5 orf19.4384 1.8 2.1 2.6 2.0 1.8 1.5 2.3 1.7 hexose transmembrane transporter activity (IEP) 
IDP2 orf19.3733 2.2 1.6 3.3 2.8 2.6 2.0 3.2 2.5 isocitrate dehydrogenase (NADP+) activity (IEA) 
IFD7 orf19.629 1.7 3.2 4.6 6.8 1.7 2.7 1.7 4.3   
MDR1 orf19.5604 5.9 5.5 15.1 8.0 6.6 6.1 5.9 5.7 drug transporter activity (ISS)|fluconazole transporter activity (IDA) 
NCP1 orf19.2672 1.6 1.7 2.6 2.0 1.7 1.9 1.9 1.9 NADPH-hemoprotein reductase activity (ISS)|electron carrier activity (IEA) 
PGA45 orf19.2451 1.7 1.5 2.1 2.2 1.7 1.9 2.0 2.3 
PGA7 orf19.5635 2.3 3.7 5.7 7.4 2.7 3.8 4.8 6.1 
PHO100 orf19.4424 1.5 3.4 4.8 2.7 1.6 1.5 2.0 2.3 acid phosphatase activity (NAS) 
SET3 orf19.7221 2.8 2.7 6.3 5.7 4.4 3.6 4.8 4.8 NAD-dependent histone deacetylase activity (IEA) 
SLD1 orf19.260 1.8 1.5 2.2 1.8 1.7 1.6 2.0 1.9 oxidoreductase activity 
TEF4 orf19.2652 16.4 16.6 55.8 90.2 29.9 32.7 65.5 67.8 translation elongation factor activity (IEA) 
YMX6 orf19.5713 1.6 2.6 2.9 2.0 1.6 1.6 1.7 1.8 NADH dehydrogenase activity (IEA) 
orf19.1801 1.7 1.6 2.4 2.0 1.9 1.6 2.0 1.8 cytochrome-b5 reductase activity (IEA) 
orf19.5535 1.5 1.6 2.2 2.7 1.5 1.9 2.7 3.2 anion:cation symporter activity (ISS)|pantothenate transporter activity (IEA) 
orf19.6169.2 1.7 1.8 2.6 2.5 1.8 1.7 2.0 1.5 
orf19.288 1.8 1.5 3.0 2.5 2.1 1.5 2.5 2.0 methylenetetrahydrofolate reductase (NADPH) activity (IEA) 
orf19.329 2.1 2.3 2.4 2.6 2.0 1.6 2.5 2.5 RNA binding (IEA) 
orf19.7547 1.8 1.5 2.8 2.7 2.0 1.5 3.1 2.3 phosphatidylinositol 3-phosphate binding (IEA)|ubiquitin-protein ligase activity (IEA) 
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orf19.7329 1.6 2.1 3.1 3.0 1.7 1.8 2.5 2.3 ubiquitin-protein ligase activity (IEA) 
orf19.3627 4.0 1.9 7.0 4.0 4.4 1.9 5.1 1.9 
orf19.5210 1.5 2.1 2.7 2.7 1.8 1.5 2.9 2.3 transcription factor activity (IEA) 
orf19.2350 1.7 1.7 3.4 4.4 2.0 1.9 3.2 3.0 drug transporter activity (ISS) 
orf19.3483 2.0 2.4 5.3 4.7 2.9 2.2 3.5 3.3 phosphatidylglycerol phospholipase C activity (IEA) 
orf19.344 8.2 9.0 25.0 20.7 9.7 7.3 13.3 10.2 
orf19.5777 1.7 2.4 4.8 3.8 1.9 1.5 3.1 2.5 
orf19.5799 1.7 2.0 3.4 2.4 1.5 1.5 2.4 2.6 
orf19.3261 1.8 2.2 2.7 3.4 1.6 2.3 4.5 4.5 
orf19.7456 1.7 2.6 4.4 4.1 2.2 2.1 3.9 3.5 
orf19.7043 2.5 1.9 5.2 3.6 2.8 2.3 4.9 3.0 
orf19.4013 2.6 2.2 4.2 3.5 3.1 2.8 4.8 3.8 
orf19.4014 1.5 2.1 2.3 2.4 1.7 1.6 2.6 2.6 
orf19.4031 1.8 1.8 2.5 2.5 1.6 1.5 2.9 2.5 
orf19.6840 2.0 2.1 4.1 4.4 2.6 2.4 3.1 2.6 
orf19.286 2.1 2.5 2.3 2.2 1.9 1.9 3.5 1.9 
orf19.1865 2.4 2.2 3.7 2.9 2.4 2.2 3.4 3.1 
orf19.7504 2.1 1.8 3.0 3.3 1.9 2.0 2.2 2.1 
orf19.3737 1.6 1.9 2.9 3.4 2.0 1.8 3.1 2.6 
orf19.7263 1.8 1.9 2.9 2.8 1.6 1.7 2.1 1.9 
orf19.1964 2.0 1.8 2.5 2.2 1.7 1.6 2.2 1.6 
orf19.1800 2.3 2.2 4.6 3.9 2.5 2.2 4.5 3.4 
orf19.6025 2.2 2.1 3.9 5.2 3.8 3.1 5.2 5.2 N-acetylglucosaminyldiphosphodolichol N-acetylglucosaminyltransferase activity  
orf19.2691 1.5 5.4 5.4 9.1 1.6 2.3 4.4 6.5 
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orf19.496 2.4 2.3 4.4 3.8 2.5 2.0 3.6 3.1 DNA-dependent ATPase activity (IEA) 
orf19.1881 1.5 1.6 2.4 2.2 1.5 1.5 2.4 2.1 1-acylglycerol-3-phosphate O-acyltransferase activity (IEA) 
orf19.2285 1.7 2.5 1.8 1.5 1.8 2.4 2.1 2.1 
a Fold change defined as the average ratio of gene expression levels in the isolates compared in two independent microarray experiments. 
Bold indicates “real” result as defined in Materials and Methods 
Red shading  indicates ratio values above 1.5. 
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CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
ABP140 orf19.3676 1.6 0.4 0.5 0.5 1.7 1.0 0.8 0.5 
ADH3 orf19.4505 0.5 1.8 0.6 0.6 0.7 1.4 0.8 0.8 alcohol dehydrogenase (NAD) activity (IEA) 
AGP2 orf19.4679 1.1 0.8 0.6 0.6 0.8 0.7 0.9 0.6 amino acid transmembrane transporter activity (IEA) 
ARX1 orf19.3015 1.2 0.5 0.4 0.6 1.2 1.0 0.7 0.6 
AYR2 orf19.5615 0.7 1.1 0.6 0.6 0.6 0.7 0.7 0.9 acylglycerone-phosphate reductase activity (IEA) 
BUD21 orf19.5430 1.1 0.6 0.4 0.4 1.2 1.2 0.7 0.5 snoRNA binding (IEA) 
BUD22 orf19.3287 1.5 0.6 0.4 0.5 1.3 0.9 0.7 0.4 
CAN2 orf19.111 0.8 0.8 0.6 0.6 0.6 0.7 0.7 0.7 arginine transmembrane transporter activity  
CCW14 orf19.1969 0.8 0.6 0.4 0.6 0.8 0.5 0.9 0.5 structural constituent of cell wall (IEA) 
CDR1 orf19.6000 1.0 0.7 0.5 0.6 0.9 0.8 0.8 0.8 ATP binding (IDA, IGI, IMP, ISS) 
CDR3 orf19.1313  0.9 0.8 0.6 0.6 0.8 0.8 0.8 0.7 
CHR1 orf19.3756 2.0 0.5 0.6 0.5 2.3 0.8 0.8 0.3 ATP-dependent RNA helicase activity (ISS) 
CHS6 orf19.5155 0.9 0.7 0.6 0.4 0.7 0.5 0.8 0.4 
CIC1 orf19.124 1.9 0.5 0.5 0.5 1.8 1.1 0.9 0.5 protein binding, bridging (IEA) 
CNS1 orf19.6052 1.2 0.7 0.6 0.6 1.3 1.0 0.7 0.6 Hsp70 protein binding (IEA)|Hsp90 protein binding (IEA) 
CSI2 orf19.5232 1.5 0.5 0.5 0.6 1.7 1.0 1.0 0.5 5S rRNA binding (IEA)|rRNA primary transcript binding (IEA) 
DBP7 orf19.6902 1.6 0.5 0.5 0.6 1.5 1.1 0.9 0.6 ATP-dependent RNA helicase activity (IEA) 
DBP8 orf19.6652 1.6 0.5 0.5 0.6 1.8 0.9 0.7 0.3 ATP-dependent RNA helicase activity (IEA) 
DFI1 orf19.7084 0.9 0.8 0.5 0.6 0.8 1.0 0.7 0.8 
DIP2 orf19.5106 1.5 0.6 0.5 0.5 1.4 1.1 0.8 0.5 snoRNA binding (IEA) 
DLD1 orf19.5805 0.8 1.0 0.6 0.6 0.6 0.8 0.5 0.7 D-lactate dehydrogenase (cytochrome) activity (IEA) 
ECM1 orf19.5299 1.9 0.6 0.5 0.6 1.6 0.9 0.8 0.4 
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ENP1 orf19.5507 1.5 0.6 0.5 0.4 1.3 1.1 0.7 0.4 snoRNA binding (IEA) 
ENP2 orf19.6686 1.5 0.5 0.3 0.5 1.6 1.0 0.9 0.3 
FAD3 orf19.4933 1.1 0.5 0.3 0.5 1.0 1.0 0.8 0.6 omega-3 fatty acid desaturase activity (IMP) 
FCR1 orf19.6817 0.7 0.9 0.6 0.6 0.6 0.7 0.7 0.7 purine nucleotide binding (ISS)|transcription factor activity (IGI, ISS) 
FCY21 orf19.1357 1.2 1.0 0.6 0.6 1.0 0.4 1.0 0.3 
GAL102 orf19.3674 0.7 0.5 0.6 0.4 1.1 0.4 0.8 0.5 UDP-glucose 4-epimerase activity (IEA) 
GAP4 orf19.4456 0.9 0.8 0.6 0.6 0.8 0.9 0.7 0.7 
GAT2 orf19.4056 1.2 1.4 0.4 0.5 0.8 1.0 0.6 0.4 transcription factor activity (IEA) 
HBR3 orf19.6955 1.3 0.6 0.5 0.5 1.5 1.3 0.7 0.5 SSU rRNA binding (IEA)|endoribonuclease activity (IEA) 
HCA4 orf19.2712 1.5 0.5 0.6 0.5 1.8 1.0 0.8 0.5 
HGT8 orf19.2021 0.8 0.8 0.5 0.5 0.7 0.7 0.6 0.7 glucose transmembrane transporter activity (ISS) 
IFD6 orf19.1048 0.7 0.7 0.6 0.4 0.9 0.6 0.8 0.6 aryl-alcohol dehydrogenase activity (NAS) 
IPT1 orf19.4769 0.8 0.8 0.5 0.6 0.6 0.8 0.7 0.6 transferase activity, transferring phosphorus-containing groups (IMP, ISS) 
KTI12 orf19.2385 1.2 0.7 0.5 0.5 1.5 0.9 0.7 0.5 chromatin binding (IEA)|enzyme regulator activity (IEA) 
MDN1 orf19.4697 1.4 1.1 0.6 0.3 1.1 1.1 0.8 0.5 ATPase activity (IEA) 
MET10 orf19.4076 0.9 0.7 0.5 0.6 0.7 0.8 0.7 0.7 sulfite reductase (NADPH) activity (IEA)|contributes_to sulfite reductase (NADPH) activity (IEA) 
MET14 orf19.946 0.9 0.8 0.6 0.5 0.9 1.0 1.0 0.9 adenylylsulfate kinase activity (IEA) 
MET3 orf19.5025 1.4 0.9 0.4 0.4 1.1 0.8 1.3 0.8 sulfate adenylyltransferase (ATP) activity (ISS) 
NGT1 orf19.5392 1.6 0.4 0.5 0.6 1.0 0.8 1.1 0.7 N-acetylglucosamine transmembrane transporter activity (IDA, IMP, ISS) 
NIP7 orf19.3478 1.4 0.5 0.4 0.5 1.2 1.0 0.7 0.4 protein binding (IEA) 
NOC4 orf19.1902 1.4 0.5 0.4 0.4 1.4 1.0 0.7 0.5 
NSA1 orf19.2185 1.3 0.5 0.5 0.6 1.7 1.1 0.7 0.5 
PGA26 orf19.2475 0.6 0.8 0.5 0.5 0.5 0.7 0.6 0.7 
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PGA32 orf19.6784 0.9 0.9 0.6 0.5 0.8 0.8 0.7 0.6 
PHO113 orf19.2619 0.8 0.7 0.6 0.6 0.8 0.8 0.7 0.7 acid phosphatase activity (IEA) 
POL93 orf19.6078 1.2 0.7 0.6 0.6 1.0 0.8 0.9 0.6 DNA binding, RNA binding, RNA directed DNA polymerase activity 
POL93 orf19.6078 1.0 0.5 0.3 0.4 0.8 0.8 0.8 0.7 
POP3 orf19.7657 1.2 0.7 0.5 0.5 1.3 1.1 0.7 0.5 ribonuclease MRP activity (IEA) 
POP4 orf19.5567 1.2 0.7 0.6 0.6 1.3 0.9 0.7 0.6 ribonuclease MRP activity (IEA) 
PRN4 orf19.2461 0.9 0.7 0.6 0.5 0.9 0.6 0.7 0.6 
PUT1 orf19.4274 1.2 0.8 0.6 0.5 1.0 0.7 0.7 0.6 proline dehydrogenase activity (IEA) 
PUT2 orf19.3974 1.2 0.9 0.6 0.6 1.0 0.8 0.8 0.8 1-pyrroline-5-carboxylate dehydrogenase activity (IEA) 
PWP2 orf19.3276 1.4 0.5 0.5 0.5 1.4 1.0 0.7 0.5 snoRNA binding (IEA) 
RCL1 orf19.1886 1.4 0.7 0.6 0.5 1.3 0.9 0.8 0.6 RNA-3'-phosphate cyclase activity (IEA 
REI1 orf19.59 1.8 0.5 0.5 0.5 1.7 1.0 0.8 0.4 sequence-specific DNA binding (IEA) 
RHD3 orf19.5305 0.8 0.9 0.4 0.5 0.7 0.8 0.6 0.8 
RIM2 orf19.4499 1.1 0.7 0.6 0.6 0.9 1.0 0.7 0.6 pyrimidine nucleotide transmembrane transporter activity (IEA) 
RLM1 orf19.4662 1.2 0.8 0.5 0.6 1.0 0.8 0.9 0.5 transcription regulator activity (IMP)|DNA bending activity (IEA) 
RPA12 orf19.2287 1.8 0.5 0.5 0.5 1.7 1.0 1.0 0.4 DNA-directed RNA polymerase activity (IEA)|exoribonuclease activity (IEA) 
RPF1 orf19.2667 1.5 0.5 0.5 0.6 1.4 1.1 1.0 0.6 rRNA primary transcript binding (IEA) 
RRN11 orf19.718 1.3 0.5 0.6 0.6 1.4 0.9 0.9 0.4 transcription factor activity (ISS)|RNA polymerase I transcription factor activity (IEA) 
RRP15 orf19.563 1.6 0.5 0.5 0.5 1.6 1.0 0.7 0.5 
RTA2 orf19.24 0.9 1.0 0.6 0.5 0.7 0.7 0.8 0.7 phospholipid-translocating ATPase activity (IEA) 
SDA1 orf19.6648 1.4 0.5 0.4 0.5 1.4 1.0 0.8 0.5 
SKN1 orf19.7362 1.5 0.4 0.3 0.3 1.2 0.7 0.8 0.3 
SNG3 orf19.1333 1.0 0.8 0.6 0.6 0.8 0.5 0.8 0.6 
  
134 
Appendix C.     Continued. 
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CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
SPC98 orf19.2600 0.9 0.9 0.4 0.6 1.2 0.7 0.8 0.6 structural constituent of cytoskeleton (IEA) 
SYG1 orf19.768 0.8 0.9 0.5 0.6 0.8 0.7 0.7 0.6 
THI4 orf19.5986 0.9 1.0 0.6 0.5 0.7 0.9 0.6 0.7 
TRM2 orf19.3327 1.4 0.7 0.5 0.5 1.5 1.0 0.7 0.4 double-stranded DNA specific 5'-3' exodeoxyribonuclease activity (IEA) 
TSR2 orf19.2998 1.4 0.5 0.5 0.6 1.6 1.0 0.8 0.5 
ULP1 orf19.353 0.8 0.6 0.6 0.6 1.0 0.8 0.8 0.6 SUMO-specific protease activity (IDA) 
UTP15 orf19.3609 1.1 0.6 0.6 0.6 1.3 0.9 0.7 0.6 snoRNA binding (IEA) 
UTP21 orf19.1566 1.6 0.5 0.6 0.5 1.4 0.8 0.7 0.4 
UTP4 orf19.1633 1.4 0.5 0.5 0.6 1.3 1.1 1.1 0.6 snoRNA binding (IEA) 
UTP5 orf19.7599 1.5 0.6 0.6 0.5 1.5 1.0 0.8 0.5 
UTP8 orf19.5436 1.1 0.7 0.5 0.6 1.0 1.1 0.7 0.6 tRNA binding (ISO)|snoRNA binding (IEA)|tRNA binding (IEA) 
UTP9 orf19.6710 1.1 0.6 0.5 0.6 1.2 1.0 0.7 0.5 snoRNA binding (IEA) 
YHB4 orf19.7637 0.7 0.8 0.6 0.6 0.8 0.8 0.7 0.7 nitric oxide dioxygenase activity (IMP, ISS) 
YTM1 orf19.4815 1.1 0.6 0.4 0.6 1.3 1.0 0.7 0.5 cytoskeletal protein binding (IEA) 
YVH1 orf19.4401 1.3 0.6 0.6 0.5 1.6 1.0 0.8 0.4 protein tyrosine/serine/threonine phosphatase activity (ISS)|protein tyrosine phosphatase activity (IEA) 
ZRT2 orf19.1585 0.7 0.8 0.5 0.6 0.6 1.0 0.6 0.8 low-affinity zinc ion transmembrane transporter activity (IEA) 
orf19.5905 1.1 0.5 0.5 0.4 1.6 0.5 0.9 0.2 
orf19.2384 1.5 0.8 0.6 0.4 1.2 0.8 0.7 0.3 
orf19.1642 2.6 0.5 0.6 0.3 2.5 0.9 0.9 0.3 mRNA binding (IEA) 
orf19.4760 1.6 0.5 0.4 0.4 2.0 0.8 0.8 0.4 
orf19.2547 1.3 0.7 0.5 0.4 1.1 0.7 0.7 0.4 
orf19.5353 1.8 0.7 0.6 0.5 1.4 0.8 0.9 0.4 
orf19.6886 2.1 0.5 0.6 0.4 2.0 0.9 1.0 0.4 rRNA binding (IEA) 
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CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
orf19.5704 1.2 0.6 0.6 0.5 1.1 0.9 0.7 0.4 
orf19.1708 2.3 0.5 0.5 0.4 2.1 1.1 0.9 0.4 
orf19.6862 1.8 0.7 0.5 0.4 1.7 0.9 0.8 0.4 
orf19.2386 1.7 0.6 0.6 0.4 2.0 1.1 1.0 0.4 0 
orf19.2320 1.7 0.4 0.5 0.3 1.7 0.9 0.7 0.4 amino acid kinase activity (IEA)|protein kinase activity (IEA) 
orf19.6828 2.0 0.3 0.4 0.4 2.0 1.1 0.9 0.4 RNA binding (IEA) 
orf19.107 1.5 0.7 0.6 0.5 1.4 1.0 0.7 0.4 RNA helicase activity (IEA) 
orf19.6234 1.8 0.5 0.6 0.4 1.5 0.9 0.9 0.4 
orf19.2167 1.2 0.7 0.6 0.6 1.5 0.6 0.8 0.4 
orf19.6297 1.5 0.7 0.6 0.6 1.4 0.9 0.7 0.4 pseudouridine synthase activity (IEA)|pseudouridylate synthase activity (IEA) 
orf19.6014 2.4 0.5 0.6 0.5 2.4 0.9 1.2 0.4 
orf19.1082 1.7 0.5 0.5 0.5 1.2 1.0 0.7 0.4 
orf19.5038 1.3 0.6 0.5 0.5 1.1 1.1 0.7 0.4 tRNA (guanine) methyltransferase activity (IEA) 
orf19.2830 1.6 0.6 0.5 0.4 1.7 1.0 0.7 0.4 snoRNA binding (IEA) 
orf19.7468 1.1 0.9 0.5 0.6 1.2 0.9 0.7 0.4 
orf19.2870 0.7 1.3 0.6 0.4 0.7 0.4 0.7 0.5 
orf19.2319 2.0 0.6 0.6 0.6 1.6 1.0 0.9 0.5 RNA binding (IEA) 
orf19.3393 1.4 0.5 0.5 0.5 1.5 1.1 0.7 0.5 ATP-dependent RNA helicase activity (IEA) 
orf19.7650 1.4 0.7 0.6 0.6 1.5 0.9 0.8 0.5 
orf19.4793 1.4 0.5 0.5 0.5 1.4 1.1 0.8 0.5 
orf19.1360 0.9 1.1 0.4 0.6 0.8 1.1 0.7 0.5 
orf19.7384 1.5 0.6 0.5 0.5 1.5 0.9 0.9 0.5 GTPase activity (IEA) 
orf19.2362 1.3 0.7 0.5 0.6 1.5 0.9 0.9 0.5 
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orf19.3463 1.6 0.6 0.6 0.5 1.6 0.9 0.8 0.5 
orf19.4792 1.4 0.8 0.5 0.6 1.2 0.9 0.8 0.5 
orf19.5039 1.5 0.8 0.6 0.6 1.6 0.9 0.7 0.5 3'-5'-exoribonuclease activity (IEA) 
orf19.715 0.8 0.5 0.4 0.4 0.8 0.7 0.8 0.5 
orf19.3252 0.9 0.7 0.5 0.5 1.0 0.8 0.8 0.5 specific RNA polymerase II transcription factor activity (IEA) 
orf19.4479 1.6 0.5 0.6 0.6 1.6 1.0 0.9 0.5 RNA binding (IEA) 
orf19.6007 0.9 0.7 0.5 0.5 0.7 0.8 0.7 0.5 
orf19.3089 1.0 0.9 0.5 0.6 0.8 0.8 0.6 0.5 
orf19.603 1.2 0.7 0.6 0.6 1.2 1.1 0.7 0.5 rRNA primary transcript binding (IEA)|single-stranded telomeric DNA binding (IEA) 
orf19.4342 1.1 0.7 0.6 0.6 0.9 0.8 0.7 0.5 specific RNA polymerase II transcription factor activity (IEA)|transcription factor activity (IEA) 
orf19.1150.1 0.9 0.9 0.6 0.5 0.8 0.7 0.7 0.5 
orf19.6431 1.5 0.7 0.6 0.6 1.5 0.8 0.9 0.5 
orf19.2090 1.4 0.6 0.6 0.5 1.4 1.0 0.8 0.5 RNA helicase activity (IEA)|snoRNA binding (IEA) 
orf19.2306 1.0 0.7 0.6 0.6 1.0 0.8 0.7 0.5 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen 
orf19.1404 1.3 0.7 0.6 0.6 1.5 0.8 0.7 0.5 tRNA dihydrouridine synthase activity (IEA) 
orf19.7296 1.1 1.0 0.6 0.4 0.8 0.4 0.9 0.5 
orf19.1687 1.3 0.6 0.5 0.6 1.3 1.0 0.8 0.5  ATP-dependent RNA helicase activity (IEA)|RNA splicing factor activity, transesterification mechanism (IEA) 
orf19.3539 1.1 0.6 0.5 0.5 1.5 1.1 0.7 0.5 
orf19.6874 1.0 0.9 0.6 0.6 0.8 0.8 0.7 0.5 
orf19.3704 1.1 0.6 0.6 0.6 1.1 0.9 0.7 0.6 ATP-dependent RNA helicase activity (IEA) 
orf19.1959 1.1 0.7 0.6 0.6 1.1 0.8 0.7 0.6 
orf19.962 1.3 0.6 0.4 0.6 1.5 0.9 0.9 0.6 
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CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
orf19.3303 1.1 0.6 0.6 0.5 1.1 0.9 0.7 0.6 tRNA methyltransferase activity (IEA) 
orf19.6137 1.0 0.6 0.6 0.6 1.0 0.7 0.7 0.6 
orf19.7190 1.3 0.8 0.4 0.6 1.2 0.8 0.7 0.6 oxidized purine base lesion DNA N-glycosylase activity (ISA, IEA) 
orf19.7593 1.3 0.7 0.6 0.5 1.2 0.8 0.8 0.6 asparaginase activity (IEA) 
orf19.4940 1.2 0.7 0.6 0.6 1.2 1.0 0.7 0.6 L-histidine transmembrane transporter activity (IEA) 
orf19.4835 1.2 0.7 0.6 0.6 1.7 0.8 0.8 0.6 snoRNA binding (IEA) 
orf19.5802 1.3 0.6 0.6 0.5 1.2 0.7 0.8 0.6 
orf19.4375 1.0 0.7 0.6 0.6 1.1 0.9 0.8 0.6 
orf19.6723 1.3 0.7 0.6 0.6 1.1 0.7 0.8 0.6 
orf19.2527 1.4 0.5 0.6 0.6 1.6 0.9 0.8 0.6 
orf19.6580 0.9 0.7 0.6 0.5 1.0 0.7 0.8 0.6 
orf19.6730 1.8 0.5 0.6 0.6 1.4 0.9 1.1 0.6 
orf19.6578 0.9 0.9 0.5 0.5 0.8 0.8 0.7 0.6 neurotransmitter transporter activity (ISS)|inorganic phosphate transmembrane transporter activity (IEA) 
orf19.7422 1.4 0.6 0.6 0.5 1.5 0.8 0.8 0.6 RNA binding (IEA) 
orf19.2319 1.4 1.0 0.5 0.4 2.0 0.9 1.3 0.6 RNA binding 
orf19.6766 1.3 0.5 0.5 0.6 1.3 1.0 0.8 0.6 RNA binding (IEA) 
orf19.1697 1.2 0.8 0.6 0.5 1.3 0.8 0.8 0.6 
orf19.254 1.0 0.9 0.5 0.5 1.1 0.8 0.7 0.6 
orf19.443 1.3 0.6 0.6 0.6 1.1 0.9 0.9 0.6 DNA-directed RNA polymerase activity (IEA) 
orf19.7107 1.3 0.5 0.6 0.6 1.5 0.9 1.0 0.6 
orf19.4666 0.9 0.8 0.6 0.5 0.7 0.8 0.7 0.6 
orf19.3270 0.9 0.9 0.6 0.6 0.7 0.8 0.7 0.6 1,3-beta-glucan synthase activity (IEA) 
orf19.2045 1.0 0.7 0.6 0.6 1.0 0.9 0.8 0.6 diacylglycerol kinase activity (IEA) 
  
138 
Appendix C.     Continued. 
          
  Change in fold expressiona  
  G648S G648D Y642F A643V  
CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
orf19.6418 1.2 0.6 0.6 0.6 1.2 1.0 0.8 0.6 
orf19.58 1.3 0.6 0.6 0.6 1.2 1.1 0.8 0.6 3'-5'-exoribonuclease activity (IEA) 
orf19.4896 1.3 0.7 0.6 0.6 1.3 1.1 0.8 0.7 DNA-directed RNA polymerase activity (IEA) 
orf19.7618 1.7 0.5 0.4 0.6 1.3 1.2 0.8 0.7 unfolded protein binding (IEA) 
orf19.7495 1.2 0.6 0.6 0.6 1.2 0.8 0.9 0.7 NADPH dehydrogenase activity (IEA) 
orf19.3887 1.0 0.6 0.4 0.6 1.2 1.0 0.7 0.7 
orf19.2263 0.9 0.6 0.6 0.6 0.9 0.9 0.9 0.7 
orf19.6938 1.1 0.7 0.6 0.6 1.0 0.9 0.7 0.7 S-methyl-5-thioadenosine phosphorylase activity (IEA) 
orf19.7011 1.2 0.5 0.5 0.6 1.1 0.9 0.8 0.7 
orf19.7502 1.0 0.7 0.4 0.5 0.9 0.8 0.9 0.7 
orf19.3778 1.3 0.6 0.5 0.6 1.2 1.0 0.8 0.7 
orf19.3475 0.7 0.8 0.4 0.5 0.7 0.8 0.6 0.7 
orf19.1646 1.4 0.6 0.6 0.5 1.4 1.0 0.7 0.7 
orf19.409 0.8 0.8 0.6 0.6 0.8 0.9 0.6 0.7 
orf19.2246 0.8 0.7 0.6 0.5 0.8 0.8 0.7 0.7 
orf19.6770 0.7 0.9 0.6 0.6 0.6 0.9 0.6 0.7 cytoskeletal adaptor activity (IEA) 
orf19.7566 1.1 0.7 0.6 0.6 0.8 0.9 0.9 0.7 amino acid transmembrane transporter activity (IEA) 
orf19.5017 0.8 1.0 0.5 0.5 0.6 0.8 0.4 0.7 urea transmembrane transporter activity (IEA) 
orf19.6996 1.7 0.5 0.6 0.6 1.5 0.9 1.1 0.7 alpha-1,3-mannosyltransferase activity (IEA) 
orf19.6679 0.9 0.9 0.6 0.5 0.8 0.7 0.8 0.7 
orf19.1363 0.7 0.8 0.0 0.4 0.5 1.1 0.6 0.8 
orf19.1449 1.2 0.3 0.4 0.4 1.6 0.9 1.1 0.8 
orf19.1179 2.4 0.5 0.6 0.6 2.4 0.6 2.0 0.8 
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orf19.4266 1.0 0.8 0.6 0.3 1.1 0.8 0.4 0.8 
orf19.2959.1 0.6 0.9 0.5 0.6 0.6 0.8 0.6 0.8 
orf19.3894 0.9 0.9 0.5 0.6 1.0 1.1 0.9 0.9 
orf19.670.2 0.8 0.4 0.3 0.4 0.7 0.5 1.5 0.9 
ARA1 orf19.2172 0.6 1.2 1.3 1.0 0.6 0.4 0.8 0.7 D-arabinose 1-dehydrogenase [NAD(P)+] activity (IDA) 
CIP1 orf19.113 0.7 2.3 1.1 0.7 0.5 0.5 0.7 0.8 
CIRT4B orf19.2839 0.8 1.4 1.6 1.3 0.6 0.6 1.4 1.3 
GAC1 orf19.7053 0.7 1.9 1.2 0.7 0.6 0.6 0.6 0.6 protein phosphatase type 1 regulator activity (IEA) 
IFC3 orf19.3749 0.6 1.7 1.4 1.1 0.6 0.6 1.0 1.1 oligopeptide transporter activity (IGI, ISS) 
IFE1 orf19.769 0.5 1.7 0.8 0.8 0.4 0.6 0.4 0.8 
LIP1 orf19.4821 0.3 0.9 1.0 0.8 0.6 0.4 0.9 0.6 lipase activity (IDA) 
MIH1 orf19.3071 0.7 0.9 0.7 0.6 0.6 0.6 0.6 0.8 protein tyrosine phosphatase activity (IEA) 
OPT7 orf19.5673 0.7 1.4 0.4 0.4 0.3 0.6 0.6 0.7 oligopeptide transporter activity (ISS) 
PRC2 orf19.4135 0.6 2.2 0.9 0.7 0.4 0.5 0.6 0.8 
PSA2 orf19.4943 0.6 1.4 0.9 0.7 0.5 0.5 0.8 1.0 mannose-1-phosphate guanylyltransferase activity (IDA, IGI, ISS) 
RBT7 orf19.2681 0.7 1.2 0.8 0.4 0.4 0.4 0.5 0.7 ribonuclease activity (ISS) 
SAP10 orf19.3839 0.5 1.3 0.8 0.5 0.5 0.5 0.6 0.7 
SKN2 orf19.348 0.7 1.1 0.6 0.7 0.5 0.6 0.8 1.0 
orf19.5775 0.9 1.2 1.1 0.8 0.6 0.4 0.9 0.6 
orf19.7311 0.6 1.0 0.7 0.8 0.6 0.6 0.6 0.6 
orf19.6795 0.7 0.8 0.5 0.7 0.5 0.5 0.7 0.7 transcription regulator activity (IEA) 
orf19.3758 0.4 0.8 0.1 0.8 0.6 0.5 0.3 0.7 
orf19.1484 0.7 0.8 0.9 1.2 0.6 0.5 1.0 0.7 
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orf19.1258 0.5 1.4 1.0 0.6 0.4 0.5 0.6 0.7 
orf19.5449 0.8 1.0 0.8 0.6 0.6 0.6 0.7 0.7 
orf19.1600 0.7 0.9 0.9 0.5 0.5 0.6 0.6 0.7 
orf19.4768 1.0 0.5 0.9 1.8 0.4 0.5 0.7 0.8 
orf19.2737 0.5 1.2 0.8 0.7 0.5 0.6 0.5 0.8 
orf19.4349 0.9 0.7 0.5 0.9 0.5 0.6 0.4 0.8 
orf19.2030 0.7 1.2 0.8 0.7 0.6 0.6 0.8 0.8 
orf19.1887 0.6 1.1 0.9 0.7 0.6 0.6 0.6 0.8 sterol esterase activity (IEA) 
orf19.764 0.1 1.0 0.6 0.8 0.6 0.1 0.6 0.8 
orf19.6017 1.2 0.9 0.8 0.7 0.6 0.6 1.0 0.9 
orf19.1159 0.8 0.9 0.6 0.7 0.6 0.6 1.0 0.9 homoserine O-acetyltransferase activity (IEA) 
orf19.4530.1 0.4 2.1 0.9 0.9 0.4 0.6 0.5 0.9 
orf19.6307 0.6 1.1 0.5 1.2 0.4 0.6 0.8 1.1 
orf19.5527 0.6 0.8 1.0 0.9 0.6 0.5 1.4 1.2 endoribonuclease activity (IEA) 
orf19.247 0.7 0.7 1.1 1.0 0.6 0.4 0.7 1.4 
orf19.4055 0.5 0.8 0.6 1.0 0.3 0.4 1.7 1.8 
ASR3 orf19.842 0.8 1.2 0.8 0.5 0.8 0.5 0.6 0.5 
BMT4 orf19.5612 0.8 1.4 1.0 0.4 0.7 0.6 0.6 0.6 
CHT3 orf19.7586 0.7 0.8 0.6 0.7 0.6 0.7 0.6 0.6 chitinase activity (IDA, IGI, ISS)|endochitinase activity (IEA) 
CLA4 orf19.4890 0.7 0.8 0.5 0.8 0.8 0.6 0.5 0.4 protein serine/threonine kinase activity (ISS) 
CRZ2 orf19.2356 0.8 1.9 1.0 0.5 0.8 0.7 0.3 0.4 transcription factor activity (ISS) 
CSP37 orf19.2531 0.6 0.9 0.7 0.6 0.7 0.5 0.6 0.6 
FCY21 orf19.1357 1.2 1.1 0.8 0.8 0.8 0.7 0.6 0.6 drug membrane transporter activity 
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FGR6 orf19.5315 0.8 0.9 0.8 0.6 0.7 0.5 0.6 0.5 
GIT1 orf19.1979 0.8 1.3 0.9 0.7 0.8 0.8 0.6 0.6 inorganic phosphate transmembrane transporter activity (ISS)|phospholipid transporter activity (IEA) 
GNP3 orf19.7565 1.0 0.8 1.0 0.7 0.8 0.8 0.6 0.6 amino acid transmembrane transporter activity (IEA) 
KRE1 orf19.4377 1.2 1.2 0.7 0.6 1.0 1.0 0.6 0.5 
MEA1 orf19.5919 1.1 1.0 0.7 0.6 0.9 0.8 0.6 0.6 
MRR1 orf19.7372 1.1 1.0 0.7 0.6 1.1 0.9 0.6 0.5 specific RNA polymerase II transcription factor activity (IMP)|sequence-specific DNA binding (IEA) 
PHO84 orf19.655 0.8 1.2 0.9 0.6 0.8 0.9 0.6 0.6 inorganic phosphate transmembrane transporter activity (ISS) 
RCL1 orf19.1886 0.9 0.7 0.5 0.7 0.8 1.0 0.6 0.6 RNA-3'-phosphate cyclase activity (IEA)|enzyme activator activity (IEA) 
SFU1 orf19.4869 1.1 1.1 0.8 0.6 0.9 0.9 0.6 0.6 DNA binding (IGI)|transcription factor activity (IGI, IMP, ISS) 
TEC1 orf19.5908 1.0 0.9 0.7 0.4 0.9 0.8 0.5 0.6 specific RNA polymerase II transcription factor activity (IMP, ISS)|transcription factor activity (ISS) 
XUT1 orf19.2882 0.9 1.1 1.0 0.4 0.9 0.5 0.5 0.5 nucleobase:cation symporter activity (ISS) 
orf19.5826 0.5 0.8 0.6 0.7 0.6 0.4 0.5 0.4 L-gamma-aminobutyric acid transmembrane transporter activity (IEA) 
orf19.6277 1.0 1.6 0.8 0.3 0.9 0.5 0.3 0.4 
orf19.7590 0.9 0.9 0.7 0.5 1.1 0.5 0.6 0.5 
orf19.5775 0.8 0.9 1.2 0.4 1.0 0.5 0.6 0.6 
orf19.3470 1.4 0.6 0.9 0.3 1.5 0.5 0.3 0.3 nitrogenase (flavodoxin) activity (ISS) 
orf19.5070 0.8 1.2 0.7 0.3 0.7 0.6 0.5 0.5 
orf19.3988 0.9 1.1 0.4 0.7 1.1 0.6 0.5 0.6 
orf19.750 0.7 1.4 0.6 0.7 0.7 0.6 0.6 0.6 
orf19.5872 1.2 1.0 0.9 0.7 0.4 0.7 0.6 0.4 general RNA polymerase II transcription factor activity (IEA) 
orf19.48 1.8 0.9 1.0 0.8 1.4 0.7 0.4 0.4 ribonuclease P activity (IEA) 
orf19.5910 1.0 0.8 1.0 0.6 1.0 0.7 0.6 0.6 histone acetyltransferase activity (IEA)|methylated histone residue binding (IEA) 
orf19.1656 0.4 1.5 1.3 0.7 0.6 0.7 0.6 0.6 phosphatidylinositol binding (IEA) 
  
142 
Appendix C.     Continued. 
          
  Change in fold expressiona  
  G648S G648D Y642F A643V  
CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
orf19.2824 0.8 0.9 0.7 0.7 0.8 0.7 0.6 0.6 double-stranded DNA binding (IDA)|specific transcriptional repressor activity (IGI) 
orf19.2604 1.3 0.7 0.7 0.4 1.3 0.7 0.5 0.4 
orf19.2231 1.1 0.9 0.8 0.8 1.2 0.7 0.6 0.5 
orf19.2547 1.3 0.6 0.7 0.5 1.1 0.8 0.6 0.4 
orf19.4143 1.5 0.6 0.8 0.4 1.2 0.8 0.6 0.4 
orf19.3170 1.5 0.6 0.8 0.7 1.5 0.8 0.6 0.5 
orf19.6976 0.9 1.0 0.8 0.7 0.9 0.8 0.6 0.6 folic acid transporter activity (ISS) 
orf19.5326 1.3 1.0 0.7 0.6 1.0 0.9 0.6 0.6 transcription factor activity (ISS)|transcription corepressor activity (IEA) 
orf19.3481 1.0 0.7 0.5 0.7 0.9 0.9 0.6 0.6 
orf19.3831 1.7 1.2 0.9 0.7 1.5 1.0 0.6 0.6 
orf19.6416 1.0 1.2 0.7 0.8 0.8 1.0 0.6 0.6 
orf19.6662 1.1 0.9 0.9 0.7 1.2 1.0 0.6 0.6 ubiquinone binding (IEA) 
orf19.5128 1.0 1.1 0.9 1.2 1.1 1.0 0.6 0.6 RNA binding (IEA) 
orf19.1772 1.8 1.1 0.6 0.8 1.7 1.2 0.6 0.5 
orf19.69 0.6 1.0 0.7 0.9 0.5 1.3 0.5 0.5 
orf19.6586 0.9 1.7 0.7 0.6 1.0 1.3 0.4 0.4 
orf19.4563 1.1 0.6 0.5 0.8 1.0 1.5 0.5 0.6 
orf19.1117 1.1 5.5 0.1 0.7 0.8 2.1 0.4 0.1 formate dehydrogenase activity (ISS) 
orf19.2442 0.5 0.5 0.3 0.5 0.5 0.7 0.5 1.0 
orf19.2163 0.3 0.5 0.6 0.7 0.4 0.3 0.7 1.1 
HAL21 orf19.99 0.4 0.4 0.4 1.2 0.2 0.4 0.4 0.6 3'(2'),5'-bisphosphate nucleotidase activity (IEA) 
AFG1 orf19.4743 0.8 0.6 0.5 0.5 0.6 0.5 0.9 0.5 ATPase activity (IEA) 
HGT1 orf19.4527 0.9 0.5 0.2 0.5 0.6 0.5 0.8 0.6 glucose transmembrane transporter activity (IGI, ISS)|sugar transmembrane transporter activity (ISS) 
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  Change in fold expressiona  
  G648S G648D Y642F A643V  
CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
HSP30 orf19.4526 0.6 2.3 0.3 0.4 0.4 0.4 0.5 0.7 
IFF11 orf19.5399 0.6 0.8 0.6 0.5 0.5 0.6 0.8 1.0 
OPT7 orf19.5673 0.7 1.4 0.4 0.4 0.3 0.6 0.6 0.7 oligopeptide transporter activity (ISS) 
SAP3 orf19.6001 0.6 1.4 0.6 0.6 0.5 0.6 0.6 1.1 aspartic-type endopeptidase activity (IDA, ISS)|drug binding (IDA,ISS) 
SIT1 orf19.2179 1.0 0.7 0.4 0.5 0.6 0.6 0.8 0.5 ferrichrome transporter activity (IGI, IMP)|siderophore-iron transmembrane transporter activity (ISS) 
orf19.675 0.5 1.5 0.6 0.6 0.4 0.6 0.4 0.7 
ARG11 orf19.5926 1.0 0.9 0.4 0.5 1.3 0.8 0.5 0.3 L-ornithine transmembrane transporter activity (IEA) 
CCC1 orf19.6948 0.8 0.9 0.4 0.4 0.7 0.9 0.3 0.4 ferrous iron transmembrane transporter activity (IEA) 
CHO2 orf19.169 1.1 0.7 0.6 0.5 0.9 0.8 0.6 0.5 methylene-fatty-acyl-phospholipid synthase activity (IEA) 
CUP9 orf19.6514 1.0 1.1 0.6 0.5 0.9 0.9 0.6 0.5 chromatin binding (IEA)|sequence-specific DNA binding (IEA) 
DIM1 orf19.5010 1.6 0.6 0.4 0.4 1.9 1.2 0.6 0.3 rRNA (adenine-N6,N6-)-dimethyltransferase activity (IEA) 
ELP3 orf19.7387 1.1 0.7 0.6 0.6 1.1 1.0 0.6 0.5 RNA polymerase II transcription elongation factor activity (IEA) 
FDH1 orf19.638 0.8 1.4 0.6 0.4 0.7 0.7 0.5 0.5 formate dehydrogenase activity (ISS) 
FET3 orf19.4211 0.9 0.5 0.3 0.4 0.7 0.7 0.6 0.5 ferroxidase activity (IGI, IMP) 
FRE30 orf19.6140 1.4 0.5 0.3 0.3 1.2 0.6 0.6 0.3 
FRE7 orf19.6139 1.1 0.6 0.2 0.4 0.8 0.9 0.5 0.5 ferric-chelate reductase activity (IEA) 
HCM1 orf19.4853 0.8 0.8 0.5 0.6 0.6 0.8 0.6 0.6 sequence-specific DNA binding (IEA) 
HMX1 orf19.6073 1.1 0.8 0.3 0.5 1.0 1.1 0.4 0.4 heme oxygenase (decyclizing) activity (IDA, IMP, ISS) 
HSP12 orf19.3160 0.6 1.2 0.6 0.4 0.6 0.7 0.5 0.6 
NOG2 orf19.5732 1.4 0.6 0.6 0.4 1.4 0.7 0.6 0.2 
NOP14 orf19.5959 2.2 0.6 0.6 0.4 2.9 0.7 0.6 0.2 snoRNA binding (IEA) 
PGA55 orf19.207 0.9 0.7 0.5 0.5 0.6 0.8 0.5 0.5 
RLI1 orf19.3034 1.1 0.7 0.6 0.5 1.1 0.9 0.6 0.5 ATP binding (ISS)|iron ion binding (IEA) 
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  Change in fold expressiona  
  G648S G648D Y642F A643V  
CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
SEN2 orf19.2735 1.3 0.5 0.4 0.3 1.2 1.1 0.5 0.3 
SMM1 orf19.1362 1.4 0.6 0.5 0.3 1.4 0.7 0.5 0.3 tRNA dihydrouridine synthase activity (IEA) 
SPB4 orf19.6298 1.5 0.6 0.5 0.5 1.6 1.1 0.6 0.4 ATP-dependent RNA helicase activity (IEA) 
UTP18 orf19.7154 1.2 0.6 0.4 0.5 1.1 1.1 0.6 0.6 
orf19.4445 1.0 0.4 0.2 0.1 1.2 0.5 0.3 0.1 
orf19.6873.1 2.2 0.8 0.3 0.2 1.6 0.9 0.5 0.2 electron carrier activity (IEA)|iron ion binding (IEA) 
orf19.1091 1.5 0.4 0.4 0.3 1.9 0.5 0.6 0.2 RNA binding (IEA) 
orf19.5049 1.9 0.5 0.5 0.5 1.4 0.9 0.4 0.2 
orf19.5207 1.2 0.6 0.4 0.5 1.1 1.1 0.3 0.2 
orf19.5500 1.7 0.6 0.5 0.4 1.9 1.2 0.5 0.3 
orf19.2934 1.6 0.5 0.4 0.4 1.8 0.7 0.6 0.3 
orf19.341 1.0 1.0 0.2 0.2 0.6 0.7 0.2 0.3 drug transporter activity (ISS) 
orf19.7077 1.0 0.4 0.2 0.3 0.7 0.6 0.4 0.3 ferric-chelate reductase activity (IEA) 
orf19.5843 0.7 0.7 0.3 0.4 0.7 0.8 0.4 0.3 
orf19.5020 1.2 0.7 0.4 0.3 1.2 0.9 0.5 0.3 
orf19.1774 1.0 1.0 0.3 0.3 0.5 0.9 0.3 0.3 
orf19.4273 1.6 0.7 0.5 0.4 1.3 1.1 0.5 0.3 
orf19.3448 0.9 1.0 0.2 0.2 0.9 0.5 0.4 0.3 
orf19.2724 0.6 1.3 0.4 0.3 0.6 0.7 0.3 0.3 
orf19.494 1.3 0.5 0.5 0.5 1.5 0.9 0.6 0.4 RNA binding (IEA) 
orf19.3088 1.3 0.5 0.4 0.4 1.3 1.0 0.6 0.4 transcription factor activity (IEA) 
orf19.2604 1.3 0.5 0.4 0.4 1.4 0.8 0.6 0.4 
orf19.1771 1.3 0.8 0.4 0.4 1.3 0.6 0.4 0.4 
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  G648S G648D Y642F A643V  
CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
orf19.6660 0.6 1.2 0.5 0.3 0.7 0.6 0.3 0.4 
orf19.2018 1.1 0.6 0.5 0.4 1.0 0.8 0.5 0.4 
orf19.22 0.8 0.7 0.4 0.3 0.6 0.7 0.4 0.4 
orf19.6899 1.0 2.7 0.4 0.5 0.6 0.9 0.2 0.4 
orf19.1287 1.7 0.8 0.6 0.5 1.5 1.1 0.6 0.4 
orf19.3759 0.9 0.8 0.4 0.4 1.3 0.7 0.5 0.4 RNA polymerase II transcription elongation factor activity (IEA) 
orf19.4634 1.6 0.6 0.6 0.6 1.2 1.0 0.6 0.4 
orf19.5431 0.7 0.7 0.3 0.3 0.5 0.7 0.4 0.4 
orf19.3048 0.6 0.8 0.6 0.5 0.8 0.5 0.6 0.5 
orf19.1388 1.5 0.5 0.5 0.5 1.6 1.1 0.5 0.5 
orf19.2330 1.2 0.5 0.4 0.5 1.2 0.9 0.5 0.5 snoRNA binding (IEA) 
orf19.7088 1.3 0.7 0.5 0.6 1.4 1.1 0.6 0.5 single-stranded telomeric DNA binding (IEA) 
orf19.4161 0.9 0.8 0.5 0.6 1.4 0.6 0.6 0.5 
orf19.4900 0.8 0.7 0.5 0.4 0.7 0.5 0.6 0.5 alpha-1,3-mannosyltransferase activity (IEA) 
orf19.7085 0.6 1.0 0.5 0.4 0.8 0.6 0.5 0.5 
orf19.3335 0.7 0.8 0.6 0.6 0.9 0.7 0.6 0.5 
orf19.6751 1.2 0.8 0.6 0.6 1.3 1.0 0.6 0.5 tRNA methyltransferase activity (IEA) 
orf19.3869 0.9 0.8 0.4 0.5 0.8 0.7 0.6 0.5 
orf19.5626 0.8 0.8 0.4 0.5 0.9 0.8 0.6 0.6 
orf19.28 0.8 0.7 0.5 0.6 1.0 0.9 0.6 0.6 thiamin transmembrane transporter activity (IEA) 
orf19.4889 1.0 0.7 0.6 0.4 0.9 0.8 0.6 0.6 drug transporter activity (ISS) 
orf19.3854 1.1 0.9 0.6 0.5 1.1 0.9 0.6 0.6 protein kinase activity (IEA) 
orf19.2022 0.8 0.8 0.5 0.5 0.7 0.7 0.6 0.6 glucose transmembrane transporter activity (ISS) 
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  G648S G648D Y642F A643V  
CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
orf19.6691 0.9 0.8 0.5 0.4 0.8 0.9 0.6 0.6 
orf19.4282 1.3 0.9 0.5 0.6 0.8 0.9 0.6 0.6 
orf19.4959 0.5 0.9 0.4 0.6 0.5 0.9 0.5 0.6 
orf19.3110 0.6 0.8 0.6 0.5 0.6 0.7 0.5 0.6 
orf19.2726 0.8 1.2 0.6 0.5 0.7 0.9 0.6 0.6 
orf19.6245 0.6 1.0 0.6 0.6 0.7 0.7 0.6 0.6 
orf19.6077 0.8 0.9 0.6 0.5 0.6 0.7 0.6 0.6 
MOH1 orf19.3369 0.4 2.1 0.8 0.3 0.4 0.4 0.4 0.4 
GAC1 orf19.7053 0.7 1.9 1.2 0.7 0.6 0.6 0.6 0.6 protein phosphatase type 1 regulator activity (IEA) 
orf19.251 0.6 1.4 0.8 0.4 0.5 0.6 0.6 0.6 
orf19.7311 0.6 1.0 0.7 0.8 0.6 0.6 0.6 0.6 
orf19.1368 0.7 1.0 0.7 0.4 0.6 0.6 0.6 0.6 
AOX1 orf19.4774 0.5 0.8 0.4 0.3 0.4 0.4 0.3 0.3 alternative oxidase activity (IMP, ISS) 
ASR2 orf19.7284 0.4 1.2 0.6 0.4 0.4 0.6 0.4 0.4 
CDG1 orf19.7314 1.2 0.6 0.6 0.5 0.6 0.5 0.6 0.5 
CFL2 orf19.1264 0.7 0.3 0.3 0.2 0.5 0.4 0.5 0.4 ferric-chelate reductase activity (IEA) 
DAL8 orf19.5859 0.7 0.8 0.6 0.6 0.5 0.5 0.5 0.4 anion:cation symporter activity (ISS) 
FMP45 orf19.6489 0.4 1.7 0.5 0.4 0.2 0.3 0.3 0.5 
FRE10 orf19.1415 1.0 0.6 0.4 0.4 0.6 0.4 0.5 0.4 ferric-chelate reductase activity (IDA, IGI, IMP) 
HSP31 orf19.3664 0.7 0.7 0.2 0.3 0.4 0.5 0.3 0.2 
RTA4 orf19.6595 0.9 0.7 0.3 0.3 0.5 0.5 0.5 0.5 phospholipid-translocating ATPase activity (IEA) 
SOU1 orf19.2896 0.5 1.3 0.5 0.4 0.4 0.6 0.5 0.6 mannitol 2-dehydrogenase (NADP+) activity (IDA) 
orf19.3107 0.2 0.9 0.6 0.0 0.4 0.5 0.1 0.4 
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  G648S G648D Y642F A643V  
CGD Name orf19 Designation Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Molecular function 
orf19.7310 0.4 1.5 0.6 0.3 0.4 0.5 0.5 0.4 
orf19.822 0.3 1.4 0.3 0.3 0.4 0.5 0.3 0.4 
orf19.3439 0.6 1.0 0.1 0.2 0.5 0.5 0.4 0.5 
orf19.6741 0.7 0.8 0.4 0.4 0.5 0.6 0.4 0.5 
orf19.1368 0.5 0.8 0.6 0.4 0.5 0.5 0.5 0.5 
orf19.2846 0.5 1.9 0.5 0.3 0.5 0.5 0.5 0.6 
orf19.3932 0.4 1.7 0.5 0.6 0.4 0.5 0.4 0.6 
orf19.94 0.5 0.7 0.4 0.4 0.5 0.5 0.4 0.6 
HAL21 orf19.99 0.4 0.4 0.4 1.2 0.2 0.4 0.4 0.6 3'(2'),5'-bisphosphate nucleotidase activity (IEA) 
SUL2 orf19.2738 0.6 0.6 0.2 0.3 0.4 0.5 0.7 0.7 sulfate transmembrane transporter activity (NAS) 
orf19.2163 0.3 0.5 0.5 0.6 0.4 0.4 0.9 1.0 peptidase activity 
HGT10 orf19.5753 0.6 0.5 0.2 0.2 0.5 0.6 0.2 0.3 glucose transmembrane transporter activity (ISS) 
SAP7 orf19.756 0.4 0.4 0.3 0.2 0.4 0.4 0.3 0.4 aspartic-type endopeptidase activity (IDA, ISS) 
orf19.716 0.4 0.5 0.4 0.4 0.6 0.6 0.4 0.4 
orf19.3621 0.3 0.5 0.3 0.3 0.6 0.4 0.5 0.5 
orf19.4873 0.4 0.5 0.6 0.5 0.6 0.6 0.6 0.6 
 
a Fold change defined as the average ratio of gene expression levels in the isolates compared in two independent microarray experiments 
Bold indicates real result as defined in Materials and Methods 
Green shading indicates ratio values of 0.6 or less. 
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